Method for analyzing antibody

HK40137415APending Publication Date: 2026-09-11CHUGAI PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125162
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-24
Filing Date
2026-06-23
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

In one embodiment, there is provided herein a method for identifying a protein by using a protease FabALACTICA (Registered Trademark) and electrophoresis and / or chromatography, and a method for identifying the protein by using the protease FabALACTICA (Registered Trademark). ANTIGEN JOINT CONTAINING A COMPOSITION OF AN ANTIGEN BINDING MOLECULE HAVING THE FORM OF AT LEAST ONE DISULFIDE BOND FORMED IN REGIONS OTHER HINGE REGION AND AN ANTIGEN BINDING MOLECULE HAVING THE FORM OF AT LEAST ONE DISULFIDE BOND FORMED IN REGIONS OTHER HINGE REGION AND A FORM NON HINGE REGION A method for measuring, determining or quantifying the ratio of the sum of the combined molecules.
Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480073561.6 (22) Application Date 2024.05.24 (30) Priority Data PCT / JP2023 / 042131 2023.11.24 JP (85) PCT International Application Entering National Phase Date 2026.05.20 (86) PCT International Application Application Data PCT / JP2024 / 019137 2024.05.24 (87) PCT International Application Publication Data WO2025 / 109783 JA 2025.05.30 (71) Applicant: Chugai Pharmaceutical Co., Ltd. Address: Japan (72) Inventors: Shusuke Nanbu, Hiroaki Oyama, Kenichiro Hashimoto, Akira Fukuoka, Suwan Yan (74) Patent Agency: China Patent & Trademark Agency Co., Ltd. 11021 Patent Attorney: Guoliang Zhang (51) Int.Cl. C07K 16 / 46 (2006.01) C07K 1 / 16 (2006.01) C07K 1 / 26 (2006.01) C12N 15 / 13 (2006.01) C12P 21 / 08 (2006.01) (54) Invention Title: Method for Analyzing Antibodies (57) Abstract: In one embodiment, this document provides a method for measuring, determining, or quantifying the ratio of antigen-binding molecules in a composition having at least one disulfide bond formed in a region other than the hinge region to the sum of antigen-binding molecules having at least one disulfide bond formed in a region other than the hinge region and antigen-binding molecules not having disulfide bonds formed in a region other than the hinge region, using the protease FabALACTICA (registered trademark) and electrophoresis and / or chromatography. Claims 6 pages, Description 122 pages, Sequence Listing (electronic publication), Drawings 11 pages, CN 122249467 A 2026.06.19 CN 1 22 24 94 67 A 1. A method for measuring, determining, or quantifying the ratio (LINC ratio) of antigen-binding molecules (LINC forms) having at least one disulfide bond formed in a region outside the hinge region, said LINC ratio being the ratio of said LINC form to the sum of said LINC form and antigen-binding molecules (unLINC forms) not having a disulfide bond formed in a region outside the hinge region, said method comprising the steps of: (a) adding a protease to a composition (1) comprising said LINC form and said unLINC form to prepare composition (2); and (b) subjecting composition (2) to electrophoresis or chromatography. 2. Claim 13. The method according to claim 1 or 2, wherein the protease is an enzyme that does not digest the LINC form but is capable of digesting the unLINC form. 4. The method according to any one of claims 1 to 3, wherein the protease is an enzyme capable of cleaving the hinge region of the human IgG1 antibody. 5. The method according to any one of claims 1 to 4, wherein the protease is an enzyme that digests the human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP. 6. The method according to any one of claims 1 to 5, wherein the protease is IgdE. 7. The method according to claim 6, wherein IgdE is derived from Streptococcus agalactiae. 8. The method according to claim 6 or 7, wherein IgdE is a protein selected from the group consisting of: (a) a protein comprising the amino acid sequence shown in SEQ ID NO: 61; (b) a protein encoded by the base sequence shown in SEQ ID NO: 62; (c) a protein comprising an amino acid sequence in which one or more amino acids are substituted, deleted, added and / or inserted relative to the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP; and (d) a protein comprising an amino acid sequence having at least 80% or more, 85% or more, 90% or more, 95% or more or 98% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP. 9. The method according to any one of claims 1 to 8, wherein the protease is FabALACTICA (registered trademark). 10. The method according to any one of claims 1 to 9, wherein step (a) further comprises obtaining a composition (3) containing the protease but excluding the LINC form and the unLINC form, wherein step (b) performs non-reducing capillary SDS gel electrophoresis (CE-SDS) on each of the compositions (1) to (3) and obtains electrophoretic maps (1) to (3) of the compositions (1) to (3), wherein electrophoretic map (1) includes: containing the LINCThe electrophoresis diagram (2) includes: peaks of the unLINC form that have not been digested by the protease, and peaks that are neither derived from the unLINC form that have not been digested by the protease nor derived from the LINC form (peak Z), wherein the electrophoresis diagram (3) includes: peaks derived from the LINC form (peak L), peaks derived from the unLINC form that have been digested by the protease (peak unL), peaks derived from the protease (peak E), and peaks that are neither derived from the unLINC form that have been digested by the protease nor derived from the LINC form nor derived from the protease (peak Z), and wherein the electrophoresis diagram (3) includes peaks derived from the protease (peak E). 11. The method of claim 10, further comprising: (c) calculating the ratio (%) using the following formula (I): where A is the area value of peak L in electrophoresis (2), B is the sum of the area values ​​of peak unL, peak E and peak Z in electrophoresis (2), C is the area value of peak Z in electrophoresis (1), and D is the area value of peak E in electrophoresis (3). 12. The method of any one of claims 1 to 9, wherein step (b) involves performing hydrophobic interaction chromatography (HIC) on the composition (2) and obtaining a chromatogram. 13. The method of claim 112, further comprising: (c) calculating the ratio (%) using the following formula (II): where A is the area value of the peaks in the chromatogram originating from the LINC form; and B is the sum of the area values ​​of all peaks in the chromatogram originating from the unLINC form digested by the protease. 14. The method of any one of claims 1 to 13, wherein the antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain capable of being linked to each other via at least one disulfide bond. 15. The method of claim 14, wherein the at least one disulfide bond is formed between the first antigen-binding domain and the second antigen-binding domain. 16. The method of claim 14 or 15, wherein the at least one disulfide bond is formed between the heavy chain of the first antigen-binding domain and the heavy chain of the second antigen-binding domain. 17. The method of any one of claims 14 to 16, wherein the at least one disulfide bond is formed between the CH1 region of the first antigen-binding domain and the CH1 region of the second antigen-binding domain. 18. The method of any one of claims 14 to 17, wherein the disulfide bond is formed between the first antigen-binding domain and the second antigen-binding domain.The amino acid residue at position 191 according to EU number in the heavy chain of the first antigen-binding domain is formed between the amino acid residue at position 195 according to EU number in the heavy chain of the second antigen-binding domain, or between the amino acid residue at position 197 according to EU number in the heavy chain of the first antigen-binding domain and the amino acid residue at position 197 according to EU number in the heavy chain of the second antigen-binding domain. 19. The method according to any one of claims 14 to 18, wherein the first antigen-binding domain and the second antigen-binding domain bind to a first antigen and a second antigen, respectively, the first antigen and the second antigen being proteins present on the surface of a cell, and wherein the antigen-binding molecule has activity that promotes interaction between cells expressing the first antigen and cells expressing the second antigen. 20. The method of claim 19, wherein the cell expressing the first antigen is a cytotoxic cell, and the cell expressing the second antigen is a target cell of the cytotoxic cell, and wherein the antigen-binding molecule promotes damage to the target cell by the cytotoxic cell. 21. The method of claim 20, wherein the cytotoxic cell is a T cell, NK cell, monocyte, or macrophage. 22. The method of any one of claims 19 to 21, wherein the first antigen and the second antigen are independently selected from the group consisting of: receptors belonging to the cytokine receptor superfamily, G protein-coupled receptors, ion channel receptors, tyrosine kinase receptors, immune checkpoint receptors, antigen receptors, CD antigens, co-stimulatory molecules, and cell adhesion molecules. 23. The method of any one of claims 14 to 22, wherein the first antigen-binding domain and the second antigen-binding domain are each capable of binding to CD3 and / or CD137. 24. The method of any one of claims 1 to 23, wherein the antigen-binding molecule further comprises a third antigen-binding domain. 25. The method of claim 24, wherein the third antigen-binding domain is fused to either the first antigen-binding domain or the second antigen-binding domain. 26. The method of claim 24 or 25, wherein the third antigen-binding domain is Fab or...scFv. 27. The method of any one of claims 24 to 26, wherein the third antigen-binding domain is fused at its C-terminus to the N-terminus of the Fab heavy chain (VH region) of either the first or second antigen-binding domain, optionally via a peptide linker. 28. The method of any one of claims 24 to 27, wherein the first, second, and third antigen-binding domains are each Fab molecules, wherein the third antigen-binding domain is fused at its C-terminus to the N-terminus of the Fab heavy chain (VH region) of either the first or second antigen-binding domain, optionally via a peptide linker. 29. The method of claim 27 or 28, wherein the peptide linker comprises an amino acid sequence selected from the group consisting of amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20. 30. The method of any one of claims 24 to 29, wherein the third antigen-binding domain is a cross-Fab molecule in which the variable regions of the Fab light chain and the Fab heavy chain are exchanged, and wherein the first antigen-binding domain and the second antigen-binding domain are conventional Fab molecules. 31. The method of any one of claims 24 to 30, wherein the third antigen-binding domain is capable of binding to an antigen expressed on cancer cells or cancerous tissue. 32. The method of any one of claims 24 to 31, wherein the third antigen-binding domain is capable of binding to DLL3, preferably human DLL3. 33. The method of any one of claims 1 to 32, wherein the antigen-binding molecule further comprises an Fc region. 34. The method according to any one of claims 14 to 33, wherein the first antigen-binding domain and the second antigen-binding domain each comprise antibody variable regions that may be the same as or different from each other, and comprise antibody variable regions independently selected from the group consisting of (a1) to (a4): (a1) comprising antibody variable regions of: a heavy chain variable region comprising: a heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 27, a heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 28, and a heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 29; and a light chain variable region comprising: a light chain CDR 1 comprisingThe amino acid sequence of SEQ ID NO: 30, light chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 31, and light chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 32; (a2) comprising the following antibody variable regions: heavy chain variable regions comprising: heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 33, heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 34, and heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 35; and light chain variable regions comprising: light chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 30, light chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 31, and light chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 32; (a3) ​​and (a1) or (a2). The antibody variable region that binds to the same epitope as the antibody variable region of (a4) and (a1) or (a2) is an antibody variable region that competes with the antigen for binding. 35. The method according to any one of claims 14 to 34, wherein the first antigen-binding domain and the second antigen-binding domain each comprise antibody variable regions that may be the same as or different from each other, and each comprises an antibody variable region independently selected from the group consisting of (a1) to (a4): (a1) an antibody variable region comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 37; (a2) an antibody variable region comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 37; (a3) ​​an antibody variable region binding to an epitope identical to the epitope bound to the antibody variable region of (a1) or (a2); and (a4) an antibody variable region competing with the antibody variable region of (a1) or (a2) for binding to an antigen. 36. The method according to any one of claims 24 to 35, wherein the third antigen-binding domain comprises an antibody variable region independently selected from the group consisting of (a1) to (a4): (a1) comprising an antibody variable region of: a heavy chain variable region comprising: a heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 46, and a heavy chain...CDR 2, comprising the amino acid sequence of SEQ ID NO: 47, and heavy chain CDR 3, comprising the amino acid sequence of SEQ ID NO: 48; and light chain variable region comprising: light chain CDR 1, comprising the amino acid sequence of SEQ ID NO: 49, light chain CDR 2, comprising the amino acid sequence of SEQ ID NO: 50, and light chain CDR 3, comprising the amino acid sequence of SEQ ID NO: 51; (a2) an antibody variable region comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 53; (a3) ​​an antibody variable region binding to an epitope identical to the epitope bound to the antibody variable region of (a1) or (a2); and (a4) an antibody variable region competing with the antibody variable region of (a1) or (a2) for binding to an antigen. 37. The method according to any one of claims 14 to 36, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising: a heavy chain variable region comprising: a heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 27, a heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 28, and a heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 29; and a light chain variable region comprising: a light chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 30, a light chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 31, and a light chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 32. 38. The method of any one of claims 14 to 37, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 37. 39. The method of any one of claims 24 to 38, wherein the third antigen-binding domain comprises an antibody variable region, the antibody variable region comprising: a heavy chain variable region comprising: a heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 46, a heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 47, and a heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 48.The method according to any one of claims 24 to 39, wherein the third antigen-binding domain comprises an antibody variable region comprising: a light chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 49, a light chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 50, and a light chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 51. 40. The method according to any one of claims 24 to 39, wherein the third antigen-binding domain comprises an antibody variable region comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 53. 41. The method according to any one of claims 24 to 40, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising: a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 37, and wherein the third antigen-binding domain comprises an antibody variable region, the antibody variable region comprising: a heavy chain variable region comprising SEQ ID NO: 52, and a light chain variable region comprising SEQ ID NO: 53. 42. The method according to any one of claims 14 to 41, wherein the first antigen-binding domain and the second antigen-binding domain are each Fab having a cysteine ​​residue at EU number positions 191, 195, or 197 in the heavy chain, and having a disulfide bond formed by two cysteine ​​residues. 43. The method according to any one of claims 1 to 42, wherein the antigen-binding molecule comprises five polypeptide chains selected from any combination of the group consisting of: (a1) a polypeptide chain (chain 1) comprising the amino acid sequence of SEQ ID NO: 39, a polypeptide chain (chain 2) comprising the amino acid sequence of SEQ ID NO: 40, a polypeptide chain (chain 3) comprising the amino acid sequence of SEQ ID NO: 41, and two polypeptide chains (chain 4 and chain 5) each comprising the amino acid sequence of SEQ ID NO: 42; (a2) a polypeptide chain (chain 1) comprising the amino acid sequence of SEQ ID NO: 43, a polypeptide chain (chain 2) comprising the amino acid sequence of SEQ ID NO: 40, a polypeptide chain (chain 3) comprising the amino acid sequence of SEQ ID NO: 44, and two polypeptide chains (chain 4 and chain 5) each comprising the amino acid sequence of SEQ ID NO: 42.5); and (a3) ​​a polypeptide chain (chain 1) comprising the amino acid sequence of SEQ ID NO: 45, a polypeptide chain (chain 2) comprising the amino acid sequence of SEQ ID NO: 40, a polypeptide chain (chain 3) comprising the amino acid sequence of SEQ ID NO: 44, and two polypeptide chains (chain 4 and chain 5) each comprising the amino acid sequence of SEQ ID NO: 42; wherein, preferably, the five polypeptide chains (chain 1 to chain 5) are connected and / or associated with each other according to the orientation shown in FIG3. Claims 6 / 6 pages 7 CN 122249467 A Method for analyzing antibodies Technical Field

[0001] This disclosure relates to a method for producing an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region. This disclosure also relates to methods for increasing or enriching such antigen-binding molecules, methods for eliminating the heterogeneity of disulfide bonds in antigen-binding molecules, etc. Background Art

[0002] Antigen-binding molecules (LINC-Ig (registered trademark)) with artificial disulfide bonds between amino acid residues in regions outside the hinge region (“LINC”) are known (PTL 1 to PTL 4). For example, LINC-Ig (registered trademark) has a disulfide bond between the CH1 region of one of the two antibody heavy chains constituting the antigen-binding molecule and the CH1 region of the other antibody heavy chain. However, when such an antigen-binding molecule is obtained by expressing it in a cell culture medium, two forms (molecules with appropriate disulfide bonds between heavy chains (LINC form) and molecules without appropriate disulfide bonds, such as mis-disulfide-bonded and non-disulfide-bonded forms of the molecule (unLINC form)) will coexist in the cell culture medium. When preparing LINC-Ig (registered trademark), molecules in the cell culture medium that do not form appropriate disulfide bonds between heavy chains, such as open-type molecules with capped sulfur atoms, must be converted into molecules with appropriate disulfide bonds.

[0003] The following are known methods for obtaining LINC-Ig (registered trademark), in which suitable disulfide bonds are formed between heavy chains via amino acid residues in regions other than the hinge region.

[0004] PTL 2 and PTL 4 disclose methods for efficiently obtaining antibodies having LINC, comprising treating a formulation containing molecules with disulfide bonds between heavy chains and molecules that do not form suitable disulfide bonds with a reducing agent, and then re-oxidizing by means of buffer exchange, etc., to form disulfide bonds.

[0005] PTL 5 discloses the use of a redox buffer (e.g., cysteine / cystine) to allow a reduction-oxidation reaction to be carried out in a downstream process to prevent antibody fragmentation.

[0006] PTL 6A method for refolding recombinant antibodies by contacting them with a reduction / oxidation coupling agent is disclosed.

[0007] NPL 1 discloses the use of a redox buffer to suppress batch-to-batch inhomogeneity caused by cysteine ​​oxidation of a specific antibody (MAB007).

[0008] Additionally, since unLINC form molecules can be classified as relatively toxic impurities in pharmaceuticals, methods for analyzing and measuring the amount of unLINC form are needed as part of quality control. However, to date, no useful method has been found for measuring, determining, or quantifying the amount or proportion of LINC and / or unLINC form molecules contained in cell culture media or their purified products (including LINC and unLINC forms).

[0009] [Citation List]

[0010] [Patent Documents]

[0011] [PTL 1] WO2020 / 027330

[0012] [PTL 2] WO2021 / 157679

[0013] [PTL 3] WO2021 / 200898

[0014] [PTL 4] WO2021 / 201087

[0015] [PTL 5] WO2020 / 037016 Specification 1 / 122 Page 8 CN 122249467 A

[0016] [PTL 6] WO2006 / 047340

[0017] [PTL 7] WO2021 / 201202

[0018] [Non-Patent Documents]

[0019] [NPL 1] Pharm Sci. February 2008; 97 (2): 775-90, Removal of Cysteinylation from an Unpaired Sulfhydryl in the Variable Region of a Recombinant Monoclonal IgG1 Antibody Improves Homogeneity, Stability, and Biological Activity

[0020] [NPL 2] Spoerry C et al., (2016) PLoS ONE 11(10): e0164809. doi: 10.1371 / journal.pone.0164809 Summary of the Invention

[0021] [Technical Problem]

[0022] As described above, it is known to use a method of treating a mixture containing antigen-binding molecules with suitable disulfide bonds between heavy chains and antigen-binding molecules that do not form suitable disulfide bonds (e.g., capped molecules) with a reducing agent and then re-oxidizing it to efficiently obtain antigen-binding molecules with suitable disulfide bonds between heavy chains.A method for producing LINC antigen-binding molecules. However, this method has problems from the perspective of productivity and ease of manufacture, including low yield and long reaction time.

[0023] To address the above problems, this disclosure aims to provide a method for efficiently and easily producing and purifying antigen-binding molecules having suitable disulfide bonds between antibody heavy chains. This disclosure relates to a method for increasing the structural homogeneity and relative abundance of antigen-binding molecules having one or more disulfide bonds formed between amino acid residues in regions other than the hinge region at each of the two antibody heavy chains. In other words, this disclosure relates to a method for reducing the relative abundance of antigen-binding molecules that do not have suitable disulfide bonds between amino acid residues in regions other than the hinge region.

[0024] This disclosure also aims to provide a method for measuring, determining, or quantifying the ratio of the LINC form to the sum of the LINC and unLINC forms in a composition comprising the LINC and unLINC forms.

[0025] [Solution to the Problem]

[0026] As a result of the examination conducted to solve the above-mentioned problem, the inventors discovered that by contacting the antigen-binding molecule with a reducing agent and then removing the reducing agent, at least one disulfide bond can be formed more effectively and reproducibly between amino acid residues in the region outside the hinge region, wherein the antigen-binding molecule binds to the affinity column and has amino acid residues that can form at least one disulfide bond between amino acid residues in the region outside the hinge region (these antigen-binding molecules include antigen-binding molecules that form suitable disulfide bonds between amino acid residues in the region outside the hinge region, and antigen-binding molecules that do not form at least one suitable disulfide bond between amino acid residues in the region outside the hinge region). Specifically, the inventors have developed a technique to stably obtain high yields of antigen-binding molecules (LINC-Ig (registered trademark) form) by inserting two steps (flowing a solution containing a reducing agent and removing the reducing agent) into the protein A affinity chromatography purification step (a commonly used technique for primary purification from cell culture medium). These antigen-binding molecules have at least one disulfide bond between amino acid residues in a region outside the hinge region (harvested cell culture medium: HCCF).

[0027] The inventors have further discovered for the first time that a commercially available enzyme called FabALACTICA (registered trademark) (also known as IgdE) digests human IgG1 at a specific site above the hinge and produces intact and homogeneous Fab and Fc fragments, cleaving the unLINC form of the antigen-binding molecule in the hinge region but not the LINC form, wherein the antigen-binding molecule has cysteine ​​residues introduced into the CH1 region. Based on this discovery, the inventors have developed a technique for using devices such as electrophoresis apparatus. (Instructions 2 / 122, page 9 CN)122249467 A Method for separating LINC and unLINC forms using equipment and chromatographic apparatus, and methods for measuring, determining or quantifying their content ratio.

[0028] This disclosure is based on these findings and specifically relates to the following:

[0029] [1] A method for producing a formulation comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region,

[0030] wherein the method comprises subjecting a mixture to chromatography in the presence of a reducing agent, the antigen-binding molecule having amino acid residues that can form at least one disulfide bond between amino acid residues in a region other than the hinge region.

[0031] [2] A method for producing a formulation comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, wherein the method comprises:

[0032] (a) contacting the antigen-binding molecule with a solution containing a reducing agent in chromatography, the antigen-binding molecule having amino acid residues capable of forming at least one disulfide bond between amino acid residues in a region other than the hinge region, and

[0033] (b) removing the reducing agent.

[0034] [3] A method for producing a formulation comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region,

[0035] wherein the method comprises subjecting a mixture to chromatography in the presence of a reducing agent, the mixture comprising:

[0036] an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, and

[0037] an incorrectly disulfide bonded form and / or a non-disulfide bonded form of the antigen-binding molecule.

[0038] [4] A method for producing a formulation comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, wherein the method comprises:

[0039] (a) contacting a mixture in a chromatogram with a solution comprising a reducing agent, the mixture comprising:

[0040] an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, and

[0041] an incorrect disulfide bond form and / or a non-disulfide bond form of the antigen-binding molecule;

[0042] and

[0043] (b) removing the reducing agent.

[0044] [5] The method according to any one of [1] to [4], wherein the antigen-binding molecule comprises two or more polypeptide chains, and the at least one disulfide bond formed between amino acid residues in a region other than the hinge region is formed between the polypeptide chains.

[0045] [6] According to [5]The method wherein any one or both of the polypeptide chains comprises mutated, substituted, or introduced cysteine ​​residues in a region outside the hinge region.

[0046] [7] The method according to any one of [1] to [6], wherein the antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain, and wherein the at least one disulfide bond formed between amino acid residues in a region outside the hinge region is formed between the first antigen-binding domain and the second antigen-binding domain.

[0047] [8] The method according to any one of [1] to [7], wherein the antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain, and wherein the at least one disulfide bond formed between amino acid residues in a region outside the hinge region is formed between the heavy chain of the first antigen-binding domain and the heavy chain of the second antigen-binding domain. Specification 3 / 122 pages 10 CN 122249467 A

[0048] [9] According to any one of [1] to [8], wherein the antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain, and wherein the at least one disulfide bond formed between amino acid residues in the region outside the hinge region is formed between the CH1 region of the first antigen-binding domain and the CH1 region of the second antigen-binding domain.

[0049]

[10] According to any one of [1] to [9], wherein the antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain, and wherein the at least one disulfide bond formed between amino acid residues in the region outside the hinge region is formed between the amino acid residue at EU number position 191 in the heavy chain of the first antigen-binding domain and the amino acid residue at EU number position 191 in the heavy chain of the second antigen-binding domain.

[0050]

[11] The method according to any one of [1] to

[10] , wherein the chromatography comprises an affinity chromatography matrix, an ion exchange chromatography matrix, a hydrophobic interaction chromatography matrix, a multimode chromatography matrix comprising both ion exchange chromatography and hydrophobic interaction chromatography, or a hydroxyapatite matrix.

[0051]

[12] The method according to

[11] , wherein the affinity chromatography matrix is ​​selected from the group consisting of: protein A matrix, protein G matrix, protein L matrix, sequence-selective peptide matrix, and matrix selectively binding to the antigen-binding molecule.

[0052]

[13] The method according to

[11] , wherein the ion exchange chromatography matrix is ​​a cation exchange ligand or an anion exchange ligand.

[0053]

[14] According to

[11] The method wherein the hydrophobic interaction chromatographic matrix is ​​a hydrophobic ligand.

[0054]

[15] The method according to

[11] wherein the multimode chromatographic matrix is ​​a matrix having a combination of cation exchange ligands and hydrophobic ligands, or a matrix having a combination of anion exchange ligands and hydrophobic ligands.

[0055]

[16] The method according to

[11] wherein the hydroxyapatite matrix is ​​hydroxyapatite or a derivative thereof (such as fluorapatite).

[0056]

[17] The method according to any one of [1] to

[16] wherein the method comprises:

[0057] contacting a mixture with a chromatographic matrix, the mixture comprising:

[0058] an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, and

[0059] an incorrect disulfide bond form and / or a non-disulfide bond form of the antigen-binding molecule;

[0060] loading the chromatographic matrix into a column for column chromatography or applying it to a membrane for membrane chromatography.

[0061]

[18] The method according to any one of [1] to

[17] , wherein the reducing agent is selected from the group consisting of monothiols, dithiols, phosphine and inorganic reagents, and combinations of two or more thereof.

[0062]

[19] The method according to any one of [1] to

[18] , wherein the reducing agent is cysteine ​​or TCEP.

[0063]

[20] The method according to any one of [1] to

[18] , wherein the reducing agent is a monothiols and the concentration of the reducing agent is from about 0.01 mM to about 100 mM.

[0064]

[21] The method according to any one of [1] to

[19] , wherein the reducing agent is cysteine ​​and the concentration of the reducing agent is about 0.01 mM to about 100 mM, about 0.0001 mM to about 100.0 mM, about 0.001 mM to about 100.0 mM, about 0.005 mM to about 75.0 mM, about 0.01 mM to about 50.0 mM, about 0.05 mM to about 25.0 mM, or about 0.1 mM to about 10 mM.

[0065]

[22] The method according to any one of [1] to

[18] , wherein the reducing agent is dithiol and the concentration of the reducing agent is about 0.001 mM to about 10 mM.

[0066]

[23] The method according to any one of [1] to

[18] , wherein the reducing agent is phosphine and the concentration of the reducing agent is from about 0.0001 mM to about 1 mM or about 0.001

[0067]

[24] According to any one of [1] to

[19] , wherein the reducing agent is TCEP and the concentration of the reducing agent is from about 0.00001 mM to about 10.0 mM, from about 0.00005 mM to about 5.0 mM, from about 0.0001 mM to about 1 mM, from about 0.0005 mM to about 0.5 mM, from about 0.001 mM to about 0.1 mM or from about 0.001 mM to about 0.01 mM.

[0068]

[25] According to any one of [1] to

[18] , wherein the reducing agent is an inorganic reagent and the concentration of the reducing agent is from about 0.0001 mM to about 10 mM or from about 0.001 mM to about 0.1 mM.

[0069]

[26] The method according to any one of [1] to

[19] , wherein the reducing agent is cysteine ​​and the concentration of the reducing agent is about 0.1 mM, about 0.15 mM, about 1.0 mM, about 10.0 mM or about 100 mM.

[0070]

[27] The method according to any one of [1] to

[19] , wherein the reducing agent is TCEP and the concentration of the reducing agent is about 0.001 mM, about 0.01 mM, about 0.1 mM or about 1.0 mM.

[0071]

[28] The method according to any one of [2] and [4] to

[27] , wherein the pH of the solution containing the reducing agent is about 4.5 to about 10.0, about 5.0 to about 9.0, about 6.5 to about 8.5, or about 7.0 to about 8.0.

[0072]

[29] The method according to any one of [2] and [4] to

[28] , wherein the pH of the solution containing the reducing agent is about 7.0, about 7.5 or about 8.0.

[0073]

[30] The method according to any one of [1] to

[29] , wherein the chromatography is column chromatography or membrane chromatography.

[0074]

[31] The method according to

[30] , wherein the solution containing the reducing agent is passed through a column for column chromatography or a device for membrane chromatography for a residence time of about 2 seconds to about 80 minutes or about 3 seconds to about 24 minutes, or the flow is temporarily stopped when the column or device is filled with the reducing agent.

[0075]

[32] The method according to

[30] or

[31] , wherein the solution containing the reducing agent is passed through a column for column chromatography or a device for membrane chromatography for a residence time of about 12 minutes or about 30 seconds, or the flow is temporarily stopped when the column or device is filled with the reducing agent.The flow is temporarily stopped when the solution containing the reducing agent is present.

[0076]

[33] The method according to any one of [2] and [4] to

[32] , wherein the mixture is contacted with the solution containing the reducing agent for about 6 seconds to about 1440 minutes, or about 18 seconds to about 300 minutes.

[0077]

[34] The method according to any one of [2] and [4] to

[33] , wherein the mixture is contacted with the solution containing the reducing agent for about 120 minutes or about 7.5 minutes.

[0078]

[35] The method according to any one of [1] to

[34] , wherein the removal of the reducing agent comprises contacting the antigen-binding molecule with a solution free of the reducing agent.

[0079]

[36] The method according to

[35] , wherein the chromatography is column chromatography or membrane chromatography, and wherein the contacting of the mixture with the solution free of the reducing agent comprises passing the solution free of the reducing agent through a column for column chromatography or a device for membrane chromatography.

[0080]

[37] The method according to

[35] or

[36] , wherein the solution without reducing agent is passed through a column for column chromatography or a device for membrane chromatography for a residence time of about 2 seconds to about 80 minutes or about 3 seconds to about 24 minutes, and optionally the flow is temporarily stopped when the column or device is filled with the solution.

[0081]

[38] The method according to any one of

[35] to

[37] , wherein the solution without reducing agent is passed through a column for column chromatography or a device for membrane chromatography for a residence time of about 4 minutes or about 30 seconds, and optionally the flow is temporarily stopped when the column or device is filled with the solution.

[0082]

[39] The method according to any one of

[35] to

[38] , wherein the mixture is contacted with the solution without the reducing agent for about 6 seconds to about 1440 minutes, or about 18 seconds to about 300 minutes.

[0083]

[40] The method according to any one of

[35] to

[39] , wherein the mixture is contacted with a solution free of the reducing agent for about 20 minutes or about 7.5 minutes.

[0084]

[41] The method according to any one of [1] to

[40] , wherein the mixture is contacted with a solution containing the reducing agent at about 4°C to about 37°C, preferably at about 15°C to about 37°C.

[0085]

[42] The method according to any one of [1] to

[41] , wherein the method further comprises: prior to step (a),

[0086] contacting the mixture with a chromatographic matrix, the mixture comprising:

[0087] An antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, and

[0088] an incorrect disulfide bond form and / or a non-disulfide bond form of the antigen-binding molecule;

[0089] to load the antigen-binding molecule onto a column for column chromatography or to immobilize the antigen-binding molecule onto a membrane for membrane chromatography.

[0090]

[43] The method according to any one of [1] to

[42] , wherein the method further comprises: removing impurities in the chromatogram prior to step (a).

[0091]

[44] The method according to any one of [1] to

[43] , wherein the method further comprises: recovering an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region before or after step (b).

[0092]

[45] The method according to any one of [1] to

[44] , wherein contact between the antigen-binding molecule and the solution containing the reducing agent results in the breaking of disulfide bonds formed between amino acid residues capable of forming disulfide bonds, and / or the decapping of sulfur atoms in the amino acid residues capable of forming disulfide bonds.

[0093]

[46] The method according to any one of [2] and [4] to

[45] , wherein the removal of the reducing agent results in the formation of disulfide bonds between amino acid residues capable of forming disulfide bonds.

[0094]

[47] The method according to any one of [1] to

[46] , wherein the amino acid residues capable of forming disulfide bonds are introduced or engineered as cysteine ​​residues.

[0095]

[48] The method according to any one of [1] to

[47] , wherein at least one disulfide bond in the region outside the hinge region is an interchain disulfide bond.

[0096]

[49] The method according to any one of [1] to

[48] , wherein at least one disulfide bond formed between amino acid residues in the region outside the hinge region is one, two, three, four or more interchain disulfide bonds.

[0097]

[50] The method according to any one of [1] to

[49] , wherein at least one disulfide bond formed between amino acid residues in the region outside the hinge region is an engineered disulfide bond not present in wild-type IgG.

[0098]

[51] The method according to any one of [1] to

[50] , the method being used to increase the ratio (LINC ratio) of antigen-binding molecules (LINC form) having at least one disulfide bond in the region outside the hinge region to the sum of the following:

[0099] (i) antigen-binding molecules (LINC form) having at least one disulfide bond formed between amino acid residues in the region outside the hinge region, and

[0100] (ii)Incorrect disulfide bonded form and / or non-disulfide bonded form (unLINC form) of antigen-binding molecules. Specification 6 / 122 page 13 CN 122249467 A

[0101]

[52] The method according to any one of [1] to

[51] is used to produce an antigen-binding molecule (LINC form) having at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% of the total of the following in a molar ratio:

[0102] (i) an antigen-binding molecule (LINC form) having at least one disulfide bond formed between amino acid residues in a region outside the hinge region and

[0103] (ii) an incorrect disulfide bonded form and / or non-disulfide bonded form (unLINC form) of antigen-binding molecules.

[0104] This disclosure also relates to the following inventions:

[0105] [A1] The method according to any one of [1] to

[52] , wherein the chromatography is column chromatography.

[0106] [A2] The method according to [A1], wherein the method comprises:

[0107] contacting a mixture with a chromatographic matrix, the mixture comprising:

[0108] an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, and

[0109] an incorrect disulfide bond form and / or a non-disulfide bond form of the antigen-binding molecule;

[0110] loading the chromatographic matrix into a column.

[0111] [A3] The method according to [A1] or [A2], wherein a solution containing a reducing agent is flowed through the column for a residence time of about 2 minutes to about 80 minutes, and optionally the flow is temporarily stopped when the column is filled with a solution containing the reducing agent.

[0112] [A4] The method according to any one of [A1] to [A3], wherein the solution containing the reducing agent is passed through the column for a residence time of about 4 minutes to about 24 minutes, and optionally the flow is temporarily stopped when the column is filled with the solution containing the reducing agent.

[0113] [A5] The method according to any one of [A1] to [A4], wherein the solution containing the reducing agent is passed through the column for a residence time of about 12 minutes, and optionally the flow is temporarily stopped when the column is filled with the solution containing the reducing agent.

[0114] [A6] The method according to any one of [A1] to [A5], wherein the solution containing the reducing agent is passed through the column for column chromatography at a rate of about 25 cm / h to about 500 cm / h, or about 50 cm / h to about 400 cm / h, and optionally the flow is temporarily stopped when the column is filled with the solution containing the reducing agent.

[0115] [A7] According to any one of [A1] to [A6], the solution containing the reducing agent is flowed through a column for column chromatography at a rate of about 100 cm / h, and optionally the flow is temporarily stopped when the column is filled with the solution containing the reducing agent.

[0116] [A8] According to any one of [A1] to [A7], the flow volume of the solution containing the reducing agent is about 0.1 times (about 0.1 CV (column volume)) to about 100 times (about 100 CV) of the column volume.

[0117] [A9] According to any one of [A1] to [A8], the flow volume of the solution containing the reducing agent is about 1 times (1 CV) to about 20 times (about 20 CV) of the column volume.

[0118] [A10] According to any one of [A1] to [A9], the flow volume of the solution containing the reducing agent is about 10.0 times the column volume (about 10.0 CV).

[0119] [A11] According to any one of [A1] to [A10], the mixture is contacted with the solution containing the reducing agent for about 4 minutes to about 1440 minutes.

[0120] [A12] According to any one of [A1] to [A11], the mixture is contacted with the solution containing the reducing agent for about 8 minutes to about 300 minutes. Specification 7 / 122 pages 14 CN 122249467 A

[0121] [A13] According to any one of [A1] to [A12], the mixture is contacted with the solution containing the reducing agent for about 120 minutes.

[0122] [A14] The method according to any one of [A1] to [A13], wherein the amount of antigen-binding molecules carried by the matrix is ​​about 5 g to about 80 g, about 7 g to about 50 g, or about 10 g to about 40 g per 1 L of matrix.

[0123] [A15] The method according to any one of [A1] to [A14], wherein a solution without reducing agent is passed through the column for a residence time of about 2 minutes to about 80 minutes, or the flow is temporarily stopped when the column is filled with the solution.

[0124] [A16] The method according to any one of [A1] to [A15], wherein a solution without reducing agent is passed through the column for a residence time of about 4 minutes to about 24 minutes, or the flow is temporarily stopped when the column is filled with the solution.

[0125] [A17] The method according to any one of [A1] to [A16], wherein a solution without reducing agent is passed through the column for a residence time of about 4 minutes to about 24 minutes, or the flow is temporarily stopped when the column is filled with the solution.The solution is passed through the column for a residence time of about 4 minutes, or the flow is temporarily stopped when the column is filled with the solution.

[0126] [A18] According to any one of [A1] to [A17], the solution without reducing agent is passed through the column for column chromatography at a rate of about 25 cm / h to about 500 cm / h, or about 50 cm / h to about 400 cm / h, or the flow is temporarily stopped when the column is filled with the solution.

[0127] [A19] According to any one of [A1] to [A18], the solution without reducing agent is passed through the column for column chromatography at a rate of about 300 cm / h, or the flow is temporarily stopped when the column is filled with the solution.

[0128] [A20] The method according to any one of [A1] to [A19], wherein the flow volume of the solution without reducing agent is from about 0.1 times (about 0.1 CV) to about 100 times (about 100 CV) of the column volume, or from about 1 times (about 1 CV) to about 20 times (about 20 CV) of the column volume.

[0129] [A21] The method according to any one of [A1] to [A20], wherein the flow volume of the solution without reducing agent is about 5.0 times (about 5.0 CV) of the column volume.

[0130] [A22] The method according to any one of [A1] to [A21], wherein the mixture is contacted with the solution without the reducing agent for about 4 minutes to about 1440 minutes.

[0131] [A23] The method according to any one of [A1] to [A22], wherein the mixture is contacted with a solution free of the reducing agent for about 8 minutes to about 300 minutes.

[0132] [A24] The method according to any one of [A1] to [A23], wherein the mixture is contacted with a solution free of the reducing agent for about 20 minutes.

[0133] This disclosure also relates to the following invention:

[0134] [B1] The method according to any one of [1] to

[52] , wherein the chromatography is membrane chromatography.

[0135] [B2] The method according to [B1], wherein the method comprises:

[0136] contacting a mixture with a chromatographic matrix, the mixture comprising:

[0137] an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, and

[0138] an incorrect disulfide bond form and / or a non-disulfide bond form of the antigen-binding molecule;

[0139] applying or immobilizing the chromatographic matrix onto a membrane for membrane chromatography.

[0140] [B3] According to [B1] or [B2]The method wherein a solution containing a reducing agent is allowed to flow through the membrane device for a residence time of about 2 seconds to about 60 minutes, or flow is temporarily stopped when the membrane device is filled with a solution containing the reducing agent.

[0141] [B4] The method according to any one of [B1] to [B3] wherein a solution containing a reducing agent is allowed to flow through the membrane device for a residence time of about 3 seconds to about 6 minutes, for example about 30 seconds, or flow is temporarily stopped when the membrane device is filled with a solution containing the reducing agent.

[0142] [B5] The method according to any one of [B1] to [B4] wherein the flow volume of the solution containing the reducing agent is about 1 times the volume of the membrane device (about 1 MV (membrane volume)) to about 500 times the volume of the membrane device (about 500 MV).

[0143] [B6] According to any one of [B1] to [B5], the flow volume of the solution containing the reducing agent is from about 2 times (about 2 MV) to about 100 times (about 100 MV) of the membrane device volume, for example, about 15 times (about 15 MV) of the membrane device volume.

[0144] [B7] According to any one of [B1] to [B6], wherein the mixture is contacted with the solution containing the reducing agent for about 6 seconds to about 600 minutes.

[0145] [B8] According to any one of [B1] to [B7], wherein the mixture is contacted with the solution containing the reducing agent for about 18 seconds to about 120 minutes, for example, about 7.5 minutes.

[0146] [B9] The method according to any one of [B1] to [B8], wherein the amount of antigen-binding molecules carried by the matrix is ​​about 5 g to about 100 g or about 7 g to about 70 g per 1 L membrane device volume, for example, about 25 g.

[0147] [B10] The method according to any one of [B1] to [B9], wherein a solution without reducing agent is passed through the membrane device for a residence time of about 2 seconds to about 60 minutes, or the flow is temporarily stopped when the membrane device is filled with the solution.

[0148] [B11] The method according to any one of [B1] to [B10], wherein a solution without reducing agent is passed through the membrane device for a residence time of about 3 seconds to about 6 minutes, for example, about 30 seconds, or the flow is temporarily stopped when the membrane device is filled with the solution.

[0149] [B12] According to any one of [B1] to [B11], the flow volume of the solution without reducing agent is about 1 times (about 1 mV) to about 1 / 2 of the membrane device volume.500 times (about 500 MV).

[0150] [B13] According to any one of [B1] to [B12], the flow volume of the solution without reducing agent is about 2 times (about 2 MV) to about 100 times (about 100 MV) of the membrane device volume, for example, about 15 times (about 15 MV) of the membrane device volume.

[0151] [B14] According to any one of [B1] to [B13], the mixture is contacted with the solution without the reducing agent for about 6 seconds to about 600 minutes.

[0152] [B15] According to any one of [B1] to [B14], the mixture is contacted with the solution without the reducing agent for about 18 seconds to about 120 minutes, for example, about 7.5 minutes.

[0153] This disclosure also relates to the following invention:

[0154]

[101]

[0155] A method for measuring, determining or quantifying the ratio (LINC ratio) of antigen-binding molecules in the form having at least one disulfide bond formed in a region outside the hinge region to the sum of antigen-binding molecules in the form of LINC and those in the form not having a disulfide bond formed in a region outside the hinge region, comprising the steps of:

[0156] (a) adding a protease to a composition (1) comprising the LINC and unLINC forms to prepare a composition (2); and

[0157] (b) subjecting the composition (2) to electrophoresis or chromatography.

[0158]

[102]

[0159] According to the method of

[101] , wherein the protease is an enzyme that does not digest the LINC form but is capable of digesting the unLINC form. Instructions for Use, Page 9 / 122, 16 CN 122249467 A

[0160]

[103]

[0161] The method according to

[101] or

[102] , wherein the protease is a cysteine ​​protease capable of digesting human IgG1 antibodies.

[0162]

[104]

[0163] The method according to any one of

[101] to

[103] , wherein the protease is an enzyme capable of cleaving the hinge region of human IgG1 antibodies.

[0164]

[105]

[0165] The method according to any one of

[101] to

[104] , wherein the protease is an enzyme that digests human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP.

[0166]

[106]

[0167] The method according to any one of

[101] to

[105] , wherein the protease is IgdE.

[0168]

[107]

[0169] The method according to

[106] , wherein IgdE is derived from Streptococcus agalactiae.

[0170]

[108]

[0171] The method according to

[106] or

[107] , wherein IgdE is a protein selected from the group consisting of the following (a) to (d):

[0172] (a) a protein comprising the amino acid sequence shown in SEQ ID NO: 61;

[0173] (b) a protein encoded by the base sequence shown in SEQ ID NO: 62;

[0174] (c) a protein comprising an amino acid sequence in which one or more amino acids are substituted, deleted, added and / or inserted relative to the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP; and

[0175] (d) comprising having at least 80% or more, 85% or more, 90% or more, 95% or more or 98% of the amino acid sequence shown in SEQ ID NO: 61. A protein with an amino acid sequence of or greater sequence identity, wherein the protein is capable of digesting human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP.

[0176]

[109]

[0177] The method according to any one of

[101] to

[108] , wherein the protease is FabALACTICA (registered trademark).

[0178]

[110]

[0179] According to any one of

[101] to

[109] ,

[0180] wherein step (a) further comprises obtaining a composition (3) containing a protease but not containing a LINC form and an unLINC form,

[0181] wherein step (b) performs non-reducing capillary SDS gel electrophoresis (CE-SDS) on each of the compositions (1) to (3) and obtains electrophoretic maps (1) to (3) of the compositions (1) to (3) respectively,

[0182] wherein electrophoretic map (1) includes: peaks originating from the unLINC form that has not been digested by the protease and peaks originating from the LINC form, and peaks that are neither originating from the unLINC form that has not been digested by the protease nor from the LINC form (peak Z),

[0183] wherein electrophoretic map (2) includes: peaks originating from the LINC form (peak L), peaks originating from the unLINC form that has been digested by the protease (peak unL), peaks originating from ...E), and peaks (peak Z) that are not derived from the unLINC form of protease digestion, nor from the LINC form, nor from the protease, and specification 10 / 122 page 17 CN 122249467 A

[0184] wherein the electrophoresis diagram (3) includes peaks (peak E) derived from the protease.

[0185]

[111]

[0186] The method according to

[110] further comprises:

[0187] (c) calculating the ratio (%) by the following formula (I);

[0188]

[0189] wherein,

[0190] A is the area value of peak L in electrophoresis (2),

[0191] B is the sum of the area values ​​of peak L, peak E and peak Z in electrophoresis (2),

[0192] C is the area value of peak Z in electrophoresis (1), and

[0193] D is the area value of peak E in electrophoresis (3).

[0194]

[112]

[0195] The method according to any one of

[101] to

[109] wherein step (b) performs hydrophobic interaction chromatography (HIC) on the composition (2) and obtains a chromatogram.

[0196]

[113]

[0197] The method according to

[112] further comprises:

[0198] (c) calculating the ratio (%) by the following formula (II);

[0199]

[0200] wherein,

[0201] A is the area value of the peak originating from the LINC form in the chromatogram; and

[0202] B is the sum of the area values ​​of all peaks originating from the unLINC form after protease digestion in the chromatogram.

[0203] This disclosure also relates to the following invention:

[0204]

[201] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15] and

[101] to

[113] , wherein the antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain that can be linked to each other via at least one disulfide bond.

[0205]

[202] According to the method of

[201] , wherein the first antigen-binding domain and the second antigen-binding domain each comprise a Fab, Fab', scFab, Fv, scFv, or VHH structure.

[0206]

[203] According to the method of

[201] or

[202] , wherein the first antigen-binding domain and the second antigen-binding domain each comprise or do not comprise a hinge region.

[0207]

[204] According to the method of any one of

[201] to

[203] , wherein the first antigen-binding domain and the second antigen-binding domain each comprise a structure forming a hinge region.The Fab and hinge regions of the F(ab')2 structure.

[0208]

[205] According to any one of

[201] to

[204] , wherein the first antigen-binding domain and the second antigen-binding domain both bind to the same antigen.

[0209]

[206] According to any one of

[201] to

[205] , wherein the first antigen-binding domain and the second antigen-binding domain both bind to the same epitope on the same antigen.

[0210]

[207] According to any one of

[201] to

[205] , wherein each of the first antigen-binding domain and the second antigen-binding domain binds to a different epitope on the same antigen.

[0211]

[208] According to any one of

[201] to

[204] , wherein each of the first antigen-binding domain and the second antigen-binding domain binds to a different antigen.

[0212]

[209] According to any one of

[201] to

[206] , wherein the first antigen-binding domain and the second antigen-binding domain both have the same amino acid sequence.

[0213]

[210] According to any one of

[201] to

[208] , wherein each of the first antigen-binding domain and the second antigen-binding domain has a different amino acid sequence.

[0214]

[211] According to any one of

[201] to

[210] , wherein at least one of the first antigen-binding domain and the second antigen-binding domain binds to a soluble protein.

[0215]

[212] According to any one of

[201] to

[211] , wherein at least one of the first antigen-binding domain and the second antigen-binding domain binds to a membrane protein.

[0216]

[213] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] and

[201] to

[212] , wherein the antigen-binding molecule has activity of regulating the interaction between two antigen molecules.

[0217]

[214] The method according to any one of

[201] to

[204] , wherein the first antigen-binding domain and the second antigen-binding domain bind to a ligand and its receptor, respectively, and wherein the antigen-binding molecule has activity of promoting ligand-mediated receptor activation.

[0218]

[215] The method according to any one of

[201] to

[204] , wherein the first antigen-binding domain...The first antigen-binding domain and the second antigen-binding domain bind to the enzyme and its substrate, respectively, and wherein the antigen-binding molecule has activity that promotes the catalytic reaction between the enzyme and the substrate.

[0219]

[216] According to any one of

[201] to

[204] , wherein both the first antigen-binding domain and the second antigen-binding domain bind to proteins (first antigen and second antigen, respectively) present on the surface of the cell, and wherein the antigen-binding molecule has activity that promotes the interaction between the cell expressing the first antigen and the cell expressing the second antigen.

[0220]

[217] According to the method of

[216] , wherein the cell expressing the first antigen is a cell with cytotoxic activity, and the cell expressing the second antigen is its target cell, and wherein the antigen-binding molecule promotes damage to the target cell by the cell with cytotoxic activity.

[0221]

[218] According to the method of

[217] , wherein the cell with cytotoxic activity is a T cell, NK cell, monocyte, or macrophage.

[0222]

[219] The method according to any one of

[205] to

[218] , wherein the antigen is selected from the group consisting of: receptors belonging to the cytokine receptor superfamily, G protein-coupled receptors, ion channel receptors, tyrosine kinase receptors, immune checkpoint receptors, antigen receptors, CD antigens, co-stimulatory molecules, and cell adhesion molecules.

[0223]

[220] The method according to any one of

[201] to

[204] , wherein the first antigen-binding domain and the second antigen-binding domain are each capable of binding to CD3 and / or CD137.

[0224]

[221] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] , and

[201] to

[220] , wherein the antigen-binding molecule further comprises a third antigen-binding domain.

[0225]

[222] According to any one of

[201] to

[221] , wherein the third antigen-binding domain is fused with either the first antigen-binding domain or the second antigen-binding domain.

[0226]

[223] According to the method of

[221] or

[222] , wherein the third antigen-binding domain is Fab or scFv. Specification 12 / 122 pages 19 CN 122249467 A

[0227]

[224] According to any one of

[202] to

[223] , wherein the third antigen-binding domain is in its COptionally, the terminal portion is fused via a peptide linker to the N-terminus of the Fab heavy chain (VH region) of either the first antigen-binding domain or the second antigen-binding domain.

[0228]

[225] According to any one of

[221] to

[224] , wherein the first antigen-binding domain, the second antigen-binding domain and the third antigen-binding domain are each Fab molecules, wherein the third antigen-binding domain is optionally fused via a peptide linker to the N-terminus of the Fab heavy chain (VH region) of either the first antigen-binding domain or the second antigen-binding domain at the C-terminus of its Fab heavy chain (CH1 region).

[0229]

[226] According to the method of

[224] or

[225] , wherein the peptide linker comprises an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20.

[0230]

[227] According to any one of

[221] to

[226] , wherein the third antigen-binding domain is a cross-Fab molecule in which the variable regions of the Fab light chain and the Fab heavy chain are exchanged, and wherein the first antigen-binding domain and the second antigen-binding domain are conventional Fab molecules.

[0231]

[228] According to any one of

[221] to

[227] , wherein the third antigen-binding domain is capable of binding to an antigen expressed on a cancer cell or cancer tissue.

[0232]

[229] According to any one of

[221] to

[228] , wherein the third antigen-binding domain is capable of binding to DLL3, preferably human DLL3.

[0233]

[230] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] and

[201] to

[229] , wherein the antigen-binding molecule further comprises an Fc region.

[0234]

[231] The method according to

[230] , wherein the Fc region is composed of a first Fc region subunit and a second Fc region subunit that can stably associate with each other.

[0235]

[232] The method according to

[231] , wherein the first antigen-binding domain and the second antigen-binding domain are Fab, wherein the first antigen-binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of either the first Fc region subunit or the second Fc region subunit of the Fc region, and wherein the second antigen-binding domain is fused at the C-terminus of the other Fc region subunit to the N-terminus of the Fab heavy chain.Terminal fusion.

[0236]

[233] The method according to any one of

[230] to

[232] , wherein the Fc region is derived from human.

[0237]

[234] The method according to any one of

[230] to

[233] , wherein the Fc region is an IgG Fc region, preferably a human IgG Fc region, or more preferably a human IgG1 Fc region.

[0238]

[235] The method according to any one of

[230] to

[234] , wherein the Fc region exhibits reduced binding affinity for human Fcγ receptors compared to the natural human IgG1 Fc region.

[0239]

[236] The method according to any one of

[230] to

[235] , wherein the Fc region exhibits enhanced FcRn binding activity under acidic pH conditions (e.g., pH 5.8) compared to the natural IgG Fc region.

[0240]

[237] The method according to any one of

[230] to

[236] , wherein the Fc region comprises: Ala at position 434; Glu, Arg, Ser or Lys at position 438; and Glu, Asp or Gln at position 440, according to EU number.

[0241]

[238] The method according to any one of

[230] to

[237] , wherein the Fc region comprises: Ala at position 434; Arg or Lys at position 438; and Glu or Asp at position 440, according to EU number.

[0242]

[239] The method according to any one of

[230] to

[238] , wherein the Fc region further comprises: Ile or Leu at position 428; and / or Ile, Leu, Val, Thr or Phe at position 436, according to EU specification 13 / 122 page 20 CN 122249467 A.

[0243]

[240] The method according to any one of

[230] to

[239] , wherein the Fc region comprises a combination of amino acid substitutions selected from the group consisting of:

[0244] (a) N434A / Q438R / S440E;

[0245] (b) N434A / Q438R / S440D;

[0246] (c) N434A / Q438K / S440E;

[0247] (d) N434A / Q438K / S440D;

[0248] (e) N434A / Y436T / Q438R / S440E;

[0249] (f) N434A / Y436T / Q438R / S440D;

[0250] (g) N434A / Y436T / Q438K / S440E;

[0251] (h) N434A / Y436T / Q438K / S440D;

[0252] (i) N434A / Y436V / Q438R / S440E;

[0253] (j) N434A / Y436V / Q438R / S440D;

[0254] (k) N434A / Y436V / Q438K / S440E;

[0255] (l) N434A / Y436V / Q438K / S440D;

[0256] (m) N434A / R435H / F436T / Q438R / S440E;

[0257] (n) N434A / R435H / F436T / Q438R / S440D;

[0258] (o) N434A / R435H / F436T / Q438K / S440E;

[0259] (p) N434A / R435H / F436T / Q438K / S440D;

[0260] (q) N434A / R435H / F436V / Q438R / S440E;

[0261] (r) N434A / R435H / F436V / Q438R / S440D;

[0262] (s) N434A / R435H / F436V / Q438K / S440E;

[0263] (t) N434A / R435H / F436V / Q438K / S440D;

[0264] (u) M428L / N434A / Q438R / S440E;

[0265] (v) M428L / N434A / Q438R / S440D;

[0266] (w) M428L / N434A / Q438K / S440E;

[0267] (x) M428L / N434A / Q438K / S440D;

[0268] (y) M428L / N434A / Y436T / Q438R / S440E;

[0269] (z) M428L / N434A / Y436T / Q438R / S440D;

[0270] (aa) M428L / N434A / Y436T / Q438K / S440E;

[0271] (ab) M428L / N434A / Y436T / Q438K / S440D;

[0272] (ac) M428L / N434A / Y436V / Q438R / S440E;

[0273] (ad) M428L / N434A / Y436V / Q438R / S440D;

[0274] (ae) M428L / N434A / Y436V / Q438K / S440E;

[0275] (af) M428L / N434A / Y436V / Q438K / S440D;

[0276] (ag) L235R / G236R / S239K / M428L / N434A / Y436T / Q438R / S440E; and

[0277] (ah) L235R / G236R / A327G / A330S / P331S / M428L / N434A / Y436T / Q438R / S440E,

[0278] according to EU number.

[0279]

[241] The method according to any one of

[230] to

[236] , wherein the Fc region comprises a combination of amino acid substitutions (see specification page 14 / 122, 21 CN 122249467 A M428L / N434A / Q438R / S440E).

[0280]

[242] The method according to any one of

[230] to

[241] , wherein the Fc region comprises a combination of one or more amino acid substitutions that promote Fc region polymerization.

[0281]

[243] According to the method of

[242] , the amino acid substitution promoting polymerization comprises an amino acid substitution at at least one position selected from the group consisting of: EU number positions 247, 248, 253, 254, 310, 311, 338, 345, 356, 359, 382, ​​385, 386, 430, 433, 434, 436, 437, 438, 439, 440 and 447.

[0282]

[244] According to the method of

[242] or

[243] , the polymerization is hexamerization.

[0283]

[245] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] and

[201] to

[244] , wherein the antigen-binding molecule comprises an amino acid residue resulting from the substitution of at least one cysteine ​​residue in its hinge region.

[0284]

[246] The method according to

[245] , wherein the cysteine ​​residue is present at EU number position 226 and / or position 229 in the hinge region.

[0285]

[247] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] and

[201] to

[246] , wherein the antigen-binding molecule is a multispecific antigen-binding molecule.

[0286]

[248] According to the method of

[247] , the multispecific antigen-binding molecule is a bispecific antigen-binding molecule or a trispecific antigen-binding molecule.

[0287]

[249] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] and

[201] to

[248] , wherein the antigen-binding molecule is an antibody.

[0288]

[250] The method according to

[249] , wherein the antibody is an IgG antibody, preferably an IgG1, IgG2, IgG3 or IgG4 antibody.

[0289]

[251] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] and

[201] to

[250] , wherein the antigen-binding molecule has the amino acid sequence KSCDKTHTCPPCP in its hinge region.

[0290]

[252] The method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] and

[201] to

[251] , wherein the antigen-binding molecule comprises an amino acid substitution of a cysteine ​​residue at one or more positions selected from the group consisting of EU number positions 119-123, 131-140, 148-150, 155-167, 174-178, 188-197, 201-214 and 218-219.

[0291] This disclosure also relates to the following invention:

[0292]

[301] The method according to any one of

[201] to

[252] , wherein at least one disulfide bond is formed between amino acid residues present at the same position in the first antigen-binding domain and the second antigen-binding domain.

[0293]

[302] According to any one of

[201] to

[252] , at least one disulfide bond is formed between amino acid residues present at different positions in the first antigen-binding domain and the second antigen-binding domain.

[0294]

[303] According to any one of

[201] to

[252] ,

[301] and

[302] , at least one disulfide bond is formed between the heavy chain of the first antigen-binding domain and the heavy chain of the second antigen-binding domain, between the light chain of the first antigen-binding domain and the light chain of the second antigen-binding domain, or between any combination of the CH1 region, CL region, VL region, VH region or VHH region of the first antigen-binding domain and the CH1 region, CL region, VL region, VH region or VHH region of the second antigen-binding domain.

[0295]

[304] According to the method of

[303] , at least one disulfide bond is formed in the CH1 region of the first antigen-binding domain and the second antigen-binding domain.Between the CH1 regions. Specification 15 / 122 pages 22 CN 122249467 A

[0296]

[305] According to the method of

[304] , the positions of the amino acid residues in the CH1 regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 119 to 123, 131 to 140, 148 to 150, 155 to 167, 174 to 178, 188 to 197, 201 to 214, and 218 to 219.

[0297]

[306] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 119, 122, 123, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 148, 150, 155, 156, 157, 159, 160, 161, 162, 163, 164, 165, 167, 174, 176, 177, 178, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 201, 203, 205, 206, 207, 208, 211, 212, 213, 214, 218, and 219.

[0298]

[307] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 134, 135, 136, 137, 191, 192, 193, 194, 195, 196, and 197.

[0299]

[308] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 135, 136, and 191.

[0300]

[309] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 119, 120, 121, 122 and 123.

[0301]

[310] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions131, 132, 133, 134, 135, 136, 137, 138, 139 and 140.

[0302]

[311] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 148, 149 and 150.

[0303]

[312] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166 and 167.

[0304]

[313] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 174, 175, 176, 177 and 178.

[0305]

[314] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 188, 189, 190, 191, 192, 193, 194, 195, 196 and 197.

[0306]

[315] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213 and 214.

[0307]

[316] According to the method of

[304] , the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: EU number positions 218 and 219. Specification 16 / 122 pages 23 CN 122249467 A

[0308]

[317] The method according to any one of

[304] to

[316] , wherein the positions of the amino acid residues in the CH1 region of the first antigen-binding domain and the second antigen-binding domain differ by 3 amino acids or less.

[0309]

[318] The method according to

[304] , wherein the amino acid residues in the CH1 region of the first antigen-binding domain are EU number position 135.The amino acid residues in the CH1 region of the first antigen-binding domain are amino acid residues at any of EU number positions 132 to 138.

[0310]

[319] According to the method of

[304] , the amino acid residues in the CH1 region of the first antigen-binding domain are amino acid residues at EU number position 136, and the amino acid residues in the CH1 region of the second antigen-binding domain are amino acid residues at any of EU number positions 133 to 139.

[0311]

[320] According to the method of

[304] , the amino acid residues in the CH1 region of the first antigen-binding domain are amino acid residues at EU number position 191, and the amino acid residues in the CH1 region of the second antigen-binding domain are amino acid residues at any of EU number positions 188 to 194.

[0312]

[321] According to the method of

[304] , the amino acid residue in the CH1 region of the first antigen-binding domain is the amino acid residue at EU number position 135, and the amino acid residue in the CH1 region of the second antigen-binding domain is the amino acid residue at EU number position 135.

[0313]

[322] According to the method of

[304] , the amino acid residue in the CH1 region of the first antigen-binding domain is the amino acid residue at EU number position 136, and the amino acid residue in the CH1 region of the second antigen-binding domain is the amino acid residue at EU number position 136.

[0314]

[323] According to the method of

[304] , wherein

[0315] (i) the amino acid residue in the CH1 region of the first antigen-binding domain is the amino acid residue at EU number position 191, and the amino acid residue in the CH1 region of the second antigen-binding domain is the amino acid residue at EU number position 191,

[0316] (ii) the amino acid residue in the CH1 region of the first antigen-binding domain is the amino acid residue at EU number position 195, and the amino acid residue in the CH1 region of the second antigen-binding domain is the amino acid residue at EU number position 195, or

[0317] (iii) the amino acid residue in the CH1 region of the first antigen-binding domain is the amino acid residue at EU number position 197, and the amino acid residue in the CH1 region of the second antigen-binding domain is the amino acid residue at EU number position 197.

[0318]

[324] The method according to any one of

[304] to

[323] , wherein the subclass of the CH1 region is γ1, γ2. γ3, γ4, α1, α2, μ, δ or ε.

[0319]

[325] The method according to any one of

[201] to

[252] and

[301] to

[324] , wherein the antigen-binding molecule comprises one, two or more additional disulfide bonds between the first antigen-binding domain and the second antigen-binding domain, wherein the additional disulfide bonds are formed via amino acid residues at the following positions according to EU numbers in the CH1 regions of each of the first and second antigen-binding domains:

[0320] (a) between amino acid residues at any of positions 131 to 138, 194 and 195 in each of the two antigen-binding domains;

[0321] (b) between amino acid residues at position 131 in each of the two antigen-binding domains and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0322] (c) between amino acid residues at position 132 in each of the two antigen-binding domains and between amino acid residues at position 194 in each of the two antigen-binding domains. Between amino acid residues at position 133 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0323] (d) Between amino acid residues at position 133 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0324] (e) Between amino acid residues at position 134 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0325] (f) Between amino acid residues at position 135 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0326] (g) Between amino acid residues at position 136 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0327] (h) Between amino acid residues at position 137 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0328] (i) between amino acid residues at position 138 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;

[0329] (j) between amino acid residues at position 131 in each of the two antigen-binding domains, and between amino acid residues at position 137 in each of the two antigen-binding domains, and between amino acid residues at position 194 in each of the two antigen-binding domains;Between amino acid residues at position 195 in each of the two antigen-binding domains;

[0330] (k) Between amino acid residues at position 132 in each of the two antigen-binding domains and between amino acid residues at position 195 in each of the two antigen-binding domains;

[0331] (l) Between amino acid residues at position 133 in each of the two antigen-binding domains and between amino acid residues at position 195 in each of the two antigen-binding domains;

[0332] (m) Between amino acid residues at position 134 in each of the two antigen-binding domains and between amino acid residues at position 195 in each of the two antigen-binding domains;

[0333] (n) Between amino acid residues at position 135 in each of the two antigen-binding domains and between amino acid residues at position 195 in each of the two antigen-binding domains;

[0334] (o) Between amino acid residues at position 136 in each of the two antigen-binding domains Between amino acid residues at position 137 and between amino acid residues at position 195 in each of the two antigen-binding domains;

[0335] (p) Between amino acid residues at position 137 and between amino acid residues at position 195 in each of the two antigen-binding domains; and

[0336] (q) Between amino acid residues at position 138 and between amino acid residues at position 195 in each of the two antigen-binding domains.

[0337]

[326] The method according to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain contains one, two or more charged amino acid residues at EU number positions 136 to 138 in the CH1 region; and the other of the first antigen-binding domain and the second antigen-binding domain contains one, two or more amino acid residues with opposite charges at EU number positions 193 to 195 in the CH1 region.

[0338]

[327] The method according to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain comprises one, two or more positively charged amino acid residues at EU number positions 136 to 138 in the CH1 region; and the other of the first antigen-binding domain and the second antigen-binding domain comprises one, two or more positively charged amino acid residues at EU number positions 193 to 198 in the CH1 region.Position 195 contains one, two or more negatively charged amino acid residues.

[0339]

[328] According to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain contains one, two or more negatively charged amino acid residues at EU number positions 136 to 138 in the CH1 region; and the other of the first antigen-binding domain and the second antigen-binding domain contains one, two or more positively charged amino acid residues at EU number positions 193 to 195 in the CH1 region.

[0340]

[329] The method according to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain contains one, two or more of the following amino acid residues in the CH1 region:

[0341] (a) the amino acid residue at EU number position 136 is glutamic acid (E) or aspartic acid (D);

[0342] (b) the amino acid residue at EU number position 137 is glutamic acid (E) or aspartic acid (D); and

[0343] (c) the amino acid residue at EU number position 138 is glutamic acid (E) or aspartic acid (D);

[0344] and wherein the other of the first antigen-binding domain and the second antigen-binding domain contains one, two or more of the following amino acid residues in the CH1 region:

[0345] (d) the amino acid residue at EU number position 193 is lysine (K) or arginine (R). Or histidine (H);

[0346] (e) The amino acid residue at EU position 194 is lysine (K), arginine (R) or histidine (H); and

[0347] (f) The amino acid residue at EU position 195 is lysine (K), arginine (R) or histidine (H).

[0348]

[330] According to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain contains one, two or more of the following amino acid residues in the CH1 region:

[0349] (a) The amino acid residue at EU position 136 is lysine (K), arginine (R) or histidine (H);

[0350] (b) The amino acid residue at EU position 137 is lysine (K), arginine (R)Or histidine (H); and

[0351] (c) the amino acid residue at EU number position 138 is lysine (K), arginine (R) or histidine (H);

[0352] and wherein the other of the first antigen-binding domain and the second antigen-binding domain contains one, two or more of the following amino acid residues in the CH1 region:

[0353] (d) the amino acid residue at EU number position 193 is glutamic acid (E) or aspartic acid (D);

[0354] (e) the amino acid residue at EU number position 194 is glutamic acid (E) or aspartic acid (D); and

[0355] (f) the amino acid residue at EU number position 195 is glutamic acid (E) or aspartic acid (D).

[0356]

[331] The method according to any one of

[201] to

[252] ,

[301] to

[324] , wherein each of the first antigen-binding domain and the second antigen-binding domain comprises any one of the combinations of specific charged amino acids (according to EU numbers) in the CH1 region as shown in Tables 1, 2 or 3.

[0357]

[332] The method according to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain comprises one, two or more hydrophobic amino acid residues at EU number positions 136 to 138 in the CH1 region; and the other of the first antigen-binding domain and the second antigen-binding domain comprises one, two or more hydrophobic amino acid residues at EU number positions 193 to 195 in the CH1 region.

[0358]

[333] According to the method of

[332] , wherein the hydrophobic amino acid residue is alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), and / or tryptophan (Trp).

[0359]

[334] According to the method of any one of

[201] to

[252] and

[301] to

[324] , wherein each of the first antigen-binding domain and the second antigen-binding domain comprises any one of a combination of specific hydrophobic amino acids (according to EU numbers) in the CH1 region as shown in Table 4.

[0360]

[335] According to the method of any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain is at EU number position 136 in the CH1 region.The first antigen-binding domain contains one "pepper" amino acid residue at position 138; and the other of the first antigen-binding domain and the second antigen-binding domain contains one, two or more "pepper" amino acid residues at EU number positions 193 to 195 in the CH1 region.

[0361]

[336] According to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain contains one, two or more "pepper" amino acid residues at EU number positions 136 to 138 in the CH1 region; and the other of the first antigen-binding domain and the second antigen-binding domain contains one "pepper" amino acid residue at EU number positions 193 to 195 in the CH1 region.

[0362]

[337] According to the method of

[336] , the "pound" amino acid residue is selected from the group consisting of tryptophan (Trp) and phenylalanine (Phe); and the "mortar" amino acid residue is selected from the group consisting of alanine (Ala), valine (Val), threonine (Thr) and serine (Ser).

[0363]

[338] According to the method of any one of

[201] to

[252] and

[301] to

[324] , either the first antigen-binding domain or the second antigen-binding domain contains one, two or more aromatic amino acid residues at EU number positions 136 to 138 in the CH1 region; and the other of the first antigen-binding domain and the second antigen-binding domain contains one, two or more positively charged amino acid residues at EU number positions 193 to 195 in the CH1 region.

[0364]

[339] According to any one of

[201] to

[252] and

[301] to

[324] , wherein either the first antigen-binding domain or the second antigen-binding domain contains one, two or more positively charged amino acid residues at EU number positions 136 to 138 in the CH1 region; and the other of the first antigen-binding domain and the second antigen-binding domain contains one, two or more aromatic amino acid residues at EU number positions 193 to 195 in the CH1 region.

[0365]

[340] According to any one of

[201] to

[252] and

[301] to

[324] , wherein the aromatic amino acid residues are selected from the group consisting of tryptophan (Trp), tyrosine (Tyr), histidine (His) and phenylalanine (Phe); and the positively charged amino acid residues are selected from lysine (Lys) and arginine.The group consisting of (Arg) and histidine (His).

[0366]

[341] According to the method of

[303] , at least one disulfide bond is formed between the CL region of the first antigen-binding domain and the CL region of the second antigen-binding domain.

[0367]

[342] According to the method of

[341] , the positions of the amino acid residues in the CL regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 108 to 112, 121 to 128, 151 to 156, 184 to 190, 195 to 196, 200 to 203, and 208 to 213. Instruction manual 20 / 122 page 27 CN 122249467 A

[0368]

[343] According to the method of

[341] , the positions of the amino acid residues in the CL region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 108, 109, 112, 121, 123, 126, 128, 151, 152, 153, 156, 184, 186, 188, 189, 190, 195, 196, 200, 201, 202, 203, 208, 210, 211, 212 and 213.

[0369]

[344] According to the method of

[341] , the positions of the amino acid residues in the CL regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 108, 109, 110, 111 and 112.

[0370]

[345] According to the method of

[341] , the positions of the amino acid residues in the CL regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 121, 122, 123, 124, 125, 126, 127 and 128.

[0371]

[346] According to the method of

[341] , the positions of the amino acid residues in the CL regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 151, 152, 153, 154, 155 and 156.

[0372]

[347] According to the method of

[341] , the positions of the amino acid residues in the CL region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 184, 185, 186, 187, 188, 189 and 190.

[0373]

[348] According to the method of

[341] , the positions of the amino acid residues in the CL regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 195 and 196.

[0374]

[349] According to the method of

[341] , the positions of the amino acid residues in the CL regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 200, 201, 202 and 203.

[0375]

[350] According to the method of

[341] , the positions of the amino acid residues in the CL regions of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 208, 209, 210, 211, 212 and 213.

[0376]

[351] According to any one of

[341] to

[350] , the amino acid residues in the CL region of the first antigen-binding domain and the second antigen-binding domain differ in position by 3 amino acids or less.

[0377]

[352] According to the method of

[341] , the amino acid residues in the CL region of the first antigen-binding domain are the amino acid residues at Kabat number position 126, and the amino acid residues in the CL region of the second antigen-binding domain are the amino acid residues at Kabat number position 126.

[0378]

[353] According to the method of

[303] , at least one disulfide bond is formed between the amino acid residues in the CH1 region of the first antigen-binding domain and the amino acid residues in the CL region of the second antigen-binding domain.

[0379]

[354] According to the method of

[353] , the position of the amino acid residue in the CH1 region is selected from the group consisting of EU number positions 188, 189, 190, 191, 192, 193, 194, 195, 196 and 197, and the position of the amino acid residue in the CL region is selected from the group consisting of Kabat number positions 121, 122, 123, 124, 125, 126, 127 and 128.

[0380]

[355] According to the method of

[353] , the amino acid residue in the CH1 region is the amino acid residue at EU number position 191, and the amino acid residue in the CL region is the amino acid residue at Kabat number position 126. Instruction manual, pages 21 / 122, CN 122249467 A

[0381]

[356] according to

[201] to

[252] and

[301] to

[324] The method according to any one of the following, wherein each of the first antigen-binding domain and the second antigen-binding domain independently contains lysine (K), arginine (R), or histidine (H) at Kabat number positions 123 and / or 124 in the CL region, and independently contains glutamic acid (E) or aspartic acid (D) at EU number positions 147 and / or 213 in the CH1 region.

[0382]

[357] The method according to

[355] , wherein each of the first antigen-binding domain and the second antigen-binding domain contains arginine (R) and lysine (K) at Kabat number positions 123 and 124 in the CL region, respectively, and contains glutamic acid (E) at EU number positions 147 and 213 in the CH1 region.

[0383]

[358] The method according to any one of

[341] to

[357] , wherein the subclass of the CL region is κ or λ.

[0384]

[359] According to the method of

[303] , at least one disulfide bond is formed between an amino acid residue in the VH region of the first antigen-binding domain and an amino acid residue in the VH region of the second antigen-binding domain.

[0385]

[360] According to the method of

[359] , the positions of the amino acid residues in the VH regions of the first and second antigen-binding domains are each independently selected from the group consisting of: EU number positions 6, 8, 16, 20, 25, 26, 28, 74 and 82b.

[0386]

[361] According to the method of

[303] , at least one disulfide bond is formed between an amino acid residue in the VL region of the first antigen-binding domain and an amino acid residue in the VL region of the second antigen-binding domain.

[0387]

[362] According to the method of

[361] , the positions of the amino acid residues in the VL region (κ subclass) of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 21, 27, 58, 77, 100, 105 and 107.

[0388]

[363] According to the method of

[361] , the positions of the amino acid residues in the VL region (λ subclass) of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 6, 19, 33 and 34.

[0389]

[364] According to the method of

[303] , at least one disulfide bond is formed between the amino acid residue in the VHH region of the first antigen-binding domain and the VHH region of the second antigen-binding domain.Between amino acid residues in the region.

[0390]

[365] According to the method of

[364] , the positions of amino acid residues in the VHH region of the first antigen-binding domain and the second antigen-binding domain are each independently selected from the group consisting of: Kabat number positions 4, 6, 7, 8, 9, 10, 11, 12, 14, 15, 17, 20, 24, 27, 29, 38, 39, 40, 41, 43, 44, 45, 46, 47, 48, 49, 67, 69, 71, 78, 80, 82, 82c, 85, 88, 91, 93, 94 and 107.

[0391] This disclosure also relates to the following invention:

[0392]

[401] A method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[101] to

[113] ,

[201] to

[252] and

[301] to

[365] , wherein the antigen-binding molecule comprises:

[0393] a first antigen-binding domain and a second antigen-binding domain capable of binding to CD3 and CD137 but not simultaneously to CD3 and CD137, and

[0394] a third antigen-binding domain capable of binding to DLL3, preferably human DLL3.

[0395]

[402] According to the method of

[401] , wherein the first antigen-binding domain and the second antigen-binding domain each comprise antibody variable regions that may be the same as or different from each other, and comprise antibody variable regions independently selected from the group consisting of (a1) to (a4):

[0396] (a1) comprising antibody variable regions comprising:

[0397] a heavy chain variable region comprising: Specification 22 / 122 page 29 CN 122249467 A

[0398] a heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 27,

[0399] a heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 28, and

[0400] a heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 29; and

[0401] a light chain variable region comprising:

[0402] a light chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 29 The amino acid sequence of SEQ ID NO: 30,

[0403] light chain CDR 2, which comprises the amino acid sequence of SEQ ID NO: 31, and

[0404] light chain CDR 3, which comprises the amino acid sequence of SEQ ID NO: 32;

[0405] (a2) comprising the antibody variable region of:

[0406] heavy chain variable region, which comprises:

[0407] heavy chain complementarity-determining region (CDR)1, comprising the amino acid sequence of SEQ ID NO: 33,

[0408] heavy chain CDR 2, comprising the amino acid sequence of SEQ ID NO: 34, and

[0409] heavy chain CDR 3, comprising the amino acid sequence of SEQ ID NO: 35; and

[0410] light chain variable region, comprising:

[0411] light chain CDR 1, comprising the amino acid sequence of SEQ ID NO: 30,

[0412] light chain CDR 2, comprising the amino acid sequence of SEQ ID NO: 31, and

[0413] light chain CDR 3, comprising the amino acid sequence of SEQ ID NO: 32;

[0414] (a3) ​​an antibody variable region that binds to the same epitope as the antibody variable region bound to (a1) or (a2); and

[0415] (a4) an antibody variable region that binds to (a1) or (a2). The antibody variable region competes with the antigen for binding to the antibody variable region.

[0416]

[403] According to the method of

[401] or

[402] , wherein the first antigen-binding domain and the second antigen-binding domain each comprise antibody variable regions that may be the same as or different from each other, and comprise antibody variable regions independently selected from the group consisting of (a1) to (a4):

[0417] (a1) comprising antibody variable regions comprising:

[0418] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36, and

[0419] a light chain variable region comprising the amino acid sequence of SEQ ID NO: 37; and

[0420] (a2) comprising antibody variable regions comprising:

[0421] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 38, and

[0422] a light chain variable region comprising the amino acid sequence of SEQ ID NO: 37;

[0423] (a3) ​​and (a1) or (a2) The antibody variable region of the antibody is bound to the same epitope as the antibody variable region of the antibody; and

[0424] (a4) the antibody variable region of ...CDR 2, comprising the amino acid sequence of SEQ ID NO: 47, and

[0430] heavy chain CDR 3, comprising the amino acid sequence of SEQ ID NO: 48; and

[0431] light chain variable region, comprising: Specification 23 / 122 page 30 CN 122249467 A

[0432] light chain CDR 1, comprising the amino acid sequence of SEQ ID NO: 49,

[0433] light chain CDR 2, comprising the amino acid sequence of SEQ ID NO: 50, and

[0434] light chain CDR 3, comprising the amino acid sequence of SEQ ID NO: 51;

[0435] (a2) comprising the following antibody variable region:

[0436] heavy chain variable region, comprising the amino acid sequence of SEQ ID NO: 52, and

[0437] light chain variable region, comprising the amino acid sequence of SEQ ID NO: 53;

[0438] (a3) ​​An antibody variable region that binds to the same epitope as the antibody variable region of (a1) or (a2); and

[0439] (a4) An antibody variable region that competes with the antibody variable region of (a1) or (a2) for binding to the antigen.

[0440]

[405] The method according to any one of

[401] to

[404] , wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising:

[0441] a heavy chain variable region comprising:

[0442] a heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 27,

[0443] a heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 28, and

[0444] a heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 29; and

[0445] a light chain variable region comprising:

[0446] a light chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 30,

[0447] a light chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 31, and

[0448] a light chain CDR 3. 3, which contains the amino acid sequence of SEQ ID NO: 32.

[0449]

[406] According to any one of

[401] to

[405] , wherein the first antigen-binding domain and the second antigen-binding domain each contain an antibody variable region, the antibody variable region comprising:

[0450] a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 36, and

[0451] a light chain variable region containing the amino acid sequence of SEQ ID NO: 32.The amino acid sequence of ID NO: 37.

[0452]

[407] The method according to any one of

[401] to

[406] , wherein the third antigen-binding domain comprises an antibody variable region, the antibody variable region comprising:

[0453] a heavy chain variable region comprising:

[0454] a heavy chain complementarity-determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO: 46,

[0455] a heavy chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 47, and

[0456] a heavy chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 48; and

[0457] a light chain variable region comprising:

[0458] a light chain CDR 1 comprising the amino acid sequence of SEQ ID NO: 49,

[0459] a light chain CDR 2 comprising the amino acid sequence of SEQ ID NO: 50, and

[0460] a light chain CDR 3 comprising the amino acid sequence of SEQ ID NO: 51. The amino acid sequence.

[0461]

[408] According to the method of any one of

[401] to

[407] , wherein the third antigen-binding domain comprises an antibody variable region, the antibody variable region comprising:

[0462] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 52, and

[0463] a light chain variable region comprising the amino acid sequence of SEQ ID NO: 53.

[0464]

[409] The method according to any one of

[401] to

[408] , wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising:

[0465] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36, and

[0466] a light chain variable region comprising the amino acid sequence of SEQ ID NO: 37,

[0467] and wherein the third antigen-binding domain comprises an antibody variable region, the antibody variable region comprising:

[0468] a heavy chain variable region comprising SEQ ID NO: 52, and

[0469] a light chain variable region comprising SEQ ID NO: 53.

[0470]

[410] According to any one of

[401] to

[409] , wherein the first antigen-binding domain and the second antigen-binding domain are each Fabs having a cysteine ​​residue at EU number position 191 in the heavy chain, and having a disulfide bond formed by two cysteine ​​residues.

[0471]

[411] According to

[401] to

[410] The method of any one of the first antigen-binding domains, the second antigen-binding domain, and the third antigen-binding domain is a Fab, the Fab comprising:

[0472] a heavy chain comprising a VH region and a CH1 region, and

[0473] a light chain comprising a VL region and a CL region,

[0474] wherein the C-terminus of the CH1 region of the heavy chain of the third antigen-binding domain is fused directly or via a peptide linker to the N-terminus of the VH region of the Fab heavy chain of either the first antigen-binding domain or the second antigen-binding domain.

[0475]

[412] The method according to

[411] , wherein the peptide linker comprises an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.

[0476]

[413] According to any one of

[401] to

[412] , the third antigen-binding domain is a cross-Fab in which the VH region is connected to the CL region and the VL region is connected to the CH1 region, and each of the first antigen-binding domain and the second antigen-binding domain is a conventional Fab in which the VH region is connected to the CH1 region and the VL region is connected to the CL region.

[0477]

[414] According to any one of

[401] to

[413] , wherein:

[0478] in the CL region of each of the first antigen-binding domain and the second antigen-binding domain, the amino acid residues at Kabat number positions 123 and 124 are arginine and lysine, respectively, and

[0479] in the CH1 region of each of the first antigen-binding domain and the second antigen-binding domain, the amino acid residues at EU number positions 147 and 213 are glutamic acid.

[0480]

[415] The method according to any one of

[401] to

[414] , wherein the antigen-binding molecule further comprises an Fc region.

[0481]

[416] The method according to

[415] , wherein the Fc region comprises a first Fc region subunit and a second Fc region subunit,

[0482] wherein the first Fc region subunit is selected from the group consisting of:

[0483] an Fc region polypeptide comprising alanine at each of positions 234 and 235;

[0484] an Fc region polypeptide comprising alanine at each of positions 234, 235 and 297; and

[0485] an Fc region polypeptide comprising alanine at each of positions 234, 235 and 297, cysteine ​​at position 354 and tryptophan at position 366, and

[0486] the second Fc region subunit comprises ... the second Fc region subunit comprises alanine at each of positions 234, 235 and 297 and tryptophan at position 366, and the second Fc region subunit comprises alanine at each of positions 234, 235 and 297 and tryptophan at position 366, and the second Fc region subunit comprises alanine at each of positions 234The Fc region subunits are selected from the group consisting of:

[0487] an Fc region polypeptide containing alanine at each of positions 234 and 235;

[0488] an Fc region polypeptide containing alanine at each of positions 234, 235 and 297; and

[0489] an Fc region polypeptide containing alanine at each of positions 234, 235 and 297, cysteine ​​at position 349 and serine at position 366, alanine at position 368 and valine at position 407, (See specification 25 / 122 pages 32 CN 122249467 A)

[0490] where all positions are according to EU numbers.

[0491]

[417] The method according to any one of

[416] or

[417] , wherein the Fc region comprises any one of the following:

[0492] (a) a first Fc region subunit comprising the amino acid sequence of SEQ ID NO: 23 and a second Fc region subunit comprising the amino acid sequence of SEQ ID NO: 24;

[0493] (b) a first Fc region subunit comprising the amino acid sequence of SEQ ID NO: 25 and a second Fc region subunit comprising the amino acid sequence of SEQ ID NO: 26; or

[0494] (c) a first Fc region subunit comprising the amino acid sequence of SEQ ID NO: 58 and a second Fc region subunit comprising the amino acid sequence of SEQ ID NO: 59.

[0495]

[418] The method according to any one of

[401] to

[417] , wherein the antigen-binding molecule comprises five polypeptide chains selected from any combination of the group consisting of:

[0496] (a1) a polypeptide chain (chain 1) comprising the amino acid sequence of SEQ ID NO: 39, a polypeptide chain (chain 2) comprising the amino acid sequence of SEQ ID NO: 40, a polypeptide chain (chain 3) comprising the amino acid sequence of SEQ ID NO: 41, and two polypeptide chains (chain 4 and chain 5) each comprising the amino acid sequence of SEQ ID NO: 42;

[0497] (a2) a polypeptide chain (chain 1) comprising the amino acid sequence of SEQ ID NO: 43, a polypeptide chain (chain 2) comprising the amino acid sequence of SEQ ID NO: 40, a polypeptide chain (chain 3) comprising the amino acid sequence of SEQ ID NO: 44, and two polypeptide chains (chain 4 and chain 5) each comprising the amino acid sequence of SEQ ID NO: 42. (a) and

[0498] (a3) ​​contain SEQ ID NO: 45The five polypeptide chains (chain 1) containing the amino acid sequence of SEQ ID NO: 40, the five polypeptide chains (chain 2) containing the amino acid sequence of SEQ ID NO: 44, the five polypeptide chains (chain 3) containing the amino acid sequence of SEQ ID NO: 44, and the five polypeptide chains (chain 4 and chain 5) each containing the amino acid sequence of SEQ ID NO: 42;

[0499] Preferably, the five polypeptide chains (chain 1 to chain 5) are connected and / or associated with each other according to the orientation shown in FIG3.

[0500]

[419] According to the method of

[401] , wherein the antigen-binding molecule comprises the following five polypeptide chains:

[0501] a polypeptide chain (chain 1) comprising the amino acid sequence of SEQ ID NO: 54, a polypeptide chain (chain 2) comprising the amino acid sequence of SEQ ID NO: 55, a polypeptide chain (chain 3) comprising the amino acid sequence of SEQ ID NO: 56, and two polypeptide chains (chain 4 and chain 5) each comprising the amino acid sequence of SEQ ID NO: 57;

[0502] wherein, preferably, the five polypeptide chains (chain 1 to chain 5) are connected and / or associated with each other according to the orientation shown in FIG3.

[0503]

[420] According to the method of

[401] , wherein the antigen-binding molecule comprises the following five polypeptide chains:

[0504] a polypeptide chain (chain 1) comprising the amino acid sequence of SEQ ID NO: 54,

[0505] a polypeptide chain (chain 2) comprising the amino acid sequence of SEQ ID NO: 55,

[0506] a polypeptide chain (chain 3) comprising the amino acid sequence of SEQ ID NO: 60, and

[0507] two polypeptide chains (chain 4 and chain 5) each comprising the amino acid sequence of SEQ ID NO: 57;

[0508] wherein, preferably, the five polypeptide chains (chain 1 to chain 5) are connected and / or associated with each other according to the orientation shown in FIG3.

[0509]

[421] According to the method of

[401] , wherein the antigen-binding molecule comprises five polypeptide chains, the five polypeptide chains being: a polypeptide chain (A chain) comprising the amino acid sequence shown in SEQ ID NO: 63, a polypeptide chain (L chain) comprising the amino acid sequence shown in SEQ ID NO: 64, a polypeptide chain (P chain) comprising the amino acid sequence shown in SEQ ID NO: 65, and two polypeptide chains (two S chains) each comprising the amino acid sequence shown in SEQ ID NO: 66, and preferably, the five polypeptide chains are connected and / or associated with each other according to the orientation shown in FIG. 6.

[0510]

[422] According to the method of

[401] , wherein the antigen-binding molecule comprises five polypeptide chains, the five polypeptide chains being: a polypeptide chain (A chain) comprising the amino acid sequence shown in SEQ ID NO: 67, a polypeptide chain (L chain) comprising the amino acid sequence shown in SEQ ID NO: 68, a polypeptide chain (P chain) comprising the amino acid sequence shown in SEQ ID NO: 69, and two polypeptide chains (two S chains) each comprising the amino acid sequence shown in SEQ ID NO: 70, and preferably, the five polypeptide chains are connected and / or associated with each other according to the orientation shown in FIG. 6.

[0511]

[423] According to the method of

[401] , wherein the antigen-binding molecule comprises five polypeptide chains, the five polypeptide chains being: a polypeptide chain (A chain) comprising the amino acid sequence shown in SEQ ID NO: 71, a polypeptide chain (L chain) comprising the amino acid sequence shown in SEQ ID NO: 72, a polypeptide chain (P chain) comprising the amino acid sequence shown in SEQ ID NO: 73, and two polypeptide chains (two S chains) each comprising the amino acid sequence shown in SEQ ID NO: 74, and preferably, the five polypeptide chains are connected and / or associated with each other according to the orientation shown in FIG. 6.

[0512]

[424] According to the method of

[401] , wherein the antigen-binding molecule is an antibody comprising a heavy chain and a light chain, the heavy chain comprising the amino acid sequence shown in SEQ ID NO: 79, and the light chain comprising the amino acid sequence shown in SEQ ID NO: 80.

[0513]

[425] According to the method of

[401] , wherein the antigen-binding molecule is an antibody comprising a heavy chain and a light chain, the heavy chain comprising the amino acid sequence shown in SEQ ID NO: 81, and the light chain comprising the amino acid sequence shown in SEQ ID NO: 82.

[0514]

[426] According to the method of

[401] , wherein the antigen-binding molecule is an antibody comprising a heavy chain and a light chain, the heavy chain comprising the amino acid sequence shown in SEQ ID NO: 83, and the light chain comprising the amino acid sequence shown in SEQ ID NO: 84.

[0515] This disclosure also relates to the following invention:

[0516]

[501] A method according to any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[201] to

[252] ,

[301] to

[365] and

[401] to

[425] , further comprising a ratio of an antigen-binding molecule (LINC form) having at least one disulfide bond in a region outside the hinge region to the sum of the following (LINCThe ratio is measured, determined, or quantified as follows:

[0517] (i) an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region (LINC form), and

[0518] (ii) an antigen-binding molecule in an incorrect disulfide bond form and / or a non-disulfide bond form (unLINC form).

[0519]

[502] According to the method of

[501] , wherein the steps of measuring, determining, or quantifying include electrophoresis or chromatography.

[0520]

[503] According to the method of

[502] , wherein the electrophoresis is selected from the group consisting of non-reducing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and non-reducing capillary SDS gel electrophoresis (CE-SDS).

[0521]

[504] According to the method of

[502] , wherein the chromatography is hydrophobic interaction chromatography (HIC).

[0522]

[505] The method according to any one of

[501] to

[504] , wherein the method further comprises adding the protease to the formulation prior to the measurement, determination or quantification step.

[0523]

[506] The method according to

[505] , wherein the protease is an enzyme that does not digest the LINC form but is capable of digesting the unLINC form.

[0524]

[507] The method according to

[505] or

[506] , wherein the protease is a cysteine ​​protease capable of digesting human IgG1 antibodies.

[0525]

[508] The method according to any one of

[505] to

[507] , wherein the protease is an enzyme capable of cleaving the hinge region of human IgG1 antibodies.

[0526]

[509] The method according to any one of

[505] to

[508] , wherein the protease is a protease that digests human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP.

[0527]

[510] The method according to any one of

[505] to

[509] , wherein the protease is IgdE.

[0528]

[511] The method according to

[510] , wherein IgdE is derived from Streptococcus agalactiae.

[0529]

[512] The method according to

[510] or

[511] , wherein IgdE is a protein selected from the group consisting of (a) to (d):

[0530] (a) a protein comprising the amino acid sequence shown in SEQ ID NO: 61;

[0531] (b) a protein encoded by the base sequence shown in SEQ ID NO: 62;

[0532] (c)A protein comprising one or more amino acids that are substituted, deleted, added, and / or inserted relative to the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP; and

[0533] (d) a protein comprising an amino acid sequence having at least 80% or more, 85% or more, 90% or more, 95% or more, or 98% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP.

[0534]

[513] The method according to any one of

[505] to

[512] , wherein the protease is FabALACTICA (registered trademark).

[0535]

[514] The method according to any one of

[505] to

[513] , wherein the steps of measuring, determining or quantifying include non-reducing capillary SDS gel electrophoresis (CE-SDS) or hydrophobic interaction chromatography (HIC).

[0536]

[515] The method according to

[514] , wherein the steps of measuring, determining or quantifying include non-reducing capillary SDS gel electrophoresis (CE-SDS), and wherein the method further includes performing non-reducing capillary SDS gel electrophoresis (CE-SDS) on formulations without added protease and samples containing only protease.

[0537]

[516] The method according to

[515] further includes obtaining electrophoresis patterns of a formulation with added protease, a formulation without added protease, and a sample containing only protease,

[0538] wherein the electrophoresis pattern of the formulation without added protease includes: peaks originating from LINC form and from unLINC form without protease digestion, and a peak (peak Z) that is neither originating from LINC form nor from unLINC form without protease digestion,

[0539] wherein the electrophoresis pattern of the formulation with added protease includes: a peak (peak L) originating from LINC form, a peak (peak unL) originating from unLINC form digested by protease, a peak (peak E) originating from protease, and a peak (peak Z) that is neither originating from LINC form nor from unLINC form digested by protease nor from protease, and

[0540] wherein the electrophoresis pattern of the sample containing protease contains only a peak (peak E) originating from protease.

[0541]

[517] According to the method of

[516] , wherein the obtained LINC ratio is (area value of peak L) and [(peak unL, peak E and peak...]

[0542]

[518] According to the method of

[514] , the step of measuring, determining or quantifying includes performing hydrophobic interaction chromatography (HIC) and obtaining a chromatogram.

[0543]

[519] According to the method of

[518] , the LINC ratio is obtained as the ratio of the area value of the peak derived from the LINC form to the sum of the area values ​​of the peak derived from the LINC form and the area values ​​of all peaks derived from the unLINC form. Instructions for Use, Page 28 / 122, 35 CN 122249467 A

[0544]

[520] The method according to any one of

[501] to

[519] , wherein the chromatography in [1] to

[52] , [B1] to [B15],

[201] to

[252] ,

[301] to

[365] and

[401] to

[425] is membrane chromatography.

[0545]

[521] The method according to any one of

[505] to

[520] , wherein the method further comprises culturing the formulation after adding the protease.

[0546] This disclosure also relates to the following invention:

[0547]

[601] A formulation comprising an antigen-binding molecule produced by any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[201] to

[252] ,

[301] to

[365] ,

[401] to

[425] and

[501] to

[521] , the antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region.

[0548]

[602] A pharmaceutical composition comprising an formulation containing an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a hinge region other than the hinge region, wherein the formulation is prepared by any one of the methods described in [1] to

[52] , [A1] to [A24], [B1] to [B15],

[201] to

[252] ,

[301] to

[365] ,

[401] to

[425] , and

[501] to

[521] .

[0549] This disclosure also relates to the following invention:

[0550]

[701] The method according to any one of

[101] to

[113] , wherein the composition (1) is obtained by [1] to

[52] , [A1] to [A24], [B1] to [B15],

[201] to

[252] ,

[301] to

[365] and

[401] A formulation produced by any one of the methods described in

[425] .

[0551]

[702] A composition obtained by any one of the methods described in

[101] to

[113] and

[701] .

[0552] This disclosure also relates to the following invention:

[0553]

[801] A method for producing a pharmaceutical composition or pharmaceutical preparation comprising an antigen-binding molecule (LINC form) having at least one disulfide bond formed in a region other than the hinge region, the method comprising:

[0554] (a) measuring, determining, or quantifying the ratio (LINC ratio) of the LINC form to the sum of the LINC form and the antigen-binding molecule (unLINC form) without a disulfide bond formed in a region other than the hinge region in a composition comprising LINC form and unLINC form by any one of

[101] to

[113] ,

[0555] (b) selecting a composition having a LINC ratio of at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, and

[0556] (c) Prepare a pharmaceutical composition or pharmaceutical formulation comprising the composition selected in step (b) and a pharmaceutically acceptable carrier.

[0557]

[802] A method for producing a pharmaceutical composition or pharmaceutical preparation comprising an antigen-binding molecule (LINC form) having at least one disulfide bond formed in a region other than the hinge region, the method comprising:

[0558] (a) measuring, determining, or quantifying the ratio (LINC ratio) of the LINC form to the sum of the LINC form and the antigen-binding molecule (unLINC form) without disulfide bonds formed in a region other than the hinge region in any one of

[101] to

[113] by the method of any one of

[101] to

[113] ,

[0559] (b) confirming that the LINC ratio of the composition is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, and specification 29 / 122 pages 36 CN 122249467 A

[0560] (c) Prepare a pharmaceutical composition or pharmaceutical formulation comprising the composition having been demonstrated in step (b) to have a LINC ratio and a pharmaceutically acceptable carrier.

[0561]

[803] The composition according to

[801] or

[802] , wherein the antigen-binding molecule is a molecule defined as any one of

[201] to

[252] ,

[301] to

[365] and

[401] to

[425] .

[0562]

[804] The method according to any one of

[801] to

[803] , wherein the composition in step (a) is a formulation produced by any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[201] to

[252] ,

[301] to

[365] and

[401] to

[425] .

[0563] This disclosure also relates to the following invention:

[0564]

[901] A composition comprising an antigen-binding molecule in the form of having at least one disulfide bond formed in a region other than the hinge region (LINC form), an antigen-binding molecule in the form of not having a disulfide bond formed in a region other than the hinge region (unLINC form), and a protease.

[0565]

[902] The composition according to

[901] , wherein the protease is an enzyme that does not digest the LINC form but is capable of digesting the unLINC form.

[0566]

[903] The composition according to

[901] or

[902] , wherein the protease is a cysteine ​​protease capable of digesting human IgG1 antibodies.

[0567]

[904] The composition according to any one of

[901] to

[903] , wherein the protease is an enzyme capable of cleaving the hinge region of human IgG1 antibodies.

[0568]

[905] The composition according to any one of

[901] to

[904] , wherein the protease is an enzyme that digests human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP.

[0569]

[906] The method according to any one of

[901] to

[905] , wherein the protease is IgdE.

[0570]

[907] The composition according to

[906] , wherein the IgdE is derived from Streptococcus agalactiae.

[0571]

[908] The composition according to

[906] or

[907] , wherein IgdE is a protein selected from the group consisting of:

[0572] (a) a protein comprising the amino acid sequence shown in SEQ ID NO: 61;

[0573] (b) a protein encoded by the base sequence shown in SEQ ID NO: 62;

[0574] (c) a protein comprising one or more amino acids that are modified relative to the amino acid sequence shown in SEQ ID NO: 61.A protein having a substituted, deleted, added, and / or inserted amino acid sequence, wherein the protein is capable of digesting human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP; and

[0575] (d) a protein comprising an amino acid sequence having at least 80% or more, 85% or more, 90% or more, 95% or more, or 98% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP.

[0576]

[909] The composition according to any one of

[901] to

[908] wherein the protease is FabALACTICA (registered trademark).

[0577]

[910] The composition according to any one of

[901] to

[909] , wherein the antigen-binding molecule is a molecule defined as any one of

[201] to

[252] ,

[301] to

[365] and

[401] to

[425] .

[0578]

[911] The composition according to any one of

[901] to

[910] , wherein the composition is a mixture of a protease and a formulation produced by any one of [1] to

[52] , [A1] to [A24], [B1] to [B15],

[201] to

[252] ,

[301] to

[365] and

[401] to

[425] .

[0579] [Effects of the Invention] Specification 30 / 122 pages 37 CN 122249467 A

[0580] This disclosure provides an efficient and easy method for the production and purification of antigen-binding molecules (LINC form) having suitable disulfide bonds in regions outside the hinge region. The method in this disclosure enables the easy, rapid and high-yield production of the LINC-Ig form. The method in this disclosure has the advantage of a wide range of reducing agent types, concentrations, pH, and reaction times.

[0581] Furthermore, compared with such production and purification in a tank, the production and purification of the LINC-Ig form in a column (such as those in the methods of this disclosure) has advantages such as reduced likelihood of antigen-binding molecule aggregation, shorter reaction times, ease of operation, the possibility of automation using programmed liquid chromatography (LC), the possibility of maintaining a constant concentration of reducing agent in the reaction, and ease of cross-scale reproducibility.

[0582] This disclosure also provides for the use of antigen-binding molecules (LINC form) having at least one disulfide bond formed in a region outside the hinge region compared to said LINC form and those not having a disulfide bond formed in a region outside the hinge region.Methods for measuring, determining, or quantifying the ratio (LINC ratio) of the sum of antigen-binding molecules in the form of disulfide bonds (unLINC forms). The methods of this disclosure allow for the measurement, determination, or quantification of the proportion of LINC-Ig forms contained in a composition. The methods of this disclosure have the advantage that the ratio of LINC and unLINC forms of antigen-binding molecules that may be contained in regions outside the hinge region (more specifically, between sites in the CH1 region of one heavy chain and sites in the CH1 region of another heavy chain) can be measured, determined, or quantified.

[0583] Figure 1 shows the analytical results of Cys-reduced samples. From left to right, it shows a control (1 sample) skipping the reduction / oxidation step and performing affinity chromatography, 0.1 to 100 mmol / L Cys solutions at pH 7.0 (4 samples), and 0.1 to 100 mmol / L Cys solutions at pH 8.0 (4 samples). At pH 7.0 and 8.0, particularly in the concentration range of 0.1 to 10 mmol / L, an effective increase in the LINC ratio was confirmed. For the results at 100 mmol / L, no bands could be confirmed on the gel, and the symbol “-” was used because the accurate LINC ratio could not be calculated.

[0584] Figure 2 shows the analytical results of the TCEP-reduced samples. From left to right, the control (1 sample) with the reduction / oxidation step skipped and affinity chromatography performed is shown, along with 0.001 to 1 mmol / L TCEP solutions at pH 7.0 (4 samples) and 0.001 to 1 mmol / L TCEP solutions at pH 8.0 (4 samples). For the results at 0.1 to 1 mmol / L, no bands could be confirmed on the gel, and the symbol “-” was used because the accurate LINC ratio could not be calculated.

[0585] Figure 3 is a diagram showing the design and nomenclature rules for trivalent antibodies in the dual / LINC (1+2) form.

[0586] Figure 4 shows an electrophoresis diagram from CE-SDS.

[0587] Figure 5 shows an electrophoresis diagram from HIS analysis, including peak names. A standard electrophoresis diagram (top) and a magnified electrophoresis diagram (bottom) are shown.

[0588] Figure 6 is a schematic diagram of the ALPS12 molecule. Dashed lines represent LINC-type disulfide bonds formed between the CH1 domains of the heavy chain.

[0589] Figure 7 is a diagram showing the digestion site of FabALACTICA (registered trademark) using the IgG1 sequence.

[0590] Figure 8 shows the digestion site of FabALACTICA (registered trademark) using the IgG1 sequence.A graph showing the changes in LINC and unLINC forms after FabALACTICA (registered trademark) digestion treatment.

[0591] Figure 9 is a graph showing the raw data corresponding to Table 12. The numbers in Table 12 correspond to the numbers in Figure 9. “Ori.” represents the undigested sample, and “dig.” represents the digested sample.

[0592] Figure 10 is a graph showing the method for calculating the content ratio of LINC forms using the data in Figure 4. Specification 31 / 122 pages 38 CN 122249467 A

[0593] Figure 11-1 is a graph showing the entire electrophoresis diagram of the HIC analysis.

[0594] Figure 11-2 is a graph of an enlarged view of Figure 11-1.

[0595] Figure 12 is a graph showing the formula for calculating the amount of LINC forms included using the data in Figures 11-1 and 11-2. Detailed Description of Embodiments

[0596] Those skilled in the art will readily understand and will generally use conventional methods to employ the techniques and procedures described or referenced herein, such as, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 3rd Edition (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Current Protocols in Molecular Biology (edited by F.M. Ausubel et al., (2003)); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (edited by M.J. MacPherson, B.D. Hames and G.R. Taylor, (1995)); Harlow and Lane, (edited by, (1988)); Antibodies, A Laboratory Manual, and Animal Cell Culture (edited by R.Freshney, (1987)); Oligonucleotide Synthesis (edited by M.J. Gait, (edited by, 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (J.E.CellisEdited by Academic Press, 1998; Animal Cell Culture (R.I. Freshney), edited, 1987; Introduction to Cell and Tissue Culture (J.P. Mather and PE. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (A. Doyle, J.B. Griffiths, and DG. Newell, edited, 1993-8) J. Wiley and Sons; Handbook of Experimental Immunology (DM. Weir and CC. Blackwell, edited); Gene Transfer Vectors for Mammalian Cells (J.M. Miller and MP. Calos, edited, 1987); PCR: The Polymerase Chain Reaction (Mullis et al., edited, 1994); Current Protocols in Immunology (J.E. Coligan et al., edited, 1991); Short Protocols in Molecular Biology (Wiley and Sons) , 1999); Immunobiology (C.A.Janeway and P.Travers, 1997); Antibodies (P.Finch, 1997); Antibodies: A Practical Approach (edited by D. Catty, IRL Press, 1988‑1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, editors, Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999)); The Antibodies (M. Zanetti and J. D. Capra, editors,The widely used methods described in Harwood Academic Publishers, 1995; and Cancer: Principles and Practice of Oncology (VT DeVita et al., editors, JBLippincott Company, 1993).

[0597] The following definitions and detailed descriptions are provided to aid in understanding the present disclosure shown herein.

[0598] I. Definitions

[0599] In this document, when describing sites of amino acid alteration, the term “and / or” means each combination of “and” and “or” appropriately combined. Specifically, for example, “amino acids at positions 33, 55 and / or 96 are substituted” includes variations of the following amino acid alterations: (a) position 33, (b) position 55, (c) position 96, (d) positions 33 and 55, (e) positions 33 and 96, (f) positions 55 and 96, and (g) amino acids at positions 33, 55 and 96.

[0600] Unless otherwise stated, the amino acid residues in the light chain constant region are numbered according to Kabat et al., and the amino acid residues in the heavy chain constant region are numbered according to the EU numbering system, also known as the EU index, as described in Kabat et al., specification 32 / 122 pages 39 CN 122249467 A Sequences of Proteins of Immunological Interest, 5th edition Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0601] Amino Acids

[0602] In this document, amino acids are described by one or three letter codes or both, such as Ala / A, Leu / L, Arg / R, Lys / K, Asn / N, Met / M, Asp / D, Phe / F, Cys / C, Pro / P, Gln / Q, Ser / S, Glu / E, Thr / T, Gly / G, Trp / W, His / H, Tyr / Y, Ile / I, or Val / V.

[0603] Amino Acid Changes

[0604] For amino acid changes in the amino acid sequence of antigen-binding molecules (also described herein as “amino acid substitution” or “amino acid mutation”), known methods may be appropriately employed, such as site-directed mutagenesis (Kunkel et al. (Proc. Natl. Acad. Sci. USA (1985) 82, 488-492)) and overlap extension PCR. In addition, several known methods may also be employed.Methods for altering amino acids to replace non-natural amino acids (Annu Rev. Biophys. Biomol. Struct. (2006) 35, 225-249; and Proc. Natl. Acad. Sci. USA (2003) 100 (11), 6353-6357). For example, a cell-free translation system containing tRNA (Clover Direct (Protein Express)) is suitable, which has a non-natural amino acid that is complementary to one of the stop codons (codon UAG (amber codon)) and inhibits tRNA binding.

[0605] Furthermore, in this document, as a representation of amino acid alteration, it is appropriate to use a representation that displays the amino acid before and after the alteration with one-letter or three-letter codes before and after the numbers indicating specific positions. For example, when replacing an amino acid contained in the variable region of an antibody, the altered N100bL or Asn100bLeu indicates that Leu is used to replace Asn at position 100b (according to the Kabat number). That is, the number shows the amino acid position according to the Kabat number, the one- or three-letter amino acid code written before the number shows the amino acid before substitution, and the one- or three-letter amino acid code written after the number shows the amino acid after substitution. Similarly, when replacing an amino acid in the Fc region contained in the constant region of an antibody, the altered P238D or Pro238Asp indicates that Pro is used to replace Pro at position 238 (according to the EU number). That is, the number shows the amino acid position according to the EU number, the one- or three-letter amino acid code written before the number shows the amino acid before substitution, and the one- or three-letter amino acid code written after the number shows the amino acid after substitution.

[0606] Polypeptide

[0607] As used herein, the term “polypeptide” refers to a molecule consisting of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "peptide" refers to any chain having two or more amino acids, not a specific length of product. Therefore, peptide, dipeptide, tripeptide, oligopeptide, "protein," "amino acid chain," or any other term used to refer to a chain having two or more amino acids is included within the definition of "peptide," and the term "peptide" may be used in place of any of these terms, or interchangeably with any of these terms. The term "peptide" is also intended to refer to post-expression modified products of peptides, including but not limited to glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. Peptides can be derived from naturally occurring...The polypeptide is derived from or produced through recombinant technology, and is not necessarily translated from a specified nucleic acid sequence. It can be generated in any manner, including through chemical synthesis. The size of the polypeptide as described herein can be about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids. Polypeptides can have a defined three-dimensional structure, but they do not necessarily have such a structure. Polypeptides with a defined three-dimensional structure are called folded; and polypeptides that do not have a defined three-dimensional structure but can take on a large number of different conformations are called unfolded, as described on page 40 of specification 33 / 122, CN 122249467 A.

[0608] Amino Acid Sequence Identity Percentage (%)

[0609] The “amino acid sequence identity percentage (%)” relative to the reference polypeptide sequence is defined as the percentage of amino acid residues in the candidate sequence that are identical to those in the reference polypeptide sequence after aligning the candidate sequence with the reference polypeptide sequence and introducing vacancies (if necessary) to achieve the maximum percentage of sequence identity, without taking into account any conserved substitutions as part of the sequence identity. Alignment used to determine the amino acid sequence identity percentage can be performed in various ways within the scope of the art, such as using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment across the full length of the sequences being compared. However, for the purposes of this document, the sequence comparison computer program ALIGN-2 is used to generate the amino acid sequence identity % value. The ALIGN-2 sequence comparison computer program was written by Genentech, Inc., and the source code has been submitted with the user documentation to the US Copyright Office, Washington DC, 20559, registered there under US Copyright Registry No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc. (South San Francisco, California) or can be compiled from the source code. The ALIGN-2 program should be compiled for use on UNIX operating systems, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and remain unchanged. When using ALIGN-2...In the case of amino acid sequence comparison, the amino acid sequence identity % of a given amino acid sequence A with or against a given amino acid sequence B (which can be alternatively expressed as a given amino acid sequence A having or containing an amino acid sequence identity % with or against a given amino acid sequence B) is calculated as follows:

[0610] 100 multiplied by the fraction X / Y

[0611] where X is the number of amino acid residues that are scored as identical matches by the sequence alignment program ALIGN-2 in the alignment of A and B, and where Y is the total number of amino acid residues in B. It should be understood that if the length of amino acid sequence A is not equal to the length of amino acid sequence B, the amino acid sequence identity % of A with B will not be equal to the amino acid sequence identity % of B with A. Unless otherwise specifically indicated, all values ​​of amino acid sequence identity % used herein are obtained using the ALIGN-2 computer program as described in the preceding paragraph.

[0612] Antigen-binding molecule

[0613] As used herein, the term “antigen-binding molecule” in its broadest sense refers to any molecule that specifically binds to an antigenic determinant (epitope) and contains an antigen-binding domain or has binding activity with an antigen, and may also refer to molecules such as peptides or proteins of about five amino acids or longer. Peptides and proteins are not limited to those derived from organisms; for example, they may be polypeptides produced by artificially designed sequences. They may also be any of naturally occurring polypeptides, synthetic polypeptides, recombinant polypeptides, etc. A scaffold molecule containing a known stable conformational structure such as an α / β barrel as a scaffold, wherein a portion of the molecule serves as an antigen-binding site, is also an embodiment of the antigen-binding molecule described herein. In one embodiment, the antigen-binding molecule may contain two or more (e.g., 2, 3, 4, 5 or more) polypeptide chains. In one embodiment, the polypeptide chains constituting the antigen-binding molecule may be antibody heavy chains or antibody light chains. Specifically, in one embodiment, the antigen-binding molecule is an antibody, an antibody fragment, or an antibody derivative. In one embodiment, the antigen-binding molecule is a trivalent antibody containing chains 1 to 5, as shown in Figure 3 of this application. In one embodiment, the antigen-binding molecule is a non-antibody protein or a fragment thereof or a derivative thereof.

[0614] Multispecific antigen-binding molecule

[0615] "Multispecific antigen-binding molecule" refers to an antigen-binding molecule that specifically binds to more than one antigen. Terminology specification 34 / 122 pages 41 CN 122249467 A "Bispecific" means that the antigen-binding molecule can specifically bind to at least two different antigenic determinants. The term "trispecific" means that the antigen-binding molecule can specifically bind to at least three different antigenic determinants.

[0616] In some embodiments, the multispecific antigen-binding molecule of this application is a trispecific antigen-binding molecule,The aforementioned three-specific antigen-binding molecules can bind to either CD3 or CD137, but not both simultaneously, and can specifically bind to DLL3.

[0617] Antigen-binding domain

[0618] In this document, an "antigen-binding domain" refers to a region that specifically binds to and complements all or part of an antigen. In this document, an antigen-binding molecule contains an antigen-binding domain. When the molecular weight of the antigen is large, the antigen-binding domain can only bind to a specific portion of the antigen. This specific portion is called an "epitope". In one embodiment, the antigen-binding domain contains an antibody fragment that binds to a specific antigen. The antigen-binding domain may be provided by one or more antibody variable domains. In a non-limiting embodiment, the antigen-binding domain contains both an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH). Examples of such antigen-binding domains include "single-chain Fv (scFv)", "single-chain antibody", "Fv", "single-chain Fv2 (scFv2)", "Fab", and "Fab'". In other embodiments, the antigen-binding domain contains a non-antibody protein that binds to a specific antigen or a fragment thereof. In a specific embodiment, the antigen-binding domain includes one or two Fabs comprising a CH1 region. In a specific embodiment, the antigen-binding domain includes a hinge region.

[0619] As used herein, the term "antigen-binding domain" is capable of directing the entity to which it is attached to to a target site, such as to a specific type of tumor cell expressing a cancer antigen (DLL3). The antigen-binding domain is capable of activating signal transduction via its target antigens, such as T-cell receptor complex antigens (particularly CD3) and / or co-stimulatory receptors (CD137)).

[0620] As used herein, the terms "first," "second," and "third" relating to antigen-binding domains, etc., are used for convenience of distinction when there is more than one of each type of part. Unless explicitly stated otherwise, the use of these terms is not intended to assign a specific order or orientation to the said antigen-binding molecule.

[0621] In this document, "specific binding" means binding in a state in which one of the molecules involved in specific binding does not show any significant binding to any molecule other than a single or multiple binding partner molecules. Furthermore, it is also used when the antigen-binding domain is specific to a specific epitope among a plurality of epitopes contained in an antigen. When an epitope that binds to an antigen-binding domain is contained in multiple different antigens, an antigen-binding molecule containing that antigen-binding domain can bind to various antigens having that epitope.

[0622] In this disclosure, the expression "binds to the same epitope" means that the epitopes bound by two antigen-binding domains at least partially overlap each other. The degree of overlap is, but is not limited to, at least 10% or more, preferably 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, and...80% or more, particularly preferably 90% or more, and most preferably 100%.

[0623] Antibody

[0624] The term “antibody” is used herein in the broadest sense and covers a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific or trispecific antibodies), and antibody fragments, as long as they exhibit the desired antigen-binding activity.

[0625] The term “immunoglobulin molecule” refers to a protein having the structure of a naturally occurring antibody. For example, IgG immunoglobulins are heterotetrameric glycoproteins of about 150,000 Daltons, consisting of two light chains and two heavy chains linked by disulfide bonds. Each heavy chain has a variable region (VH) (also called a variable heavy chain domain or heavy chain variable domain) from the N-terminus to the C-terminus, followed by three constant domains (CH1, CH2, and CH3) (also called heavy chain constant regions). Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL) (also called a variable light chain domain or light chain variable domain), followed by a constant light chain (CL) domain (also called a light chain constant region). The heavy chains of immunoglobulins can be assigned to one of five types, referred to as α (IgA), δ (IgD), ε (IgE), γ (IgG), or µ (IgM), some of which can be further subdivided into subtypes such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1), and α2 (IgA2). The light chains of immunoglobulins can be assigned to one of two types based on the amino acid sequence of their constant domains, referred to as κ and λ. Immunoglobulins are essentially composed of two Fab molecules linked by an immunoglobulin hinge region and an Fc domain.

[0626] As used herein, the term “monoclonal antibody” refers to an antibody obtained from a substantially homogeneous group of antibodies, i.e., the individual antibodies comprising this group are identical and / or bind to the same epitope, except for possible variant antibodies (e.g., containing naturally occurring mutations or generated during the production of a monoclonal antibody formulation, such variants are typically present in small quantities). In contrast to polyclonal antibody formulations, which typically comprise different antibodies targeting different determinants (epitaxes), each monoclonal antibody in a monoclonal antibody formulation targets a single determinant on the antigen. Therefore, the modifier “monoclonal” indicates that the antibody is characterized by being obtained from a substantially homogeneous group of antibodies and should not be interpreted as requiring the antibody to be produced by any particular method. For example, monoclonal antibodies can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage methods, etc.Methods for preparing monoclonal antibodies, including methods for demonstrating and utilizing transgenic animals containing all or part of the human immunoglobulin loci, are described herein.

[0627] The terms “full-length antibody,” “intact antibody,” and “whole antibody” are used interchangeably herein to refer to antibodies having a structure substantially similar to that of natural antibodies or having a heavy chain containing an Fc region as defined herein.

[0628] The “class” of an antibody refers to the type of constant domain or constant region possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of them can be further subdivided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The constant domains of the heavy chain corresponding to different classes of immunoglobulins are referred to as α, δ, ε, γ, and μ, respectively.

[0629] The term “variable region” or “variable domain” refers to a domain of the antibody heavy or light chain involved in the binding of the antibody to the antigen. The variable domains (VH and VL, respectively) of the heavy and light chains of natural antibodies typically have similar structures, with each domain containing four conserved frame regions (FRs) and three hypervariable regions (HVRs). (See, for example, Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies binding to a specific antigen can be isolated using either the VH or VL domain from the antibody binding that antigen, to screen libraries containing complementary VL or VH domains. See, for example, Portolano et al., J. Immunol. 150:880–887 (1993); Clarkson et al., Nature 352:624–628 (1991).

[0630] As used herein, the term “hypervariant region” or “HVR” refers to each of the following: a region of an antibody variable domain that is hypervariable in sequence (“complementarity-determining region” or “CDR”) and / or forms a structurally defined loop (“hypervariant loop”) and / or contains antigen contact residues (“antigen contact site”). Typically, an antibody contains six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). Exemplary HVRs herein include:

[0631] (a) a hypervariant loop present at amino acid residues 26–32 (L1), 50–52 (L2), 91–96 (L3), 26–32 (H1), 53–55 (H2), and 96–101 (H3) (Chothia and Lesk, J.).Mol. Biol. 196:901-917 (1987));

[0632] (b) CDRs present at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2) and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th edition. Public Health Service, National Institutes of Health, Bethesda, MD (1991));

[0633] (c) CDRs present at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2) and 93-101 (H3). The antigen contact site at the location (MacCallum et al. J. Mol. Biol. 262: 732-745 (1996)); and

[0634] (d) combinations of (a), (b) and / or (c), including HVR amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3) and 94-102 (H3).

[0635] Unless otherwise specified, HVR residues and other residues (e.g., FR residues) in the variable domain are referenced herein from Kabat et al., cited as above.

[0636] HVR-H1, HVR-H2, HVR-H3, HVR-L1, HVR-L2, and HVR-L3 are also referred to as “H-CDR1”, “H-CDR2”, “H-CDR3”, “L-CDR1”, “L-CDR2”, and “L-CDR3”, respectively.

[0637] “Frame” or “FR” refers to the variable domain residues other than the hypervariable region (HVR) residues. The variable domain FR is usually composed of the following four FR domains: FR1, FR2, FR3, and FR4. Therefore, HVR and FR sequences usually appear in VH (or VL) in the following sequence: FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

[0638] “Human common frame” is a frame that represents the selection of frame sequences in human immunoglobulin VL or VH.The most commonly found amino acid residues. Generally, the selection of human immunoglobulin VL or VH sequences is derived from a subgroup of variable domain sequences. Generally, the subgroup of sequences is the subgroup in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, NIH Publication 91-3242, Bethesda MD (1991), Volumes 1-3. In one embodiment, for VL, the subgroup is subgroup κ I in Kabat et al. (ibid.). In one embodiment, for VH, the subgroup is subgroup III in Kabat et al. (ibid.).

[0639] The term “hinge region” refers to the antibody heavy chain polypeptide portion in the wild-type antibody heavy chain that links the CH1 domain and the CH2 domain, for example from about position 216 to about position 230 according to the EU numbering system, or from about position 226 to about position 243 according to the Kabat numbering system. It is known that in native IgG antibodies, a disulfide bond is formed between a cysteine ​​residue at position 220 (EU number) in the hinge region and a cysteine ​​residue at position 214 in the antibody light chain. It is also known that, between the two antibody heavy chains, disulfide bonds are formed between cysteine ​​residues at position 226 and at position 229 (EU number) in the hinge region. Generally, the "hinge region" is defined as extending from 216 to 238 (EU number) or from 226 to 251 (Kabat number) in human IgG1. This hinge can be further divided into three distinct regions: the upper hinge, the central hinge, and the lower hinge. In human IgG1 antibodies, these regions are typically defined as follows:

[0640] Upper hinge: 216 to 225 (EU number) or 226 to 238 (Kabat number),

[0641] Central hinge: 226 to 230 (EU number) or 239 to 243 (Kabat number),

[0642] Lower hinge: 231 to 238 (EU number) or 244 to 251 (Kabat number).

[0643] Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by placing the first and last cysteine ​​residues forming the inter-heavy chain SS bond in the same position (e.g., Brekke et al., 1995, Immunol (see Table 1 of Today 16: 85-90). Hinge regions in this document include wild-type hinge regions and variants in which the amino acid residues in the wild-type hinge region are altered by substitution, addition, or deletion.

[0644] The terms “capable of linking” (amino acid residues) and “capable of forming” (disulfide bond) include cases where a disulfide bond has already formed, as well as cases where a disulfide bond has not formed but may subsequently form under appropriate conditions.

[0645] The term “disulfide bond not formed between amino acids in the hinge region” (or “disulfide bond formed between amino acid residues in a region outside the hinge region”) means a disulfide bond formed, connected, or linked by amino acids located in any antibody region outside the “hinge region” as defined above. For example, such disulfide bonds are formed, connected, or linked by amino acids at any location outside the hinge region in the antibody (e.g., from about position 216 to about position 230 according to the EU numbering system, or from about position 226 to about position 243 according to the Kabat numbering system). In some embodiments, such disulfide bonds are formed, linked, or connected by amino acids located in the CH1, CL, VL, VH, and / or VHH regions. In some embodiments, such disulfide bonds are formed, linked, or connected by amino acids located in the CH1 region at positions 119 to 123, 131 to 140, 148 to 150, 155 to 167, 174 to 178, 188 to 197, and 201 to 214 according to EU numbers. In some embodiments, such disulfide bonds are formed, linked, or connected by amino acids located in the CH1 region at positions 119, 122, 123, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 148, 150, 155, 156, 157, 159, 160, 161, 162, 163, 164, 165, 167, 174, 176, 177, 178, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 201, 203, 205, 206, 207, 208, 211, 212, 213, 214 according to EU numbers. In some embodiments, such disulfide bonds are formed, linked, or connected by amino acids located at positions 188, 189, 190, 191, 192, 193, 194, 195, 196, and 197 according to EU numbers in the CH1 region. In a preferred embodiment, such disulfide bonds are formed, linked, or connected by amino acids located at position 191 according to EU numbers in the CH1 region.

[0646] The term “incorrect disulfide bond form” means the formation between amino acid residues that are different from the desired amino acid residues.Antigen-binding molecules with disulfide bonds. Such antigen-binding molecules are included in the erroneous disulfide bond forms herein when they contain disulfide bonds formed between desired amino acid residues and disulfide bonds formed between amino acid residues different from the desired amino acid residues.

[0647] The term “non-disulfide bond form” refers to an antigen-binding molecule in which cysteine ​​residues remain free, or in which cysteine ​​residues form disulfide bonds with molecules different from those forming the antigen-binding molecule (such as impurity molecules). The “non-disulfide bond forms” described herein only need to have such characteristics, and for example, they are included in the “non-disulfide bond forms” herein even if they contain disulfide bonds formed between amino acid residues in regions outside the hinge region (desired disulfide bonds), or disulfide bonds different from the desired disulfide bonds (erroneous disulfide bond portions), provided they have the aforementioned characteristics.

[0648] The constant region is preferably an antibody constant region, more preferably an IgG1, IgG2, IgG3, and IgG4 type antibody constant region, and even more preferably a human IgG1, IgG2, IgG3, and IgG4 type antibody constant region. Furthermore, the constant region is preferably a heavy chain constant region, more preferably an IgG1, IgG2, IgG3, and IgG4 type heavy chain constant region, and even more preferably a human IgG1, IgG2, IgG3, and IgG4 type heavy chain constant region. The amino acid sequences of the human IgG1, human IgG2, human IgG3, and human IgG4 constant regions are known. For the constant regions of human IgG1, human IgG2, human IgG3, and human IgG4, several allomorphic sequences with genetic polymorphism are described in Sequences of proteins of immunological interest, NIH Publication No. 91-3242, and any of them can be used in this invention. Amino acid-modified constant regions may contain other amino acid mutations or modifications, as long as they include the amino acid mutations of this invention.

[0649] In this document, the term "Fc region" or "Fc domain" refers to a region comprising a segment consisting of a hinge or portion thereof in an antibody molecule, as well as CH2 and CH3 domains. The Fc region of IgG class antibodies refers to, but is not limited to, the region extending from, for example, cysteine ​​226 (EU number (also referred to herein as the EU index)) to the C-terminus or from proline 230 (EU number) to the C-terminus. The Fc region can preferably be obtained by partially digesting monoclonal antibodies such as IgG1, IgG2, IgG3, or IgG4 with a proteolytic enzyme such as pepsin, followed by elution of fractions adsorbed onto a protein A column or a protein G column.There are no particular limitations on the white hydrolase, as long as the enzyme can digest the entire antibody under appropriately set reaction conditions (e.g., pH) to restrictively form Fab or F(ab')2. Examples of such enzymes may include pepsin and papain.

[0650] The Fc region derived from, for example, naturally occurring IgG can be used as "Fc region". In this case, naturally occurring IgG means a polypeptide containing the same amino acid sequence as naturally occurring IgG and belonging to the antibody class encoded essentially by the immunoglobulin γ gene. Naturally occurring human IgG means, for example, naturally occurring human IgG1, naturally occurring human IgG2, naturally occurring human IgG3, or naturally occurring human IgG4. Naturally occurring IgG also includes variants spontaneously derived therefrom. In the target immunological protein sequence of NIH Publication No. 91-3242, multiple allomorphic sequences based on gene polymorphism are described as constant regions of human IgG1, human IgG2, human IgG3, and human IgG4 antibodies, any of which can be used in this invention. In particular, the sequence of human IgG1 may have a DEL or EEM as the amino acid sequence at EU number positions 356 to 358.

[0651] The Fc domain of the antigen-binding molecule consists of a pair of polypeptide chains containing the heavy chain domain of an immunoglobulin molecule. For example, the Fc domain of an immunoglobulin G (IgG) molecule is a dimer, each subunit of which contains CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domain can stably associate with each other. In one embodiment, the antigen-binding molecule described herein contains no more than one Fc domain.

[0652] In this document, the Fc domain of the antigen-binding molecule is the IgG Fc domain. In a particular embodiment, the Fc domain is an IgG1 Fc domain. In another embodiment, the Fc domain is an IgG1 Fc domain. In a further particular embodiment, the Fc domain is a human IgG1 Fc region.

[0653] Chimeric Antibody

[0654] The term "chimeric" antibody refers to an antibody in which a portion of the heavy chain and / or light chain is derived from a specific source or species, while the remainder of the heavy chain and / or light chain is derived from a different source or species. Similarly, the term "chimeric antibody variable domain" refers to a variable region of an antibody in which a portion of the variable region of the heavy chain and / or light chain is derived from a specific source or species, while the remainder of the variable region of the heavy chain and / or light chain is derived from a different source or species.

[0655] Humanized Antibody

[0656] A "humanized" antibody refers to a chimeric antibody that contains a portion of a non-human source or species.The amino acid residues of HVR and amino acid residues from human FR. In some embodiments, the humanized antibody will substantially contain at least one of all, typically two variable domains, wherein all or substantially all HVRs (e.g., CDRs) correspond to the HVRs of the non-human antibody, and all or substantially all FRs correspond to the FRs of the human antibody. The humanized antibody may optionally contain at least a portion of the antibody constant region derived from the human antibody. An antibody in a “humanized form”, such as a non-human antibody, refers to an antibody that has undergone humanization. A “humanized antibody variable region” refers to the variable region of the humanized antibody.

[0657] Antibody Fragment

[0658] An “antibody fragment” is a molecule other than the complete antibody that contains a portion of the complete antibody that binds to the antigen bound by the complete antibody. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, bisomatic antibodies, linear antibodies, single-chain antibody molecules (e.g., scFv), and single-domain antibodies. For reviews of certain antibody fragments, see Hudson et al., Nat Med 9, 129–134 (2003). For reviews of scFv fragments, see, for example, Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, eds. Rosenburg and Moore, Springer-Verlag, New York, pp. 269–315 (1994); see also WO 93 / 16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments containing salvage receptor-binding epitope residues and having an increased in vivo half-life, see U.S. Patent No. 5,869,046. Biantibodies are antibody fragments having two antigen-binding sites, which can be bivalent or bispecific. See, for example, EP 404,097; WO 1993 / 01161; Hudson et al., Nat Med 9, 129-134 (2003); and specification 39 / 122 pages 46 CN 122249467 A Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Trisomic and tetrasomic antibodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single-domain antibodies are antibody fragments containing all or part of the heavy chain variable domain or all or part of the light chain variable domain. In some embodimentsIn this context, single-domain antibodies are human single-domain antibodies (Domantis, Inc., Waltham, MA; see, for example, U.S. Patent No. 6,248,516 B1). Antibody fragments can be prepared by various techniques, including but not limited to the proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E. coli or bacteriophages), as described herein.

[0659] Fv (Variable Fragment)

[0660] In this document, the term “variable fragment (Fv)” refers to the smallest unit of an antibody-derived antigen-binding domain consisting of a pair of antibody light chain variable regions (VL) and antibody heavy chain variable regions (VH). In 1988, Skerra and Pluckthun discovered that homogeneous and active antibodies could be prepared from E. coli periplasmic fractions by inserting an antibody gene downstream of a bacterial signal sequence and inducing the expression of that gene in E. coli (Science (1988) 240 (4855), 1038-1041). In Fv prepared by periplasmic fractionation, VH associates with VL in a manner that binds to the antigen.

[0661] scFv, single-chain antibody and sc(Fv)2

[0662] In this document, the terms “scFv”, “single-chain antibody” and “sc(Fv)2” all refer to antibody fragments containing a single polypeptide chain containing variable regions rather than constant regions derived from the heavy and light chains. Generally, single-chain antibodies also contain a polypeptide linker between the VH and VL domains, which allows for the formation of desired structures that are thought to allow antigen binding. Pluckthun discusses single-chain antibodies in detail in “The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Rosenburg and Moore, Springer-Verlag, New York, 269-315 (1994)”. See also International Patent Publication WO 1988 / 001649; U.S. Patents 4,946,778 and 5,260,203. In certain embodiments, the single-chain antibody may be bispecific and / or humanized.

[0663] scFv is an antigen-binding domain in which the VH and VL forming Fv are linked together by a peptide linker (Proc. Natl. Acad. Sci. USA (1988) 85(16), 5879-5883). The VH and VL may be kept in very close proximity by the peptide linker.

[0664] sc(Fv)2 is a single-chain antibody in which the four variable regions of the two VL and two VH are linked by a linker such as a peptide linker to form a single chain (J Immunol. Methods).(1999) 231(1-2), 177-189). The two VH and two VL can be derived from different monoclonal antibodies. Such sc(Fv)2 preferably includes, for example, a bispecific sc(Fv)2 that recognizes two epitopes present in a single antigen, as disclosed in Journal of Immunology (1994) 152(11), 5368-5374. sc(Fv)2 can be produced by methods known to those skilled in the art. For example, sc(Fv)2 can be produced by linking scFv with a linker such as a peptide linker.

[0665] In this document, the form in which the antigen-binding domain of sc(Fv)2 forms includes an antibody in which the two VH units and the two VL units are arranged in the order of VH, VL, VH, and VL ([VH]-linker-[VL]-linker-[VH]-linker-[VL]) starting from the N-terminus of a single-chain polypeptide. The order of the two VH units and the two VL units is not limited to the above form, and they can be arranged in any order. Examples of the form are listed below.

[0666] [VL]-connector-[VH]-connector-[VH]-connector-[VL]

[0667] [VH]-connector-[VL]-connector-[VL]-connector-[VH]

[0668] [VH]-connector-[VH]-connector-[VL]-connector-[VL]

[0669] [VL]-connector-[VL]-connector-[VH]-connector-[VH]

[0670] [VL]-connector-[VH]-connector-[VL]-connector-[VH]

[0671] The molecular form of sc(Fv)2 is also described in detail in WO 2006 / 132352. Based on these descriptions, those skilled in the art can suitably prepare the desired sc(Fv)2 to produce the polypeptide complexes disclosed herein.

[0672] Furthermore, the antigen-binding molecules or antibodies of this disclosure can be conjugated with a carrier polymer (such as PEG) or an organic compound (such as an anticancer agent). Alternatively, it is preferred to insert a glycan addition sequence into the antigen-binding molecule or antibody such that the glycan produces the desired effect.

[0673] The adapters for linking the variable regions of the antibody comprise any peptide adapters that can be introduced by genetic engineering, synthetic adapters, and adapters disclosed, for example, in Protein Engineering, 9(3), 299-305, 1996. However, peptide adapters are preferred in this disclosure. The length of the peptide adapter is not particularly limited and can be suitably selected by those skilled in the art according to the purpose. The length is preferably five amino acids or more (without particular limitation, the upper limit is generally 30 amino acids or more).It contains at least 20 amino acids, preferably 15 amino acids. When sc(Fv)2 contains three peptide linkers, their lengths may be all the same or different.

[0674] For example, such peptide linkers include:

[0675] Ser,

[0676] Gly-Ser,

[0677] Gly-Gly-Ser,

[0678] Ser-Gly-Gly,

[0679] Gly-Gly-Gly-Ser (SEQ ID NO: 5),

[0680] Ser-Gly-Gly-Gly (SEQ ID NO: 6),

[0681] Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 7),

[0682] Ser-Gly-Gly-Gly-Gly (SEQ ID NO: 8),

[0683] Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 9),

[0684] Ser-Gly-Gly-Gly-Gly-Gly (SEQ ID NO: 10),

[0685] Gly-Gly-Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 11),

[0686] Ser-Gly-Gly-Gly-Gly-Gly-Gly (SEQ ID NO: 12),

[0687] (Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 7))n and

[0688] (Ser-Gly-Gly-Gly-Gly (SEQ ID NO: 8))n,

[0689] where n is an integer of 1 or greater. Those skilled in the art can select the length or sequence of the peptide linker accordingly for their purpose.

[0690] Synthetic linkers (chemical crosslinking agents) are commonly used for crosslinking peptides, and examples include:

[0691] N-hydroxysuccinimide (NHS),

[0692] disuccinimide octanoate (DSS),

[0693] bis(sulfosuccinimide)octanoate (BS3),

[0694] dithiobis(succinimide propionate) (DSP),

[0695] dithiobis(sulfosuccinimide propionate) (DTSSP),

[0696] ethylene glycol bis(succinimide succinate) (EGS),

[0697] ethylene glycol bis(sulfosuccinimide succinate) (sulfon-EGS),

[0698] tartaric acid disuccinimide (DST), disulfosuccinimide tartrate (sulfon-DST),

[0699] bis[2-(succinimideoxycarbonyloxy)ethyl] sulfone (BSOCOES), and

[0700] Bis[2-(sulfosuccinimideoxycarbonyloxy)ethyl] sulfone (sulfonyl-BSOCOES). These crosslinking agents are commercially available. Specification 41 / 122 pages 48 CN 122249467 A

[0701] Generally, three linkers are required to connect the four antibody variable regions together. The linkers used can be of the same type or different types.

[0702] Fab, F(ab')2 and Fab'

[0703] A “Fab molecule” refers to a protein consisting of the VH and CH1 domains of the heavy chain (“Fab heavy chain”) and the VL and CL domains of the light chain (“Fab light chain”) of an immunoglobulin. The heavy chain of a wild-type Fab molecule cannot form a disulfide bond with another heavy chain molecule. In this document, in addition to the wild-type Fab molecule, Fab variants in which the amino acid residues in the wild-type Fab molecule are altered by substitution, addition or deletion are also included. In specific embodiments, mutated amino acid residues contained in the Fab variant (e.g., substituted, added, or inserted cysteine ​​or lysine residues) may form disulfide bonds with another heavy chain molecule or a portion thereof (e.g., the Fab molecule).

[0704] scFab is an antigen-binding domain in which the single light chain forming Fab and the CH1 region and variable region from the single heavy chain are linked together by a peptide linker. The light chain, the CH1 region from the heavy chain, and the variable region may be kept in close proximity by the peptide linker.

[0705] “F(ab')2” or “Fab” is produced by treating immunoglobulin (monoclonal antibody) with a protease such as pepsin and papain, and refers to an antibody fragment generated by digesting immunoglobulin (monoclonal antibody) near the disulfide bond present between the hinge regions of each of the two H chains. For example, papain cleaves IgG upstream of a disulfide bond between the hinge regions of each of the two H chains to generate two homologous antibody fragments, wherein the L chain containing VL (variable region of L chain) and CL (constant region of L chain) is linked via a disulfide bond at its C-terminal region to an H chain fragment containing VH (variable region of H chain) and CHγ1 (γ1 region in constant region of H chain). Each of these two homologous antibody fragments is referred to as Fab'.

[0706] "F(ab')2" consists of two light chains and two heavy chains, the heavy chains containing a constant region of the CH1 domain and a portion of the CH2 domain, thereby forming a disulfide bond between the two heavy chains. The F(ab')2 disclosed herein can preferably be produced as follows: a complete monoclonal antibody or a monoclonal antibody containing the desired antigen-binding domain is partially digested with a protease such as pepsin; and the Fc fragment is adsorbed onto protein A.On-column removal. There are no particular limitations on the protease, as long as it can selectively cleave the entire antibody to produce F(ab')2 under suitable enzymatic reaction conditions such as pH. Such proteases include, for example, pepsin and figase.

[0707] Fusion

[0708] “Fusion” means that the components (e.g., a Fab molecule and an Fc domain subunit) are linked directly or via one or more peptide linkers by peptide bonds.

[0709] “Cross-Fab”

[0710] A “cross-Fab” molecule (also called “Crossfab”) means a Fab molecule in which the variable or constant regions of the Fab heavy chain and light chain are exchanged, i.e., a cross-Fab molecule contains a peptide chain consisting of a light chain variable region and a heavy chain constant region, and a peptide chain consisting of a heavy chain variable region and a light chain constant region. For clarity, in a cross-Fab molecule in which the variable regions of the Fab light chain and Fab heavy chain are exchanged, the peptide chain containing the heavy chain constant region is referred to herein as the “heavy chain” of the cross-Fab molecule. Conversely, in cross-Fab molecules where the constant regions of the Fab light chain and the Fab heavy chain are exchanged, the peptide chain containing the variable region of the heavy chain is referred to herein as the “heavy chain” of the cross-Fab molecule.

[0711] “Conventional” Fab

[0712] In contrast, a “conventional” Fab molecule means a Fab molecule in its natural form, i.e., a heavy chain (VH-CH1) consisting of a variable region and a constant region of the heavy chain, and a light chain (VL-CL) consisting of a variable region and a constant region of the light chain. Specification 42 / 122 pages 49 CN 122249467 A

[0713] Single-domain antibody

[0714] In this document, the term “single-domain antibody” refers to an antibody whose structure is not particularly limited, as long as the domain itself can exert antigen-binding activity. A common antibody, such as an IgG antibody, exerts antigen-binding activity in the state where the variable region is formed by the pairing of VH and VL. In contrast, known single-domain antibodies are capable of antigen-binding activity solely through their own domain structure without pairing with another domain. Single-domain antibodies typically have relatively low molecular weights and exist in monomeric form.

[0715] Examples of single-domain antibodies include, but are not limited to, naturally occurring antigen-binding molecules lacking a light chain, such as VHH from camels and VNAR from sharks, as well as antibody fragments containing all or part of the antibody VH domain or all or part of the antibody VL domain. Examples of single-domain antibodies that are antibody fragments containing all or part of the antibody VH / VL domains include, but are not limited to, artificially prepared single-domain antibodies derived from human antibody VH or human antibody VL, such as, for example, U.S. Patent No. 6,248,516 B1.As described in [the document]. A single-domain antibody has three CDRs (CDR1, CDR2, and CDR3).

[0716] Single-domain antibodies can be obtained from animals capable of producing single-domain antibodies, or by immunizing animals capable of producing single-domain antibodies. Examples of animals capable of producing single-domain antibodies include, but are not limited to, camels and transgenic animals in which genes capable of producing single-domain antibodies have been introduced. Camels include camels, llamas, alpacas, dromedary camels, guanacos, etc. Examples of transgenic animals in which genes capable of producing single-domain antibodies have been introduced include, but are not limited to, the transgenic animals described in International Publication No. WO2015 / 143414 or US Patent Publication No. US2011 / 0123527 A1. Humanized single-chain antibodies can also be obtained by replacing the frame sequence of a single-domain antibody obtained from an animal with a human germline sequence or a sequence similar thereto. Humanized single-domain antibodies (e.g., humanized VHH) are one embodiment of single-domain antibodies.

[0717] Alternatively, single-domain antibodies can be obtained from peptide libraries containing single-domain antibodies by means of ELISA, panning, etc. Examples of peptide libraries containing single-domain antibodies include, but are not limited to, initial antibody libraries obtained from various animals or humans (e.g., Methods in Molecular Biology 2012 911 (65–78) and Biochimica et Biophysica Acta - Proteins and Proteomics 2006 1764:8 (1307–1319)), antibody libraries obtained by immunizing various animals (e.g., Journal of Applied Microbiology 2014 117:2 (528–536)), and synthetic antibody libraries prepared from antibody genes of various animals or humans (e.g., Journal of Biomolecular Screening 2016 21:1 (35–43), Journal of Biological Chemistry 2016 291:24 (12641–12657) and AIDS 2016 30:11 (1691–1701)).

[0718] As used herein, an "agonist" antigen-binding molecule or "agonist" antibody is an antigen-binding molecule or antibody that significantly enhances the biological activity of the antigen it binds to.

[0719] As used herein, a "blocking" antigen-binding molecule or "blocking" antibody, or an "antagonistic" antigen-binding molecule or "antagonistic" antibody, is an antigen-binding molecule or antibody that significantly inhibits (partially or completely) the biological activity of the antigen it binds to.

[0720] Antigen

[0721] As used herein, the term "antigen" refers to a site on a polypeptide macromolecule (e.g., a continuous amino acid sequence or a conformation composed of different regions of non-continuous amino acids) to which an antigen-binding moiety binds, thereby forming an antigen-binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virus-infected cells, on the surface of other diseased cells, on the surface of immune cells, in serum, and / or in the extracellular matrix (ECM). Unless otherwise stated, proteins referred to herein as antigens (e.g., CD3, CD137, DLL3) can be any naturally occurring protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). In specific embodiments, the antigen is human CD3, human CD137, or human DLL3. When referring to a specific protein herein, the term encompasses "full-length," unprocessed proteins, and any form of protein produced by intracellular processing. The term also covers naturally occurring protein variants, such as splice variants or allele variants.

[0722] Fc region with reduced Fc γ receptor binding activity

[0723] In this document, "reduced Fc γ receptor binding activity" means, for example, that, based on the above-described analytical methods, the competitive activity of the test antigen-binding molecule or antibody is 50% or less, preferably 45% or less, 40% or less, 35% or less, 30% or less, 20% or less, or 15% or less, and particularly preferably 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less.

[0724] Antigen-binding molecules or antibodies containing the Fc domain of monoclonal IgG1, IgG2, IgG3, or IgG4 antibodies may be suitably used as control antigen-binding molecules or antibodies. The Fc domain structures are shown in SEQ ID NO: 1 (A is added to the N-terminus of RefSeq accession number AAC82527.1), 2 (A is added to the N-terminus of RefSeq accession number AAB59393.1), 3 (A is added to the N-terminus of RefSeq accession number CAA27268.1), and 4 (A is added to the N-terminus of RefSeq accession number AAB59394.1). Furthermore, when using antigen-binding molecules or antibodies containing Fc domain mutants of a specific isotype as test substances, Fc domains containing the same isotype are used.Antigen-binding molecules or antibodies containing the Fc domain are used as controls to assess the effect of the mutation on Fcγ receptor binding activity. As described above, antigen-binding molecules or antibodies containing Fc domain mutants determined to have reduced Fcγ receptor binding activity are appropriately prepared.

[0725] Such known mutants include, for example, mutants with deletions of amino acids 231A to 238S (EU number) (WO 2009 / 011941), and mutants C226S, C229S, P238S, (C220S) (J. Rheumatol (2007) 34, 11); C226S and C229S (Hum. Antibod . Hybridomas (1990) 1(1), 47-54); C226S, C229S, E233P, L234V and L235A (Blood (2007) 109, 1185-1192).

[0726] Specifically, preferred antigen-binding molecules or antibodies include antigen-binding molecules or antibodies comprising an Fc domain, wherein the Fc domain of the amino acid forming a particular isotype of antibody has a mutation (such as substitution) of at least one amino acid selected from the following amino acid positions: 220, 226, 229, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 264, 265, 266, 267, 269, 270, 295, 296, 297, 298, 299, 300, 325, 327, 328, 329, 330, 331, 332, 439, 445, 449 or 451 (EU number). There are no particular limitations on the isotype of the antibody derived from the Fc domain, and a suitable Fc domain derived from a monoclonal IgG1, IgG2, IgG3, or IgG4 antibody can be used. It is preferred to use an Fc domain derived from an IgG1 antibody.

[0727] Preferred antigen-binding molecules or antibodies include, for example, antigen-binding molecules or antibodies comprising an Fc domain having any of the substitutions shown below, the positions of which are specified according to EU numbers in the amino acids forming the Fc domain of the IgG1 antibody (each number represents the position of an amino acid residue in the EU number; and the single-letter amino acid symbol before the number represents the amino acid residue before substitution, while the single-letter amino acid symbol after the number represents the amino acid residue after substitution):

[0728] (a) L234F, L235E, P331S;

[0729] (b) C226S, C229S, P238S;

[0730] (c) C226S, C229S; or page 51 of specification 44 / 122.CN 122249467 A

[0731] (d) C226S, C229S, E233P, L234V, L235A;

[0732] (e) L439M, A445N, R449Q, E451S

[0733] ​​(f) M428L, N434A, Q438R, S440E,

[0734] and antigen-binding molecules or antibodies having an Fc domain with a deletion of an amino acid sequence at positions 231 to 238.

[0735] Furthermore, preferred antigen-binding molecules or antibodies also include antigen-binding molecules or antibodies comprising an Fc domain having any of the substitutions shown below, the positions of which are specified according to EU numbers in the amino acids of the Fc domain forming the IgG2 antibody:

[0736] (e) H268Q, V309L, A330S, and P331S;

[0737] (f) V234A;

[0738] (g) G237A;

[0739] (h) V234A and G237A;

[0740] (i) A235E and G237A; or

[0741] (j) V234A, A235E, and G237A. Each number represents the position of an amino acid residue in the EU number; and the single-letter amino acid symbol before the number represents the amino acid residue before substitution, while the single-letter amino acid symbol after the number represents the amino acid residue after substitution.

[0742] Furthermore, preferred antigen-binding molecules or antibodies also include antigen-binding molecules or antibodies comprising an Fc domain having any of the substitutions shown below, the positions of which are specified according to EU numbers in the amino acids of the Fc domain forming the IgG3 antibody:

[0743] (k) F241A;

[0744] (l) D265A; or

[0745] (m) V264A. Each number represents the position of an amino acid residue in the EU number; and the single-letter amino acid symbol before the number represents the amino acid residue before substitution, while the single-letter amino acid symbol after the number represents the amino acid residue after substitution.

[0746] Furthermore, preferred antigen-binding molecules or antibodies also include antigen-binding molecules or antibodies comprising an Fc domain having any of the substitutions shown below, the positions of which are specified according to EU numbers in the amino acids of the Fc domain forming the IgG4 antibody:

[0747] (n) L235A, G237A, and E318A;

[0748] (o) L235E; or

[0749] (p) F234A and L235A. Each number represents the position of an amino acid residue in the EU number; and the numbersThe single-letter amino acid symbol preceding the number represents the amino acid residue before substitution, while the single-letter amino acid symbol following the number represents the amino acid residue after substitution.

[0750] Other preferred antigen-binding molecules or antibodies include, for example, antigen-binding molecules or antibodies containing an Fc domain, wherein any amino acid at positions 233, 234, 235, 236, 237, 327, 330, or 331 (EU number) of the amino acids in the Fc domain forming the IgG1 antibody is substituted with the corresponding amino acid at the corresponding position in the EU number of the corresponding IgG2 or IgG4.

[0751] Preferred antigen-binding molecules or antibodies also include, for example, antigen-binding molecules or antibodies containing an Fc domain, wherein any or more of the amino acids at positions 234, 235, and 297 (EU number) of the amino acids in the Fc domain forming the IgG1 antibody are substituted with other amino acids. The type of substituted amino acid is not particularly limited; however, antigen-binding molecules or antibodies comprising an Fc domain in which any one or more of the amino acids at positions 234, 235, and 297 are substituted with alanine are particularly preferred, as described on pages 45 / 122 of the specification, CN 122249467 A.

[0752] Preferred antigen-binding molecules or antibodies also include, for example, antigen-binding molecules or antibodies comprising an Fc domain in which the amino acid at position 265 (EU number) of the Fc domain forming the IgG1 antibody is substituted with another amino acid. The type of substituted amino acid is not particularly limited; however, antigen-binding molecules or antibodies comprising an Fc domain in which the amino acid at position 265 is substituted with alanine are particularly preferred.

[0753] (Preferred) enrichment (or increase)

[0754] The term “(preferred) enrichment (or increase)” means an increase in the relative abundance of the desired form, or an increase in the relative proportion of the desired form, or an increase in the population of the desired form (structural isoform). In some embodiments, the methods described herein increase the relative abundance of antibody structural isoforms, such as antibodies having at least one disulfide bond formed between amino acid residues outside the hinge region. In one embodiment, the at least one disulfide bond is formed between amino acid residues at position 191 according to EU number in the respective CH1 region of the first antigen-binding domain and the second antigen-binding domain. In some embodiments, the methods produce homogeneous antibody formulations having at least 50%, 60%, 70%, 80%, 90%, preferably at least 95% molar ratio of the antibody having at least one disulfide bond formed outside the hinge region.

[0755] Homogeneous

[0756] A “homogeneous” population of antibodies means a population of antibodies that primarily comprises a single form of antibody, for example, at least in a solution or composition.50%, 60%, 70%, 80% or more, preferably at least 90%, 95%, 96%, 97%, 99% or 100% of the antibody is in its correctly folded form. Similarly, a “homogeneous” population of antibodies having at least one disulfide bond formed outside the hinge region means a population of antibodies that primarily comprises a single, correctly folded form (e.g., at least 50%, 60%, 70%, 80% or more, preferably at least 90%, 95%, 96%, 97%, 99% or 100% molar ratio of said antibody having at least one disulfide bond formed outside the hinge region). In a preferred embodiment, the “homogeneous” population of antibodies comprises at least one disulfide bond formed between amino acid residues at position 191 according to EU number in the respective CH1 regions of the first and second antigen-binding domains (i.e., “paired cysteine” at position 191 according to EU number in the CH1 region).

[0757] Any of a variety of analytical and / or qualitative techniques can be used to determine whether the antibody population is homogeneous, and the relative abundance or proportion of protein / antibody conformations in the mixture. Such purification techniques can be used to determine the relative proportion of conformations in the mixture if the two conformations are dissociated differently during separation techniques such as chromatography, electrophoresis, filtration, or other purification techniques. For example, at least two different conformations of recombinant IgG can be dissociated by hydrophobic interaction chromatography. Furthermore, since far-UV circular dichroism has been used to estimate the secondary structural composition of proteins (Perczel et al., 1991, Protein Engrg. 4:669-679), such techniques can determine the presence of alternative conformations of proteins. Another technique for determining conformations is fluorescence spectroscopy, which can be used to determine complementary differences in the tertiary structure that can be allocated to tryptophan and tyrosine fluorescence. Other techniques that can be used to determine conformational differences and thus the relative proportions of conformations include: online SEC for measuring aggregation states, differential scanning calorimetry for measuring melt transition (Tm) and component enthalpy, and ionizing agent defolding. Another technique that can be used to determine conformational differences and thus the relative proportions of conformations is LC / MS detection to determine protein heterogeneity.

[0758] Alternatively, if there are activity differences between antibody / protein conformations, the relative proportions of conformations in the mixture can be determined by activity assays (e.g., binding to ligands, enzyme activity, biological activity, etc.). Protein biological activity can also be used. Alternatively, binding assays can be used, where activity is expressed as activity units / mg protein.

[0759] To determine antibody / protein heterogeneity, IEC chromatography is used. In this case, the antibody is purified or is described on page 53 of the specification 46 / 122.CN 122249467 A considers it "homogeneous," meaning that no peptide peaks or fractions corresponding to other peptides were detected during IEC chromatography analysis. In some embodiments, the antibody is purified or considered "homogeneous" such that no peptide bands corresponding to other peptides were detected during SDS-PAGE analysis. Those skilled in the art will recognize that multiple bands corresponding to a peptide can be visualized by SDS-PAGE due to differential glycosylation, differential post-translational processing, etc. Most preferably, the peptide is purified to be substantially homogeneous, as indicated by a single peptide band after SDS-PAGE analysis. Peptide bands can be visualized by silver staining, Coomassie brilliant blue staining, and / or (if the peptide is radiolabeled) by autoradiography.

[0760] Examples of conditions for SDS-PAGE analysis are given below. Non-reducing SDS-PAGE was performed using 4% to 20% Mini-PROTEAN (registered trademark) TGX Stain-Free™ pre-prepared gels (Bio-Rad) and 1x Tris / glycine / SDS run buffer (Bio-Rad). Monoclonal antibody samples were heated at 70°C for 10 minutes. 0.2 μg of sample was loaded and electrophoresis was performed at 200 V for 90 minutes. Protein visualization was performed using the Chemidoc imaging system (Bio-Rad). The percentage of individual bands was analyzed using Image Lab software version 6.0 (Bio-Rad), where the intensity % of a single band (e.g., faster migration (lower band) and slower migration (upper band)) was calculated by dividing the band intensity by the sum of the two bands. The gel was then stained with CBB, and gel images were captured, allowing for band quantification using the imaging device. In gel imaging, several bands can be observed for antibody variant samples, such as two bands, namely the "upper band" and the "lower band." In this case, the molecular weight of the upper band corresponds to the molecular weight of the parent antibody (before modification). Structural changes (such as disulfide crosslinking via Fab) may be caused by cysteine ​​substitution, which can lead to changes in electrophoretic mobility. In this case, the lower band can be considered to correspond to an antibody with one or more engineered disulfide bonds formed between the CH1 regions. Antibody variant samples with additional cysteine ​​substitutions show a higher lower band to upper band ratio compared to control samples. Additional cysteine ​​substitution can enhance / promote disulfide crosslinking of Fab; and can increase the percentage or structural homogeneity of antibody formulations with engineered disulfide bonds formed at the mutation site; and can reduce antibody formulations that do not form engineered disulfide bonds at the mutation site.The percentage. In this document, the term “lower band to upper band ratio” refers to the ratio between the number / intensity of the lower band and the upper band, which can be quantified in the above SDS-PAGE experiment.

[0761] The terms “pharmaceutical formulation” and “pharmaceutical composition” refer to a formulation in a biologically effective form of the active ingredient permitted to be contained therein, and which does not contain any additional components that would have unacceptable toxicity to the subject to whom the formulation will be administered.

[0762] “Pharmaceuticalally acceptable carrier” refers to a component in a pharmaceutical formulation that is non-toxic to the subject other than the active ingredient. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0763] “Individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., human and non-human primates, such as monkeys), rabbits, and rodents (e.g., mice and rats). In some embodiments, the individual or subject is a human.

[0764] II. A method for producing an antigen-binding molecule comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region outside the hinge region (LINC form), and a method for measuring, determining, or quantifying the ratio of the LINC form to the sum of the LINC form and the antigen-binding molecule not having a disulfide bond formed between amino acid residues in a region outside the hinge region (unLINC form)

[0765] This disclosure relates to a method for producing a formulation comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region outside the hinge region. The method in this disclosure includes a step of chromatographically reacting a mixture in the presence of a reducing agent, wherein the mixture comprises the antigen-binding molecule and the antigen-binding molecule in an incorrectly disulfide bonded form and / or a non-disulfide bonded form, the antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region outside the hinge region (hereinafter, the mixture may be referred to as a "mixture comprising an antigen-binding molecule", "mixture of antigen-binding molecules", etc.). In the methods of this disclosure, a mixture containing antigen-binding molecules may undergo one or more chromatography sessions of one type. Alternatively, the mixture containing antigen-binding molecules may be subjected to one or more (e.g., two, three, or more) chromatography sessions of multiple types (e.g., two, three, or more types). When multiple chromatographic processes are performed, these processes may be performed sequentially or non-sequentially.

[0766] In the methods of this disclosure, chromatography well known to those skilled in the art can be used. Examples include, but are not limited to, column chromatography, membrane chromatography, and thin-layer chromatography.

[0767] In the production method of this disclosure, the step of chromatographically processing the mixture containing antigen-binding molecules is carried out in the presence of a reducing agent. There are no limitations on the embodiments of the step of chromatographically processing the mixture containing antigen-binding molecules in the production method of this disclosure, as long as a reducing agent is present. For example, the antigen-binding molecules can be pre-loaded onto a chromatographic matrix and then contacted with a reducing agent, or the mixture containing antigen-binding molecules can be mixed with a reducing agent to obtain a substance that is passed through a chromatogram.

[0768] In one aspect, when using column chromatography, the method of this disclosure may include the step of contacting a chromatographic matrix loaded in a column for column chromatography with a mixture containing antigen-binding molecules and misdisulfide-bonded and / or non-disulfide-bonded forms of said antigen-binding molecules, said antigen-binding molecules having at least one disulfide bond formed between amino acid residues in a region other than the hinge region. In one aspect, when using membrane chromatography, the method of this disclosure may include the step of contacting a chromatographic matrix applied to a membrane for membrane chromatography with a mixture comprising an antigen-binding molecule and an incorrect disulfide bonded form and / or a non-disulfide bonded form of the antigen-binding molecule, the antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region outside the hinge region. The mixture comprising the antigen-binding molecule may be pre-contaminated with a reducing agent.

[0769] In this disclosure, the step of chromatographically performing a mixture comprising an antigen-binding molecule and an incorrect disulfide bonded form and / or a non-disulfide bonded form of the antigen-binding molecule may include the steps of the antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region outside the hinge region:

[0770] (a) contacting the mixture comprising the antigen-binding molecule and the incorrect disulfide bonded form and / or a non-disulfide bonded form of the antigen-binding molecule with a solution comprising a reducing agent, the antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region outside the hinge region; and

[0771] (b) removing the reducing agent.

[0772] In one aspect, the methods of this disclosure generate or purify populations of homologous antigen-binding molecules or formulations or concentrates of homologous antigen-binding molecules through the steps described herein.

[0773] In one aspect, relative to antigen-binding molecules loaded onto a matrix having amino acid residues having at least one disulfide bond between amino acid residues in regions other than the hinge region (such antigen-binding molecules include antigen-binding molecules that suitably form at least one disulfide bond between amino acid residues in regions other than the hinge region, and antigen-binding molecules that do not suitably form at least one disulfide bond between amino acid residues in regions other than the hinge region (i.e., incorrect disulfide bonded forms and / or non-disulfide bonded forms of antigen-binding molecules)), the methods of this disclosure can improve the efficiency of antigen-binding molecules having amino acid residues having at least one disulfide bond between amino acid residues in regions other than the hinge region.The proportion of antigen-binding molecules having at least one disulfide bond between amino acid residues in regions outside the hinge region.

[0774] In one aspect, relative to antigen-binding molecules loaded onto a matrix having amino acid residues that can form at least one disulfide bond between amino acid residues in regions outside the hinge region (such antigen-binding molecules include antigen-binding molecules that suitably form at least one disulfide bond between amino acid residues in regions outside the hinge region, and antigen-binding molecules that do not suitably form at least one disulfide bond between amino acid residues in regions outside the hinge region (or in other words, erroneous disulfide bonded forms and / or non-disulfide bonded forms of antigen-binding molecules)), the method of this disclosure produces antigen-binding molecules having at least one disulfide bond between amino acid residues in regions outside the hinge region at a molar ratio of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%.

[0775] Therefore, in one embodiment, this disclosure relates to a method for producing a formulation comprising an increased concentration of an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region. In one embodiment, the formulation produced by the method of this disclosure may be a concentrate of an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region. Furthermore, in one embodiment, this disclosure relates to a method for increasing the concentration of an antigen-binding molecule in a mixture of antigen-binding molecules having at least one disulfide bond formed between amino acid residues in a region other than the hinge region. In another embodiment, this disclosure relates to a method for purifying a formulation comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region from a mixture comprising an antigen-binding molecule having at least one disulfide bond formed between amino acid residues in a region other than the hinge region, and mis-disulfide bonded forms and / or non-disulfide bonded forms of the antigen-binding molecule. In this disclosure, antigen-binding molecules that do not have disulfide bonds formed between amino acid residues in regions other than the hinge region include antigen-binding molecules in regions other than the hinge region where cysteine ​​residues are capped, or antigen-binding molecules that exist only as cysteine.

[0776] In the methods of this disclosure, a mixture of antigen-binding molecules is contacted with a solution containing a reducing agent. In a specific embodiment, a mixture of antigen-binding molecules loaded onto a matrix is ​​contacted with a solution containing a reducing agent in chromatography. In one aspect, examples of chromatographic matrices of this disclosure include, but are not limited to, affinity chromatography matrices, ion exchange chromatography matrices, and hydrophobic chromatography matrices.Water-interacting chromatographic matrices, matrices for multimode chromatography incorporating both ion-exchange chromatography and hydrophobic interaction chromatography, and hydroxyapatite matrices. In this disclosure, the terms "matrix," "resin," "ligand," and "substrate" are used interchangeably.

[0777] In this disclosure, affinity chromatographic matrices are not limited to any particular type that exhibits affinity chromatographic activity. In one aspect, examples of affinity chromatographic matrices include, but are not limited to, protein A matrices, protein G matrices, protein L matrices, sequence-selective peptide matrices, and matrices that selectively bind to antigen-binding molecules.

[0778] In the methods of this disclosure, commercially available products can be used as affinity chromatographic matrices. In specific respects, including but not limited to the following:

[0779] MabSelect SuRe (registered trademark) (Cytiva Corporation),

[0780] MabSelect Xtra (registered trademark) (Cytiva Corporation),

[0781] MabSelect SuRe (registered trademark) LX (Cytiva Corporation),

[0782] MabSelect SuRe (registered trademark) pcc (Cytiva Corporation),

[0783] MabSelect PrismA (registered trademark) (Cytiva Corporation),

[0784] MabSpeed ​​(registered trademark) rP202 (Cytiva Corporation),

[0785] TOYOPEARL (registered trademark) r Protein A HC-650F (TOSOH Corporation),

[0786] Praesto (registered trademark) Jetted A50 (Purolite Corporation),

[0787] Amsphere (registered trademark) A3 (JSR Corporation),

[0788] Amsphere (registered trademark) Protein A JWT203 (JSR Corporation),

[0789] Eshmuno A (registered trademark) (Merck Millipore Corporation),

[0790] Capto L (registered trademark) (Cytiva Corporation), and specification page 49 / 122, 56 CN 122249467 A

[0791] MabSelect (registered trademark) VL (Cytiva Corporation)

[0792] can be examples of affinity chromatography matrices.

[0793] In one aspect, the ion exchange chromatography matrix of this disclosure includes anion exchange resins (anion exchange ligands) or cation exchange resins (cation exchange ligands). The anion exchange resins and cation exchange resins of this disclosure are not limited, as long as they exhibit anion exchange activity and cation exchange activity, respectively.

[0794] In the methods of this disclosure, commercially available products can be used as the anion exchange chromatography matrix. In specific respects, including but not limited to the following:

[0795] YMC-BioPro (YMC Corporation),

[0796] Q Sepharose (registered trademark) High Performance (Cytiva Corporation),

[0797] Q Sepharose (registered trademark) Fast Flow (Cytiva Corporation),

[0798] Q Sepharose (registered trademark) XL (Cytiva Corporation),

[0799] Q Sepharose (registered trademark) Large Bead (Cytiva Corporation),

[0800] Capto (registered trademark) Q ImpRes (Cytiva Corporation),

[0801] Capto (registered trademark) Q (Cytiva Corporation),

[0802] Capto (registered trademark) Q XP (Cytiva Corporation),

[0803] Capto (registered trademark) DEAE (Cytiva Corporation),

[0804] SOURCE (registered trademark) 30Q (Cytiva Corporation),

[0805] SOURCE (registered trademark) 15Q (Cytiva Corporation).

[0806] DEAE Sepharose (registered trademark) Fast Flow (Cytiva Corporation),

[0807] ANX Sepharose (registered trademark) 4 Fast Flow (Cytiva Corporation),

[0808] POROS (registered trademark) 50 PI (Thermo Fisher Corporation),

[0809] POROS (registered trademark) 50 HQ (Thermo Fisher Corporation),

[0810] POROS (registered trademark) HQ (Thermo Fisher Corporation),

[0811] POROS (registered trademark) D (Thermo Fisher Corporation),

[0812] POROS (registered trademark) PI (Thermo Fisher Corporation),

[0813] Eshumuno (registered trademark) Q (Merck Millipore Corporation),

[0814] Fractogel (registered trademark) TMAE (Merck Millipore Corporation),

[0815] Fractogel (registered trademark) DEAE (Merck Millipore Corporation),

[0816] Macro-Prep (registered trademark) Q (Bio-Rad Laboratories Corporation),

[0817] Macro-Prep (registered trademark) DEAE (Bio-Rad Laboratories Corporation),

[0818] Giga Cap (registered trademark) Q-650M (TOSOH Corporation),

[0819] Giga Cap (registered trademark) DEAE-650M (TOSOH Corporation) and

[0820] Q HyperCel (registered trademark) (PALL Corporation)

[0821] can be examples of anion exchange chromatography matrices.

[0822] Commercially available products can also be used as cation exchange chromatography matrices. In particular, not limited to the following:

[0823] Capto (registered trademark) S (Cytiva Corporation),

[0824] Capto (registered trademark) SP ImpRes (Cytiva Corporation),

[0825] Capto (registered trademark) S ImpaAct (Cytiva Corporation), Specification 50 / 122 pages 57 CN 122249467 A

[0826] SP Sepharose (registered trademark) Fast Flow (Cytiva Corporation),

[0827] CM Sepharose (registered trademark) Fast Flow (Cytiva Corporation),

[0828] SP Sepharose (registered trademark) High Performance (Cytiva Corporation),

[0829] CM Sepharose (registered trademark) High Performance (Cytiva Corporation),

[0830] SP Sepharose (registered trademark) XL (Cytiva Corporation),

[0831] SPSepharose (registered trademark) (Cytiva Corporation),

[0832] Eshumuno (registered trademark) CPX (Merck Millipore Corporation),

[0833] Eshumuno (registered trademark) CP-FT (Merck Millipore Corporation),

[0834] POROS (registered trademark) 50HS (Thermo Fisher Corporation), and

[0835] POROS (registered trademark) XS (Thermo Fisher Corporation)

[0836] can be examples of cation exchange chromatography matrices.

[0837] In this disclosure, the matrix used for hydrophobic interaction chromatography is not limited, as long as it exhibits hydrophobic interaction chromatographic activity. In one aspect, the hydrophobic interaction chromatography matrix includes hydrophobic ligands.

[0838] In the methods of this disclosure, commercially available products can be used as hydrophobic interaction chromatography matrices. In specific respects, including but not limited to the following:

[0839] Phenyl Sepharose (registered trademark) High Performance (Cytiva Corporation),

[0840] Butyl Sepharose (registered trademark) High Performance (Cytiva Corporation),

[0841] Phenyl Sepharose (registered trademark) 6 Fast Flow (Cytiva Corporation),

[0842] Butyl-S Sepharose (registered trademark) 6 Fast Flow (Cytiva Corporation),

[0843] Butyl Sepharose (registered trademark) 4 Fast Flow (Cytiva Corporation),

[0844] Octyl Sepharose (registered trademark) 4 Fast Flow (Cytiva Corporation),

[0845] Capto (registered trademark) Phenyl ImpRes (Cytiva Corporation),

[0846] Capto (registered trademark) Phenyl (Cytiva Corporation),

[0847] Capto (registered trademark) Phenyl (High Sub) (Cytiva Corporation),

[0848] Capto (registered trademark) Butyl (Cytiva Corporation),

[0849] Capto (registered trademark) Butyl ImpRes (Cytiva Corporation),

[0850] Capto (registered trademark) Cyclic (Cytiva Corporation)

[0851] Phenyl Sepharose (registered trademark) 6 Fast Flow (Low Sub) (Cytiva Corporation),

[0852] Phenyl Sepharose (registered trademark) 6 Fast Flow (High Sub) (Cytiva Corporation),

[0853] POROS (registered trademark) Ethyl (Thermo Fisher Corporation),

[0854] Fractogel (registered trademark) Phenyl (Merck Millipore Corporation),

[0855] Fractogel (registered trademark) Propyl (Merck Millipore Corporation),

[0856] TOYOPEARL (registered trademark) Butyl (TOSOH Corporation),

[0857] TOYOPEARL (registered trademark) Diethyl Ether (TOSOH Corporation),

[0858] TOYOPEARL (registered trademark) Hexyl (TOSOH Corporation),

[0859] TOYOPEARL (registered trademark) Phenyl (TOSOH Corporation),

[0860] TOYOPEARL (registered trademark) PPG (TOSOH Corporation),

[0861] TOYOPEARL (registered trademark) ultrabutyl (TOSOH Corporation),

[0862] TOYOPEARL (registered trademark) butyl-600 (TOSOH Corporation), specification 51 / 122 page 58 CN 122249467 A

[0863] TOYOPEARL (registered trademark) phenyl-650C (TOSOH Corporation),

[0864] TOYOPEARL (registered trademark) phenyl-650M (TOSOH Corporation),

[0865] TOYOPEARL (registered trademark) phenyl-650S (TOSOH Corporation),

[0866] TOYOPEARL (registered trademark) phenyl-600M (TOSOH Corporation) and

[0867] Macro-Prep (registered trademark) HIC (Bio-Rad Laboratories Corporation)

[0868] can be examples of hydrophobically interacting chromatographic matrices.

[0869] In one aspect, the multimode chromatographic matrix of this disclosure may include a combination of cation exchange ligands and hydrophobic ligands.A matrix, or a matrix combining anion exchange ligands and hydrophobic ligands. In the methods of this disclosure, commercially available products can be used as multimode chromatography matrices. For example, not limited to, the following:

[0870] Capto (registered trademark) adhere (Cytiva Corporation),

[0871] Capto (registered trademark) adhere ImpRes (Cytiva Corporation),

[0872] Capto (registered trademark) MMC (Cytiva Corporation),

[0873] Capto (registered trademark) MMC ImpRes (Cytiva Corporation), and

[0874] Eshmuno (registered trademark) CMX (Merck Millipore Corporation)

[0875] can be examples of matrices for multimode chromatography.

[0876] In one aspect, a hydroxyapatite chromatographic matrix may include hydroxyapatite or derivatives thereof (such as fluorapatite). In the methods of this disclosure, commercially available products can also be used as hydroxyapatite chromatographic matrices. In specific embodiments, the following are not limited to:

[0877] Ceramic hydroxyapatite (registered trademark) Type I (Bio-Rad Laboratories Corporation),

[0878] Ceramic hydroxyapatite (registered trademark) Type II (Bio-Rad Laboratories Corporation),

[0879] Ceramic fluorapatite (registered trademark) (Bio-Rad Laboratories Corporation),

[0880] MPC (registered trademark) ceramic hydroxyfluorapatite (Bio-Rad Laboratories Corporation),

[0881] HA Ultrogel (registered trademark) (PALL Corporation), and

[0882] Ca++Pure-HA (registered trademark) (TOSOH Corporation).

[0883] These can be examples of matrices used for hydroxyapatite chromatography.

[0884] In the methods of this disclosure, commercially available products can also be used for membrane chromatography. In specific embodiments, the following are not limited to:

[0885] Mustang (registered trademark) Q (PALL Corporation),

[0886] Mustang (registered trademark) S (PALL Corporation),

[0887] Sartobind (registered trademark) Q (Sartorius Corporation),

[0888] Sartobind (registered trademark) S

[0889] Sartobind (registered trademark) STIC (Sartorius Corporation),

[0890] Sartobind (registered trademark) Protein A (Sartorius Corporation),

[0891] Fibro (Cytiva Corporation),

[0892] Protein Capture (GORE Corporation),

[0893] Natrix (registered trademark) Q (Merck Millipore Corporation),

[0894] Purexa (registered trademark)-MQ (Purilogics Corporation),

[0895] Purexa (registered trademark)-A (Purilogics Corporation), and

[0896] Purexa (registered trademark)-DMAE (Purilogics Corporation) Specification 52 / 122 pages 59 CN 122249467 A

[0897] can be cited as examples of products for use in membrane chromatography.

[0898] In this disclosure, the terms “reducing reagent,” “reducing agent,” and “solution containing a reducing agent” are used interchangeably. In some embodiments, the reducing agent is a free thiol. Furthermore, in one aspect, the reducing agent in this disclosure may be a monothiol, a dithiol, a phosphine, or an inorganic reagent. Examples of monothiols in this disclosure include, but are not limited to, glutathione, cysteine, lipoic acid, 2-mercaptoethanol, and 2-MEA. Examples of dithiols in this disclosure include, but are not limited to, dithiothreitol (DTT), DTE, and DTBA. Examples of phosphine in this disclosure include, but are not limited to, tris(2-carboxyethyl)phosphine (TCEP) and THPP. Examples of inorganic reagents in this disclosure include, but are not limited to, sodium sulfite and sodium metabisulfite.

[0899] The reducing agent is preferably composed of a compound selected from the group consisting of: glutathione (GSH), dithiothreitol (DTT), 2-mercaptoethanol, 2-aminoethanethiol (2-MEA), tris(2-carboxyethyl)phosphine (TCEP), dithionitrobenzoate, cysteine, sodium sulfite, sodium metabisulfite, and Na2SO3. In some embodiments, TCEP, 2-MEA, DTT, cysteine, GSH, or Na2SO3 may be used. In some preferred embodiments, cysteine ​​may be used. In some preferred embodiments, TCEP may be used. In the methods of this disclosure, one or more types (e.g., two, three, or more types) of reducing agents may be used.

[0900] In one embodiment, the reducing agent may be a solution, or preferably in the form of a buffer. Examples of buffers include, but are not limited to, buffers used in chromatographic techniques such as phosphate buffer, Tris buffer, acetate buffer, citrate buffer, tartrate buffer, and borate buffer. Additionally, examples of bases include sodium hydroxide, potassium hydroxide, lithium hydroxide, and Tris.

[0901] In this disclosure, “contact” means subjecting or exposing a mixture of antigen-binding molecules to a solution containing a reducing agent, or mixing a mixture of antigen-binding molecules with a solution containing a reducing agent. In the methods of this disclosure, a mixture of antigen-binding molecules may be contacted with a solution containing a reducing agent while the molecules are in a state of binding to a solid matrix (e.g., a column chromatography column or a membrane chromatography membrane).

[0902] While not bound by the following theory, it is thought that the presence of unLINC forms (i.e., divalent or trivalent antigen-binding molecules without engineered disulfide bonds or “paired cysteines”) may be due to the frequent formation of disulfide bonds between unpaired Cys residues and molecules containing free thiol groups, such as cysteine ​​and glutathioneization, which prevent LINC formation (formation of engineered disulfide bonds in regions outside the hinge region) by “capping” unpaired Cys residues. To remove molecules with unpaired capped cysteines, reducing agents can facilitate the decapping of surface cysteines, and further re-oxidation of the decapped antigen-binding molecule (e.g., by removing the reducing agent) can promote the formation of disulfide bonds between decapped cysteines for LINC formation. Therefore, by removing cysteine ​​from unpaired thiol groups in unLINC forms through reduction and re-oxidation, unLINC forms can be removed and antibody homogeneity improved.

[0903] In one aspect, in the method of this disclosure, a mixture of antigen-binding molecules is contacted with a solution containing a reducing agent, resulting in the breaking of disulfide bonds formed between amino acid residues that can form disulfide bonds in the antigen-binding molecules. In one aspect, contacting the mixture of antigen-binding molecules with a solution containing a reducing agent results in the decapping of capped cysteine ​​residues in the antigen-binding molecules.

[0904] In one aspect, in the method of this disclosure, removal of the reducing agent results in the formation of disulfide bonds between amino acid residues that can form disulfide bonds in the antigen-binding molecules.

[0905] The contacting of the mixture of antigen-binding molecules with a solution containing a reducing agent is performed for a time sufficient to increase the relative proportion of the desired conformation. Any relative increase in proportion is desired, including, for example, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% of antigen-binding molecules having an undesired conformation are converted to antigen-binding molecules having the desired conformation. Specification 53 / 122 pages 60 CN122249467 A

[0906] In one aspect, in the method of this disclosure, a solution containing a reducing agent is passed through a chromatographic system containing a matrix carrying antigen-binding molecules. In a specific embodiment, the antigen-binding molecules constitute a stationary phase immobilized to the chromatographic matrix, and the solution containing the reducing agent is part of the mobile phase. In this case, contact can be performed as part of a chromatographic purification procedure.

[0907] The reducing agent is present at a concentration sufficient to increase the desired conformation (e.g., an antigen-binding molecule in the form of "paired cysteine" having one or more engineered disulfide bonds between the two Fabs of the antibody (e.g., between regions outside the hinge region). The optimal absolute concentration and molar ratio of the reducing agent depend on the total concentration of the antigen-binding molecules, and in some cases also on the concentration of a particular antigen-binding molecule. Furthermore, the reducing agent concentration also depends on the number and availability of unpaired cysteines in the antigen-binding molecules.

[0908] In one aspect, examples of the concentration of the reducing agent include a range that can be specified by any combination of the following: a lower limit selected from the group consisting of about 0.0001 mM, about 0.0005 mM, about 0.001 mM, about 0.005 mM, about 0.01 mM, about 0.05 mM, about 0.1 mM, about 0.5 mM and about 1.0 mM; and an upper limit selected from the group consisting of about 100.0 mM, about 75.0 mM, about 50.0 mM, about 25.0 mM, about 10.0 mM, about 5.0 mM, about 1.0 mM, about 0.5 mM, about 0.1 mM and about 0.01 mM. In some embodiments, the concentration of the reducing agent may range from about 0.00001 mM to about 10.0 mM, about 0.00005 mM to about 5.0 mM, about 0.0001 mM to about 1.0 mM, about 0.0005 mM to about 0.5 mM, about 0.001 mM to about 0.1 mM, or about 0.001 mM to about 0.01 mM. In other embodiments, the concentration of the reducing agent may range from about 0.001 mM to about 100.0 mM, about 0.005 mM to about 75.0 mM, about 0.01 mM to about 50.0 mM, about 0.05 mM to about 25.0 mM, or about 0.1 mM to about 10 mM. In another embodiment, the concentration of the reducing agent ranges from about 0.0001 mM to about 100.0 mM, from about 0.0005 mM to about 50.0 mM, from about 0.001 mM to about 10.0 mM, and from about 0.005 mM to about 5.0 mM.Examples of reducing agents include mM, or from about 0.01 mM to about 1.0 mM. In specific embodiments, the concentration of the reducing agent may be about 0.001 mM, about 0.01 mM, about 0.1 mM, about 0.15 mM, about 1.0 mM, or about 10.0 mM.

[0909] In some preferred embodiments, when the reducing agent is cysteine, the concentration of the reducing agent may be from about 0.01 mM to about 100.0 mM, from about 0.05 mM to about 50.0 mM, from about 0.1 mM to about 10.0 mM, or from about 0.5 mM to about 5.0 mM. In a further preferred embodiment, when the reducing agent is cysteine, the concentration of the reducing agent can be from about 0.001 mM to about 100.0 mM, from about 0.005 mM to about 75.0 mM, from about 0.01 mM to about 50.0 mM, from about 0.05 mM to about 25.0 mM, or from about 0.1 mM to about 10 mM. In a further preferred embodiment, when the reducing agent is cysteine, the concentration of the reducing agent can be from about 0.0001 mM to about 100.0 mM, from about 0.001 mM to about 75.0 mM, from about 0.01 mM to about 50.0 mM, or from about 0.1 mM to about 10.0 mM. In some preferred embodiments, when the reducing agent is dithiol, the concentration of the reducing agent can be from about 0.001 mM to about 10 mM. In some preferred embodiments, when the reducing agent is phosphine, the concentration of the reducing agent can be from about 0.0001 mM to about 1 mM or from about 0.001 mM to about 0.01 mM. In some preferred embodiments, when the reducing agent is TCEP, the concentration of the reducing agent can be from about 0.00001 mM to about 10.0 mM, from about 0.00005 mM to about 5.0 mM, from about 0.0001 mM to about 1 mM, from about 0.0005 mM to about 0.5 mM, from about 0.001 mM to about 0.1 mM, or from about 0.001 mM to about 0.01 mM. In some preferred embodiments, when the reducing agent is an inorganic reagent, the concentration of the reducing agent can be from about 0.0001 mM to about 10 mM or from about 0.001 mM to about 0.1 mM.

[0910] In a specific embodiment, when the reducing agent is cysteine, the concentration of the reducing agent can be about 0.1 mM, about 0.15 mM, about 1.0 mM, about 10.0 mM, or about 100 mM. In a specific embodiment, when the reducing agent is TCEP, the concentration of the reducing agent can be about 0.001 mM, about 0.01 mM, or about 100 mM.0.1 mM or about 1.0 mM. Specification 54 / 122 pages 61 CN 122249467 A

[0911] In order to maximize the yield of antigen-binding molecules having the desired conformation, the pH of the solution containing the reducing agent is selected to protect the stability of the antigen-binding molecules and is most suitable for disulfide bond exchange. In one aspect, the pH of the solution containing the reducing agent of this disclosure can be about 4.5 to about 10.0, about 5.0 to about 9.0, about 6.5 to about 8.5, or about 7.0 to about 8.0. In non-limiting embodiments of the invention, the optimal pH is found to be about 7.0, about 7.5, or about 8.0. However, the optimal pH in specific embodiments of the invention can be readily determined by those skilled in the art through experimentation.

[0912] In the method of this disclosure, the contact between the chromatographic matrix, the antigen-binding molecule, and the reducing agent occurs in chromatography. In one embodiment, in the method of this disclosure, the contact between the antigen-binding molecule loaded on the matrix and the reducing agent occurs in chromatography. In other words, in the method of this disclosure, the contact between the reducing agent and the antigen-binding molecule can be achieved by passing a solution containing the reducing agent through a column chromatography column or membrane chromatography device containing antigen-binding molecules loaded onto a matrix.

[0913] In some embodiments, the solution containing the reducing agent is passed through a column chromatography column or membrane chromatography device for a residence time of about 2 seconds to about 80 minutes or about 3 seconds to about 24 minutes. In a specific embodiment, the solution containing the reducing agent is passed through a column chromatography column or membrane chromatography device for a residence time of about 12 minutes or about 30 seconds. In some embodiments, flow can be temporarily stopped while the column or device is filled with a solution containing the reducing agent.

[0914] In one aspect, when using column chromatography, the solution containing the reducing agent is passed through the column for a residence time of about 2 minutes to about 80 minutes or about 4 minutes to about 24 minutes. In a specific embodiment, when using column chromatography, the solution containing the reducing agent is passed through the column for a residence time of about 12 minutes. In one aspect, flow can be temporarily stopped while the column is filled with a solution containing the reducing agent. In one aspect, when using column chromatography, a solution containing the reducing agent of this disclosure can be passed through the column at a rate of about 25 cm / h to about 500 cm / h, about 50 cm / h to about 400 cm / h, about 75 cm / h to about 350 cm / h, or about 100 cm / h to about 300 cm / h. In some embodiments, a solution containing the reducing agent of this disclosure can be passed through the column at a rate of about 100 cm / h. In one aspect, flow can be temporarily stopped when the column is filled with a solution containing the reducing agent.

[0915] In one aspect, when using membrane chromatography, a solution containing a reducing agent is passed through the membrane device for a residence time of about 2 seconds to about 60 minutes or about 3 seconds to about 6 minutes, for example, about 30 seconds. In some embodiments, flow may be temporarily stopped once the membrane device is filled with a solution containing a reducing agent. In one aspect, when using membrane chromatography, a solution containing the reducing agent of the present disclosure may be passed through the membrane device at a rate of about 0.017 MV / min to about 30 MV / min, about 0.17 MV / min to about 20 MV / min, about 1 MV / min to about 10 MV / min, or about 2 MV / min to about 5 MV / min. In a specific embodiment, a solution containing the reducing agent of the present disclosure may be passed through the membrane device at a rate of about 2 MV / min. Flow may be temporarily stopped once the membrane device is filled with solution.

[0916] There is no particular limitation on the amount of solution containing the reducing agent flowing through the column, but for example, when using column chromatography, the flow volume of the solution containing the reducing agent can be about 0.1 times (about 0.1 column volume (CV)) to about 100 times (about 100 CV), about 1 times (about 1 CV) to about 20 times (about 20 CV), or about 3 times (about 3 CV) to about 10 times (about 10 CV) of the column volume. In some embodiments, the amount of solution containing the reducing agent flowing through the column can be about 10 times the column volume (about 10 CV). Furthermore, when using membrane chromatography, the flow volume of the solution containing the reducing agent can be about 1 times (about 1 membrane volume (MV)) to about 500 times (about 500 MV), or about 2 times (about 2 MV) to about 100 times (about 100 MV) of the membrane device volume. In some embodiments, the amount of the solution containing the reducing agent flowing through the column can be about 15 column volumes (about 15 MV).

[0917] The reaction time (contact time) between the mixture of antigen-binding molecules and the solution containing the reducing agent is not particularly limited, but examples include about 6 seconds to about 1440 minutes, about 18 seconds to about 300 minutes, about 5 minutes to about 180 minutes, about 10 minutes to about 150 minutes, or about 12 minutes to about 120 minutes. In a particular embodiment, the contact time between the mixture of antigen-binding molecules and the solution containing the reducing agent can be about 120 minutes or about 7.5 minutes.

[0918] In one aspect, when using column chromatography, the contact time between the mixture of antigen-binding molecules and the solution containing the reducing agent can be about 4 minutes to about 1440 minutes, about 8 minutes to about 300 minutes, about 30 minutes to about 240 minutes, or about 60 minutes.From minutes to about 180 minutes or about 120 minutes. In a specific embodiment, the contact time between the mixture of antigen-binding molecules and the solution containing the reducing agent can be about 120 minutes.

[0919] In one aspect, when membrane chromatography is used, the contact time between the mixture of antigen-binding molecules and the solution containing the reducing agent can be from about 6 seconds to about 600 minutes or from about 18 seconds to about 120 minutes, for example, about 7.5 minutes.

[0920] In the methods of this disclosure, the antigen-binding molecules can be contacted with the reducing agent in a suitable variety of volumes, such as at the analytical scale (1 mL to 50 mL), the preparative scale (50 mL to 10 L), and the manufacturing scale (10 L or more). In one aspect, the amount of antigen-binding molecules loaded onto the substrate can be about 5 to 100 g, about 7 to 70 g, about 10 to 40 g, for example, about 10 g or about 25 g per 1 L of chromatographic matrix containing the substrate.

[0921] In one aspect, when column chromatography is used, the amount of antigen-binding molecules loaded onto the substrate can be about 5 g to about 80 g, about 7 g to about 70 g, or about 10 g to about 40 g per 1 L of chromatographic matrix containing the substrate, for example, about 10 g.

[0922] In one aspect, when membrane chromatography is used, the amount of antigen-binding molecules loaded onto the membrane can be about 5 g to about 100 g, about 7 g to about 50 g, or about 10 g to about 40 g per 1 L of membrane device volume, for example, about 25 g.

[0923] The methods of this disclosure include the step of removing a reducing agent. In this disclosure, removing a reducing agent includes completely removing the reducing agent, reducing the concentration of the reducing agent, and chemically inactivating the reducing agent. Removal of the reducing agent promotes the re-oxidation of disulfide bonds in regions other than the hinge region between the two Fabs constituting the antigen-binding molecule.

[0924] In one aspect, the reducing agent can be removed by contacting the antigen-binding molecule with a solution that does not contain a reducing agent. In one aspect, the reducing agent can be removed by passing a solution free of the reducing agent through a column chromatography column or a membrane chromatography device.

[0925] In some embodiments, the solution free of the reducing agent is passed through a column chromatography column or a membrane chromatography device for a residence time of about 2 seconds to about 80 minutes or about 3 seconds to about 24 minutes. In a specific embodiment, the solution free of the reducing agent is passed through a column chromatography column or a membrane chromatography device for a residence time of about 4 minutes. In some embodiments, flow can be temporarily stopped when the column or device is filled with solution.

[0926] In some embodiments, when using column chromatography, the solution free of the reducing agent is passed through the column for a residence time of about 2 minutes to about 80 minutes or about 4 minutes to about 24 minutes.Minutes. In a particular embodiment, when using column chromatography, a solution without a reducing agent is passed through the column for a residence time of about 4 minutes. In some embodiments, flow may be temporarily stopped when the column is filled with solution.

[0927] In some embodiments, when using column chromatography, a solution without a reducing agent may be passed through the column at a rate of about 25 cm / h to about 500 cm / h, about 50 cm / h to about 450 cm / h, about 200 cm / h to about 400 cm / h, or about 250 cm / h to about 350 cm / h. Furthermore, in a particular embodiment, a solution without the reducing agent of this disclosure may be passed through the column at a rate of about 300 cm / h. Flow may be temporarily stopped when the column is filled with solution.

[0928] In some embodiments, when using membrane chromatography, a solution without a reducing agent is passed through the membrane device for a residence time of about 2 seconds to about 60 minutes or about 3 seconds to about 6 minutes, for example, about 30 seconds. In some embodiments, flow may be temporarily stopped when the device is filled with solution. Specification page 56 / 122 63 CN 122249467 A

[0929] In some embodiments, when using membrane chromatography, a solution without a reducing agent can be flowed through the membrane device at a rate of about 0.017 MV / min to about 30 MV / min, about 0.17 MV / min to about 20 MV / min, about 1 MV / min to about 10 MV / min, or about 2 MV / min to about 5 MV / min. Furthermore, in a specific embodiment, a solution without a reducing agent of the present disclosure can be flowed through the membrane device at a rate of about 2 MV / min. Flow can be temporarily stopped when the membrane device is filled with solution.

[0930] There are no particular limitations on the solution without a reducing agent, but in one instance, a buffer solution can be used, and more specifically, buffer solutions commonly used in chromatographic techniques, such as phosphate buffer, Tris buffer, acetate buffer, citrate buffer, tartrate buffer, and borate buffer, can be used. Furthermore, examples of bases include sodium hydroxide, potassium hydroxide, lithium hydroxide, and Tris. In one aspect, in the methods of this disclosure, for the solution not containing a reducing agent, a solution of the same type as the solution containing a reducing agent used in the contact step can be used, except that a reducing agent is absent.

[0931] In one aspect, when using column chromatography, the flow volume of the solution not containing a reducing agent can be from about 0.1 times (about 0.1 CV) to about 100 times (about 100 CV), from about 1 times (about 1 CV) to about 20 times (about 20 CV), or from about 3 times (about 3 CV) to about 10 times (about 10 CV).Column volume (CV). In some embodiments, the flow volume of the solution without reducing agent may be about 5.0 column volumes (about 5.0 CV).

[0932] In one aspect, when using membrane chromatography, the flow volume of the solution without reducing agent may be about 1 (1 MV) to about 500 (500 MV), or about 2 (2 MV) to about 100 (100 MV) membrane device volume, for example about 15 times the membrane device volume (15 MV).

[0933] In one aspect, the reaction time (contact time) between the mixture of antigen-binding molecules and the solution without reducing agent may be about 6 seconds to about 1440 minutes, about 18 seconds to about 300 minutes, about 5 minutes to about 60 minutes, about 10 minutes to about 50 minutes, or about 12 minutes to about 40 minutes. In a particular embodiment, the reaction time (contact time) between the mixture of antigen-binding molecules and the solution without reducing agent may be about 20 minutes.

[0934] In one aspect, when column chromatography is used, the reaction time (contact time) between the mixture of antigen-binding molecules and the solution without a reducing agent can be from about 4 minutes to about 1440 minutes or from about 8 minutes to about 300 minutes. In a particular embodiment, when column chromatography is used, the reaction time (contact time) between the mixture of antigen-binding molecules and the solution without a reducing agent can be about 20 minutes.

[0935] In one aspect, when membrane chromatography is used, the reaction time (contact time) between the mixture of antigen-binding molecules and the solution without a reducing agent can be from about 6 seconds to about 600 minutes or from about 18 seconds to about 120 minutes, for example, about 7.5 minutes.

[0936] The method of the present invention can be carried out over a wide temperature range. For example, the method of the present invention can be carried out from about 4°C to about 37°C or from about 15°C to about 37°C. Typical temperatures for contacting formulations of partially or completely purified antigen-binding molecules are from about 4°C to about 25°C (ambient temperature), or preferably at 23°C, but the contact can also be carried out at lower and higher temperatures. In some embodiments, the methods of this disclosure can be carried out at a temperature of about 20°C to 37°C, preferably at 23°C, 25°C, or 37°C, and more preferably at 23°C.

[0937] Furthermore, for solutions that do not contain a reducing agent, the optimal pH can be readily determined experimentally by those skilled in the art. Examples can be about 4.5 to about 10.0, about 5.0 to about 9.0, about 6.5 to about 8.5, or about 7.0 to about 8.0. Furthermore, in specific embodiments, the optimal pH can be about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about...7.6, about 7.7, about 7.8, or about 7.9.

[0938] In one aspect, in the method of this disclosure, prior to the step of contacting the mixture of antigen-binding molecules with a solution containing a reducing agent, the method may include contacting the mixture with a chromatographic matrix to fill the interior of the column with antigen-binding molecules or immobilizing antigen-binding molecules onto a membrane. In a specific embodiment, when the mixture is a cell culture medium containing antigen-binding molecules (harvested cell culture medium: HCCF), prior to the step of contacting the cell culture medium with a solution containing a reducing agent, the method may include contacting the cell culture medium with a chromatographic matrix to fill the interior of the column with antigen-binding molecules or immobilizing antigen-binding molecules onto a membrane. In one aspect, the mixture of antigen-binding molecules includes antigen-binding molecules having at least one disulfide bond in the region outside the hinge region (i.e., LINC form) and antigen-binding molecules not having disulfide bonds in the region outside the hinge region (i.e., unLINC form).

[0939] In some aspects, the antigen-binding molecules may be at least partially purified prior to the contact step with a solution containing a reducing agent. In some embodiments, the production method of this disclosure may include a step of affinity chromatography (preferably protein A chromatography) on a cell culture medium containing antigen-binding molecules prior to the contact step.

[0940] In one aspect, the method of this disclosure may include a step of removing impurities from the chromatography prior to the contact step. As described in the example, impurities can be removed by methods well known to those skilled in the art, such as passing a buffer through a column carrying a substrate adsorbed with antigen-binding molecules.

[0941] In one aspect, the method of this disclosure may further include a step of collecting or eluting antigen-binding molecules having at least one disulfide bond in a region outside the hinge region, and / or purifying the antigen-binding molecules, prior to or after the step of removing the reducing agent. In one embodiment, the collection and elution of antigen-binding molecules may be performed by eluting the antigen-binding molecules from a chromatographic column by methods well known to those skilled in the art, such as using an elution buffer. Those skilled in the art may appropriately adjust the pH and composition of the elution buffer according to the characteristics of the antigen-binding molecules to be purified.

[0942] In one embodiment, a formulation of an antigen-binding molecule produced as described herein can be further purified using techniques known in the art, such as high-performance liquid chromatography, ion-exchange chromatography, gel electrophoresis, affinity chromatography, and size exclusion chromatography. The specific conditions used to purify a particular antigen-binding molecule will depend in part on factors such as net charge, hydrophobicity, and hydrophilicity, which will be apparent to those skilled in the art. For affinity chromatography purification, antigen-binding molecules can be purified using...Antigen-binding molecules are antibodies, ligands, receptors, or antigens that bind to each other. For example, for affinity chromatography purification of antigen-binding molecules, a matrix having protein A or protein G can be used. Sequential protein A or G affinity chromatography and size exclusion chromatography can be used to separate antigen-binding molecules. The purity of antigen-binding molecules can be determined by any of a variety of well-known analytical methods, including gel electrophoresis and high-performance liquid chromatography.

[0943] In some embodiments, antigen-binding molecules having at least one disulfide bond in a region outside the hinge region, produced or purified by the methods described herein, are further processed in a separate processing step using a dissociative denaturing agent, such as sodium dodecyl sulfate (SDS), urea, or guanidine hydrochloride (GuHCl). A large amount of dissociative agent is required to observe perceptible unfolding. In some embodiments, the processing step uses a dissociative agent between 0.1 M and 2 M, which produces an effect equivalent to using 0.1 M to 2 M guanidine hydrochloride. In specific embodiments, oxidative refolding is achieved in the presence of approximately 1.0 M guanidine hydrochloride or a quantity of other dissociative agent that produces the same or similar amount of refolding as 1 M guanidine hydrochloride. In some embodiments, the method uses a dissociative agent between approximately 1.5 M and 0.5 M. The amount of dissociative agent used is based on the structural stability of the antigen-binding molecule in the presence of said dissociative agent. Sufficient dissociative agent is required to disrupt the local tertiary and / or quaternary structures of the domain interactions of the antigen-binding molecule, but less than the amount required for complete unfolding of the molecule and / or the secondary structures of the individual domains. To determine the point at which the antigen-binding molecule will begin to unfold through equilibrium denaturation, those skilled in the art titrate the dissociative agent into a solution containing the antigen-binding molecule and monitor the structure using techniques such as circular dichroism or fluorescence. Other parameters can be used to unfold or slightly disrupt the structure of the antigen-binding molecule, which can be used instead of a dissociative agent. Temperature and pressure are two fundamental parameters previously used to alter the structure of antigen-binding molecules and can be used instead of a dissociative agent when in contact with oxidizing and / or reducing agents. The inventors anticipate that those skilled in the art can use any parameter proven to denature or disrupt the structure of the antigen-binding molecule as described on page 58 / 122 of the specification, CN 122249467 A, instead of the ionizing agent.

[0944] The method of this disclosure improves the "LINC ratio," which is the ratio of antigen-binding molecules in LINC form to antigen-binding molecules loaded onto the matrix (i.e., antigen-binding molecules in LINC form having at least one disulfide bond in a region outside the hinge region, and the sum of antigen-binding molecules in unLINC form). For example, as described in WO2021 / 157679, cross-linked LINC forms and uncross-linked unLINC forms can be combined by non-reducing SDS-PAGE.The LINC ratio is calculated by separating the forms (open forms) and comparing their respective abundance ratios.

[0945] In one embodiment, the formulation of antigen-binding molecules produced as described herein may be further subjected to techniques such as electrophoresis and chromatography to determine the LINC ratio. More specifically, after the purification step by chromatography, the production method of this disclosure may include the step of measuring, determining, or quantifying the LINC ratio (i.e., the ratio of antigen-binding molecules having at least one disulfide bond in a region outside the hinge region (LINC form) to (i) antigen-binding molecules having at least one disulfide bond formed between amino acid residues in a region outside the hinge region (LINC form) and (ii) the sum of incorrectly disulfide-bonded forms and / or non-disulfide-bonded forms (unLINC forms) of antigen-binding molecules) in the formulation obtained from the purification step. In one embodiment, the production method of this disclosure may include the steps of measuring, determining, or quantifying the ratio (LINC ratio) of antigen-binding molecules having at least one disulfide bond in a region outside the hinge region to (i) antigen-binding molecules having at least one disulfide bond formed between amino acid residues in a region outside the hinge region and (ii) the sum of antigen-binding molecules with non-disulfide bonds (unLINC forms).

[0946] This disclosure also relates to a method for measuring, determining, or quantifying the ratio (LINC ratio) of LINC forms to the sum of LINC and unLINC forms in a composition comprising antigen-binding molecules having at least one disulfide bond formed between amino acid residues in a region outside the hinge region and mis-disulfide bonds and / or non-disulfide bonds (unLINC forms) of antigen-binding molecules. In some embodiments, this disclosure relates to a method for measuring, determining, or quantifying the ratio (LINC ratio) of the LINC form to the sum of the LINC and unLINC forms in a composition comprising an antigen-binding molecule (LINC form) having at least one disulfide bond formed between amino acid residues in a region outside the hinge region and a non-disulfide bond-bound form (unLINC form) of the antigen-binding molecule.

[0947] In other embodiments, this disclosure relates to a method for measuring, determining, or quantifying the ratio (LINC ratio) of the LINC form to the sum of the LINC and unLINC forms in a composition comprising an antigen-binding molecule (LINC form) having at least one disulfide bond formed in a region outside the hinge region and an antigen-binding molecule (unLINC form) not having a disulfide bond formed in a region outside the hinge region.

[0948] The methods for measuring, determining or quantifying in this disclosure include the steps (a) and (b):

[0949] (a) preparing composition (2) by adding a protease to a composition (1) comprising LINC and unLINC forms; and

[0950] (b) subjecting composition (2) to electrophoresis or chromatography.

[0951] There are no particular limitations on the composition (1) comprising LINC and unLINC forms in this disclosure, as long as it comprises both LINC and unLINC forms. The ratio of LINC to unLINC forms or the degree of purification are also not limited. In one embodiment, the composition (1) comprising LINC and unLINC forms in this disclosure may comprise the LINC form disclosed herein and its corresponding unLINC form. In one embodiment, the composition (1) comprising LINC and unLINC forms in this disclosure may be a formulation obtained by the methods for production disclosed herein, or may be a formulation disclosed herein. In one embodiment, the composition (1) comprising the LINC form and unLINC form of this disclosure (page 59 / 122, 66 CN 122249467 A) may be in the form of a crude purified product. In another embodiment, the composition (1) comprising the LINC form and unLINC form of this disclosure may be in the form of a drug substance or a standard product.

[0952] In one embodiment, the steps for measuring, determining, or quantifying the LINC ratio include electrophoresis, chromatography, etc. In one embodiment, the method for measuring, determining, or quantifying the LINC ratio in this disclosure includes the steps of electrophoresis or chromatography of the compositions (1) and / or (2) and / or (3) described later. In one embodiment, the method for measuring, determining, or quantifying the LINC ratio in this disclosure includes the steps of electrophoresis or chromatography of the compositions (1) and (2) and (3) described later. In one embodiment, non-reducing SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and non-reducing capillary SDS gel electrophoresis (CE-SDS) can be examples of electrophoresis. Furthermore, in one embodiment, hydrophobic interaction chromatography (HIC) can be an example of chromatography. These techniques can be employed using devices well known to those skilled in the art. LabChip™ (PerkinElmer), PA800 (SCIEX), etc., can be examples of non-reducing capillary SDS gel electrophoresis (CE-SDS) devices. As for the use of hydrophobic phases...Examples of devices for interaction chromatography include Proteomix (registered trademark) (Sepax Technologies, Inc.), Shim-pack Bio HIC series (Shimadzu), and MabPAC HIC-10 (Thermo Fisher Scientific).

[0953] In one embodiment, the method of production described herein may include the step of adding a protease to a formulation of an antigen-binding molecule produced as described herein prior to the step of measuring, determining, or quantifying the LINC ratio. In one embodiment, the method of measuring, determining, or quantifying the LINC ratio described herein includes the step of adding a protease to a composition (1) comprising both LINC and unLINC forms to prepare composition (2). The protease described herein is not particularly limited, as long as it is an enzyme that does not digest the LINC form but is capable of digesting the unLINC form. In one embodiment, the protease may be a cysteine ​​protease capable of digesting the hinge region of an antibody. Such an enzyme can break down the antibody to produce Fab and Fc regions. In one embodiment, preferably, the antibody is human IgG1.

[0954] In other embodiments, the protease of this disclosure may be IgdE derived from Streptococcus bacteria. Examples of Streptococcus bacteria include *Streptococcus agalactiae*, *Streptococcus dysgalactiae*, *Streptococcus equi*, *Streptococcus suis*, *Streptococcus porcinus*, *Streptococcus pseudoporcinus*, *Streptococcus canis*, *Streptococcus castoreus*, or *Streptococcus merionis*, but they are not limited to these examples.

[0955] In one embodiment, the protease of this disclosure is preferably a protease that digests human IgG1 antibodies between the T and H of the amino acid sequence KSCDKT / HTCPPCP located in the hinge region of the human IgG1 antibody. On one hand, the protease in this disclosure may be IgdE derived from Streptococcus agalactiae. IgdE derived from Streptococcus agalactiae is described in Spoerry C et al. (PLoS ONE 11(10): e0164809. doi:10.1371 / journal.pone.0164809).The enzyme is disclosed in the literature (2016) or elsewhere. Those skilled in the art will be able to obtain the enzyme without difficulty using well-known techniques.

[0956] In another specific embodiment, a protein selected from the group consisting of the following (a) to (d) may serve as an example of IgdE derived from *Streptococcus agalactiae* of this disclosure:

[0957] (a) a protein comprising the amino acid sequence shown in SEQ ID NO: 61;

[0958] (b) a protein encoded by the base sequence shown in SEQ ID NO: 62;

[0959] (c) a protein comprising an amino acid sequence in which one or more amino acids are substituted, deleted, added, and / or inserted relative to the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibody between T and H in the amino acid sequence specification 60 / 122 pages 67 CN 122249467 A KSCDKT / HTCPPCP; and

[0960] (d) comprising having at least 80% or more, 85% or more, 90% or more, or 95% of the amino acid sequence shown in SEQ ID NO: 61. Proteins with an amino acid sequence of 98% or more sequence identity, wherein the protein is capable of digesting human IgG1 antibodies between T and H in the amino acid sequence KSCDKT / HTCPPCP.

[0961] The addition, deletion, substitution and / or insertion of amino acids can be performed by methods known in the relevant art. For example, site-specific mutagenesis (Kunkel et al., Proc. Natl. Acad. Sci. USA 82, 488-492 (1985)) or overlap extension PCR can be performed on nucleic acids encoding amino acid sequences. Such techniques can be used alone or in combination as appropriate.

[0962] Generally, it is known that one or more amino acid modifications (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) in a protein do not affect the function of the protein or even enhance the function of the original protein. Amino acids are classified into hydrophobic (A, I, L, M, F, P, W, Y, V) amino acids and hydrophilic (R, D, N, C, E, Q, G, H, K, S, T) amino acids based on the characteristics of their side chains. Amino acid side chains can also be classified into aliphatic side chains (G, A, V, L, I, P), side chains containing hydroxyl groups (S, T, Y), side chains containing sulfur atoms (C, M), side chains containing carboxylic acids and amides (D, N, E, Q), side chains containing bases (R, K, H), and aromatic side chains (H, F, Y, W). The amino group represented in SEQ ID NO: 61 will be included.Proteins obtained by modifying the amino acid sequence of a protein to different amino acids but classified into the same phenotypic group are also included as IgdEs in this disclosure. Note that IgdEs in this disclosure may also contain non-conservative modifications, provided that their function is equivalent to that of a protein containing the amino acid sequence shown in SEQ ID NO: 61.

[0963] In one embodiment, proteins containing amino acid sequences having high sequence identity with the amino acid sequence represented in SEQ ID NO: 61 are also included as IgdEs in this disclosure. High sequence identity in this disclosure means sequence identity of at least 50% or more, more preferably 70% or more, 75% or more, 80% or more, 85% or more, or further preferably 90% or more (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more) over the entire amino acid or nucleic acid sequence.

[0964] IgdE derived from *Streptococcus agalactiae* is commercially available from Genovis under the trademark "FabALACTICA (registered trademark) (IgdE)". That is, in one embodiment, the protease in this disclosure may be FabALACTICA (registered trademark) (IgdE). The inventors have discovered that by adding IgdE derived from *Streptococcus agalactiae*, more specifically FabALACTICA (registered trademark) (IgdE), to a composition comprising both LINC and unLINC forms, for example, by preparing an antigen-binding molecule as disclosed herein, and then subjecting the formulation containing IgdE to electrophoresis, chromatography, etc., a LINC ratio of the composition or formulation can be obtained.

[0965] Therefore, this disclosure also relates to compositions comprising an antigen-binding molecule (LINC form) having at least one disulfide bond formed in a region outside the hinge region, an antigen-binding molecule (unLINC form) not having a disulfide bond formed in a region outside the hinge region, and a protease. These compositions can be used to determine the LINC ratio. In one embodiment, the LINC form of the antigen-binding molecule, its corresponding unLINC form, and the protease contained in the composition may be those disclosed herein. These compositions may include other components, as long as they can be used to obtain the LINC ratio.

[0966] There are no particular limitations on the concentration of the protease added to the formulation, but in one embodiment, examples include 0.6 to 1.8 units-enzyme / μg-protein, etc. In a particular embodiment where the LINC ratio is measured, determined, or quantified using CE-SDS, a protease of 1.25 units-enzyme / μg-protein may be used. In the case of using HIC to measure, determine, or quantify the LINC ratio...In one embodiment where the ratio is measured, determined, or quantified, a protease at a ratio of 1.2 units of enzyme / μg protein may be used. Specification 61 / 122 pages 68 CN 122249467 A

[0967] In one embodiment, when the method of production in this invention includes the step of adding a protease to a formulation of an antigen-binding molecule produced as described herein, non-reducing capillary SDS gel electrophoresis (CE-SDS) or hydrophobic interaction chromatography (HIC) may be used in the step of measuring, determining, or quantifying the LINC ratio. Furthermore, in one embodiment, the chromatography used to obtain the formulation of the antigen-binding molecule may be membrane chromatography.

[0968] In one embodiment, in the step of measuring, determining, or quantifying the LINC ratio in the method of production of this disclosure, the LINC ratio may be calculated as follows. For example, when non-reducing capillary SDS gel electrophoresis (CE-SDS) is used in the measurement, determination, or quantification step, it includes the step of preparing a "formulation with added protease" by adding a protease to a formulation obtained through a purification step. In addition, the procedure includes obtaining a "sample containing only protease". Electrophoresis patterns are obtained for each of the following: "formulation with added protease", "formulation without added protease", and "sample containing only protease". The electrophoresis pattern obtained from the "formulation without added protease" includes peaks originating from the LINC form and from the unLINC form (not digested by protease), and a peak (peak Z) that is neither originating from the LINC form nor from the unLINC form (not digested by protease). The electrophoresis pattern obtained from the "formulation with added protease" includes peaks originating from the LINC form (peak L), peaks originating from the unLINC form (peak unL), peaks originating from the protease (peak E), and peaks that are not originating from the LINC form, not from the unLINC form (not digested by protease), or not originating from the protease (peak Z). The electrophoresis pattern obtained from the "sample containing only protease" includes a peak from the protease (peak E).

[0969] When the LINC ratio is measured, determined, or quantified using CE-SDS, the LINC ratio can be obtained as the ratio of the "area value of peak L" to a value calculated by subtracting the "area value of peak Z" and the "area value of peak E" from the "sum of the area values ​​of peak L, peak E, and peak Z" and adding the "area value of peak L", as shown in Equation (I) described later. Those skilled in the art will be able to obtain these area values ​​(area values) according to the analysis manual of the CE-SDS device. Alternatively, the analysis manual can be modified as needed, and the area values ​​can be obtained according to the modified manual.

[0970] In the above-mentioned "formulation with added protease", in addition to LINCIn addition to the LINC form, the unLINC form digested by the protease, and the protease itself, it also includes degradation products of target proteins, etc. Therefore, the above-mentioned "peak Z" includes peaks derived from such products. The above-mentioned "sample containing only protease" is not particularly limited, as long as it does not contain the LINC form and the unLINC form and contains the protease of this disclosure. FabALACTICA (registered trademark) (Genovis) and the like can be examples of "sample containing only protease" of this disclosure, but are not limited thereto. In one embodiment, the "sample containing only protease" can be added in the same amount to a formulation to which no sample has been added.

[0971] In another embodiment, in the method of this disclosure, the LINC ratio can be calculated as follows. For example, when hydrophobic interaction chromatography (HIC) is used in the measurement, determination, or quantification step, a "formulation containing protease" is obtained by adding the protease to the formulation obtained by the purification step. The "formulation containing protease" is subjected to HIC and a chromatogram is obtained. In this case, the LINC ratio is obtained as the ratio of the area value of the peak derived from the LINC form to the sum of the area values ​​of the peak derived from the LINC form and the area values ​​of all peaks derived from the unLINC form, as shown in Equation (II) described later. Those skilled in the art will be able to obtain these area values ​​(area values) according to the analysis manual of the HIC device. Alternatively, the analysis manual can be modified as needed, and the area values ​​can be obtained according to the modified manual. Those skilled in the art can also appropriately prepare mobile phase A and mobile phase B for hydrophobic interaction chromatography (HIC) with reference to common technical knowledge. Those skilled in the art can appropriately select the chromatographic carrier and can use, for example, the carriers disclosed herein.

[0972] When the LINC ratio is quantified using non-reducing capillary SDS gel electrophoresis (CE-SDS), the method for measuring, determining, or quantifying the LINC ratio in this disclosure further includes the step of preparing a composition (3) containing a protease but not containing the LINC form and the unLINC form, in addition to the above-described compositions (1) and (2). These methods further include performing CE-SDS on each of compositions (1) to (3) and obtaining electrophoretic patterns (1) to (3) from pages 69 of the specification (62 / 122, CN 122249467 A). Composition (3) is not particularly limited, provided it does not contain either the LINC or unLINC form and contains the protease described in this disclosure; however, in one embodiment, the aforementioned FabALACTICA (registered trademark) (Genovis) may be used as an example.

[0973] In this disclosure, electrophoresis pattern (1) includes peaks originating from the LINC form and from the unLINC form that has not been digested by the protease, as well as peaks that are not originating from the LINC form or from the unLINC form that has not been digested by the protease (peak Z). Electrophoresis pattern (2) includes: electrophoresis pattern obtained from "preparation with added protease" includes peaks originating from the LINC form (peak L), peaks originating from the unLINC form that has been digested by the protease (peak unL), peaks originating from the protease (peak E), and peaks that are not originating from the LINC form, not originating from the unLINC form that has been digested by the protease, or not originating from the protease (peak Z). Electrophoresis pattern (3) includes peaks originating from the protease (peak E).

[0974] When using non-reducing capillary SDS gel electrophoresis (CE-SDS), the LINC ratio is calculated by formula (I) shown below.

[0975]

[0976] In this formula,

[0977] A is the area value of peak L in electrophoresis diagram (2),

[0978] B is the sum of the area values ​​of peak unL, peak E and peak Z in electrophoresis diagram (2),

[0979] C is the area value of peak Z in electrophoresis diagram (1), and

[0980] D is the area value of peak E in electrophoresis diagram (3).

[0981] Theoretically, when unLINC form is digested by protease, three fragments as shown on the right side of Figure 8 are produced (i.e., when the antigen-binding molecule is a trivalent antibody composed of a molecule consisting of five chains as shown in Figure 3, it produces (i) a fusion of the first antigen-binding domain or the second antigen-binding domain and the third antigen-binding domain, (ii) the remaining one of the first antigen-binding domain and the second antigen-binding domain that does not constitute the fusion, and (iii) the Fc region). The inventors have discovered that, when the unLINC form is digested by a protease, in addition to the three fragments mentioned above, sometimes only one of the two hinge regions in the antigen-binding molecule is digested (specifically, when the antigen-binding molecule is a trivalent antibody composed of a molecule consisting of five chains as shown in FIG3, the hinge region on chain 3), while the hinge region in the other chain (i.e., chain 1) is not digested. Therefore, the "peaks derived from the (protease-digested) unLINC form" in this disclosure include peaks derived from the three fragments mentioned above (i) to (iii) and peaks derived from the fragments generated when only the hinge region on chain 3 is digested in the case of a trivalent antibody composed of a molecule consisting of five chains as shown in FIG3.

[0982] The methods used in this disclosure for measuring, determining, or quantifying the LINC ratio, for example, when measuring, determining, or quantifying the LINC ratio, include hydrophobic interaction chromatography (HIC).The process includes performing hydrophobic interaction chromatography (HIC) on the above composition (2) to obtain a chromatogram. In this case, the LINC ratio can be calculated based on formula (II) described below.

[0983]

[0984] In this formula,

[0985] A is the area value of the peaks originating from the LINC form in the chromatogram; and

[0986] B is the area value of all peaks originating from the unLINC form after protease digestion in the chromatogram.

[0987] "All peaks originating from the unLINC form after (protease digestion)" includes peaks originating from all unLINC form fragments produced by protease digestion of the unLINC form, or more specifically, peaks originating from the above four fragments. Specification 63 / 122 pages 70 CN 122249467 A

[0988] In this disclosure, the unLINC ratio, i.e., the ratio of the unLINC form to the sum of the LINC form and the unLINC form, can be obtained by subtracting the LINC ratio (%) from 100%.

[0989] In one embodiment, the method of this disclosure may further include a step of culturing the formulation or composition after adding the protease to the formulation or composition and before electrophoresis or chromatography. There are no particular limitations on the culture conditions, but incubation may be performed, for example, in phosphate buffer (pH 6 to 8), at 37°C for 16 to 20 hours, such as 16 hours, 18 hours, or 20 hours.

[0990] Additionally, in this disclosure, the antigen-binding molecule subjected to chromatography for purification may contain a signal sequence. Specifically, when an antigen-binding molecule having amino acid residues that can form at least one disulfide bond between amino acid residues in regions other than the hinge region is recombinantly expressed in cells, the antigen-binding molecule may sometimes have a signal sequence to promote expression and / or secretion. In one embodiment, when the translation product from the nucleic acid sequence used for recombinant expression of the antigen-binding molecule contains a signal sequence, the method of this disclosure may include a step of cleaving the signal sequence from the antigen-binding molecule. The signal sequence may be cleaved before or after the step of performing chromatography for purification of the antigen-binding molecule, or before or after the step of quantifying the LINC ratio of the substance purified by chromatography. The signal sequence can be cleaved using methods well known to those skilled in the art.

[0991] In one aspect, the amino acid residues that can form disulfide bonds are mutated, substituted, introduced, or engineered cysteine ​​residues.

[0992] In one aspect, at least one disulfide bond is formed in a region other than the hinge region between polypeptides constituting the antigen-binding molecule. More specifically, in a particular embodiment, at least one disulfide bond in a region other than the hinge region of this disclosureInterchain disulfide bonds. In some embodiments, at least one disulfide bond in the region outside the hinge region is 1, 2, 3, 4, 5 or more interchain disulfide bonds.

[0993] In one aspect, at least one disulfide bond in the region outside the hinge region is an engineered disulfide bond that is not present in wild-type IgG.

[0994] III. Antigen-binding molecule

[0995] In the antigen-binding molecule of this disclosure, disulfide bonds may be formed between a region outside the hinge region in one heavy chain constituting the antigen-binding molecule and a region outside the hinge region in another heavy chain. In this disclosure, an antigen-binding molecule having a disulfide bond between a region outside the hinge region in one heavy chain and a region outside the hinge region in another heavy chain is called a LINC form, and an antigen-binding molecule not having such a disulfide bond is called an unLINC form. In this disclosure, the CH1 region may be referred to as a region outside the hinge region. The unLINC form in this disclosure includes mis-disulfide bonded forms and / or non-disulfide bonded forms. In this disclosure, the LINC form may be referred to as the LINC form, and the unLINC form may be referred to as the unLINC form.

[0996] In one aspect, the antigen-binding molecule of this disclosure comprises a first antigen-binding domain and a second antigen-binding domain that can be linked to each other via at least one disulfide bond. In one aspect, in an antigen-binding molecule produced or purified by the method of this disclosure, the first antigen-binding domain and the second antigen-binding domain are linked via at least one disulfide bond. In embodiments of the above aspects, the first antigen-binding domain and the second antigen-binding domain are linked via two, three, four or more disulfide bonds.

[0997] In embodiments, at least one of the first antigen-binding domain and the second antigen-binding domain is itself active in binding to an antigen (i.e., a single antigen-binding domain independently has antigen-binding activity). In some embodiments, each of the first antigen-binding domain and the second antigen-binding domain is itself active in binding to an antigen.

[0998] In one aspect, each of the first antigen-binding domain and the second antigen-binding domain in this disclosure (64 / 122 pages, 71 CN 122249467 A) may have a Fab, Fab', scFab, Fv, scFv, or VHH structure.

[0999] In one aspect, each of the first antigen-binding domain and the second antigen-binding domain is a Fab molecule, and the antigen-binding molecule contains at least one disulfide bond formed between the first antigen-binding domain and the second antigen-binding domain. Preferably, at least one disulfide bond is formed between amino acid residues (cysteine) not present in the hinge region, or preferably between amino acid residues (cysteine) in the CH1 region of each antigen-binding domain.

[1000] In embodiments described above, both the first antigen-binding domain and the second antigen-binding domain comprise a Fab and a hinge region.

[1001] In some embodiments, at least one of the amino acid residues forming disulfide bonds between the antigen-binding domains is a mutant amino acid residue not present in the wild-type Fab or hinge region, and for example, the amino acid residue is a cysteine ​​residue not present in the wild-type Fab or hinge region. Such a mutant amino acid residue can be introduced into the wild-type Fab or hinge region by, for example, amino acid substitution.

[1002] Alternatively, in another embodiment, in the antigen-binding molecule of this disclosure, amino acid residues (e.g., cysteine ​​residues) present in the wild-type Fab or hinge region and potentially involved in disulfide bonds between the antigen-binding domains can be substituted or deleted by other amino acid residues. Examples of such cysteine ​​residues include cysteine ​​residues at positions 220, 226, and 229 in the hinge region according to EU numbers, and cysteine ​​residue at position 214 in the CL region.

[1003] In one embodiment of the above aspects, at least one of the first antigen-binding domain and the second antigen-binding domain comprises an antibody fragment that binds to a specific antigen. In some embodiments, the antibody fragment is Fab, Fab', scFab, Fv, scFv, or a single-domain antibody. In some embodiments, the first and / or second antigen-binding domain comprises a hinge region. Amino acid residues forming disulfide bonds are respectively present in the first antigen-binding domain and the second antigen-binding domain, and the bonds between the antigen-binding domains are formed by the linkage between these amino acid residues. In some embodiments, at least one amino acid residue forming a disulfide bond between the antigen-binding domains is present within the antibody fragment.

[1004] In one aspect, each of the first antigen-binding domain and the second antigen-binding domain of the present disclosure may or may not include a hinge region. In some embodiments, the first antigen-binding domain and the second antigen-binding domain of the present disclosure may each include a Fab and a hinge region forming an F(ab')2 structure.

[1005] In embodiments of the above aspects, both the first antigen-binding domain and the second antigen-binding domain bind to the same antigen. In some embodiments, both the first antigen-binding domain and the second antigen-binding domain bind to the same epitope on the same antigen. In some other embodiments, each of the first antigen-binding domain and the second antigen-binding domain binds to a different epitope on the same antigen. In some embodiments, the antigen-binding molecule of this disclosure is a bicomponent antigen-binding molecule (e.g., a bicomponent antibody) targeting a specific antigen.

[1006] In another embodiment of the above aspects, each of the first antigen-binding domain and the second antigen-binding domain binds to a different antigen.

[1007] In another embodiment of the above aspects, the antigen-binding molecule in this disclosure is a clamp antigen-binding molecule (e.g., a clamp antibody). As used herein, a clamp antigen-binding molecule means an antigen-binding molecule that specifically binds to an antigen / antigen-binding molecule complex formed between a given antigen A and an antigen-binding molecule (binding to antigen A), thereby enhancing the binding activity of the antigen-binding molecule bound to antigen A for antigen A (or alternatively, stabilizing the antigen / antigen-binding molecule complex formed by antigen A and the antigen-binding molecule bound to antigen A). For example, a CD3 clamp antibody specifically binds to an antigen-antibody complex formed between CD3 and an antibody with reduced binding ability to CD3 (a weakened CD3 antibody), thereby enhancing the binding activity of the weakened CD3 antibody for CD3 (or alternatively, stabilizing the antigen-antibody complex formed by CD3 and the weakened CD3 antibody). In some embodiments, the first and / or second antigen-binding domains in the antigen-binding molecule of this disclosure may be antigen-binding domains derived from clamp antigen-binding molecules (clamp antigen-binding domains).

[1008] In embodiments of the above aspects, both the first and second antigen-binding domains have the same amino acid sequence. In another embodiment, each of the first and second antigen-binding domains has a different amino acid sequence.

[1009] In another embodiment of the above aspects, the antigen-binding molecule of this disclosure has the activity of modulating the interaction between two antigen molecules. Without being bound by any particular theory, the activity of modulating the interaction is considered to arise from the antigen-binding molecule of this disclosure holding the two antigen molecules in a spatially closer position and reducing their migration rate. In some embodiments, the antigen-binding molecule of this disclosure may enhance or weaken the interaction between two antigen molecules compared to a control antigen-binding molecule. The control antigen-binding molecule differs from the antigen-binding molecule of this disclosure only in that the control antigen-binding molecule has one less disulfide bond between the two antigen-binding domains. In another embodiment, the missing disulfide bond may be selected from a bond originating from a mutated amino acid residue not present in the wild-type Fab or hinge region (e.g., a cysteine ​​residue not present in the wild-type Fab or hinge region). The mutated amino acid residue is, for example, an artificially mutated, substituted, introduced, or engineered cysteine ​​residue.

[1010] In one embodiment, the antigen molecule is selected from the group consisting of: receptors belonging to the cytokine receptor superfamily, G protein-coupled receptors, ion channel receptors, tyrosine kinase receptors, immune checkpoint receptors, antigen receptors, CD4+ receptors, etc.Antigen, co-stimulatory molecules, and cell adhesion molecules.

[1011] In some embodiments, the two antigen molecules bound by the antigen-binding molecule of this disclosure may be a ligand and its receptor, respectively. The antigen-binding molecule of this disclosure has the activity of promoting receptor activation through the ligand. In some other embodiments, the two antigen molecules bound by the antigen-binding molecule of this disclosure may be an enzyme and its substrate, respectively. The antigen-binding molecule of this disclosure has the activity of promoting the catalytic reaction of the enzyme and the substrate.

[1012] Furthermore, in some other embodiments, two of the two antigen molecules bound by the antigen-binding molecule of this disclosure may be antigens (e.g., proteins) present on the cell surface. The antigen-binding molecule of this disclosure has the activity of promoting the interaction between a cell expressing a first antigen and a cell expressing a second antigen. For example, a cell expressing a first antigen and a cell expressing a second antigen may be a cell with cytotoxic activity and its target cell, respectively. The antigen-binding molecule of this disclosure promotes damage to the target cell by the cell with cytotoxic activity. Cells with cytotoxic activity are, for example, T cells, NK cells, monocytes, or macrophages.

[1013] In embodiments of the above aspects, the antigen-binding molecules of this disclosure are resistant to protease cleavage. In some embodiments, the antigen-binding molecules of this disclosure have increased resistance to protease cleavage compared to control antigen-binding molecules. In some embodiments, the proportion of the full-length molecule (e.g., full-length IgG molecule) remaining after protease treatment is increased in the antigen-binding molecules of this disclosure compared to control antigen-binding molecules. In some embodiments, the proportion of a specific fragment (e.g., Fab monomer) generated after protease treatment is reduced in the antigen-binding molecules of this disclosure compared to control antigen-binding molecules.

[1014] In embodiments of the above aspects, when the antigen-binding molecules of this disclosure are treated with a protease, dimers of the antigen-binding domain or fragments thereof (e.g., cross-linked Fab dimers) are cleaved. In one embodiment, the protease may cleave the hinge region of the antigen-binding molecule.

[1015] In one aspect, at least one of the first antigen-binding domain and the second antigen-binding domain of this disclosure may bind to a soluble protein. In another embodiment, at least one of the first antigen-binding domain and the second antigen-binding domain in this disclosure can bind to a membrane protein.

[1016] The first antigen-binding domain and the second antigen-binding domain in this disclosure can bind to a first antigen and a second antigen, respectively. In some embodiments, the first antigen and the second antigen are derived from humans, mice, rats, monkeys, rabbits, or dogs. In some embodiments, examples of the first antigen and the second antigen include, but are not limited to, immune cell surface molecules (e.g., T cell surface molecules, NK cells).Cell surface molecules, dendritic cell surface molecules, B cell surface molecules, NKT cell surface molecules, MDSC cell surface molecules and macrophage surface molecules), or antigens expressed not only on tumor cells, tumor blood vessels, stromal cells, etc. but also on normal tissues (integrin, tissue factor, VEGFR, PDGFR, EGFR, IGFR, MET chemokine receptor, heparan sulfate proteoglycan, CD44, fibronectin, DR5, TNFRSF, etc.), receptors belonging to the cytokine receptor superfamily, G protein-coupled receptors, ion channel receptors, tyrosine kinase receptors, immune checkpoint receptors, antigen receptors, CD antigens, co-stimulatory molecules and cell adhesion molecules.

[1017] In some embodiments, either the first antigen or the second antigen may be a molecule specifically expressed on T cells, for example, and the other antigen may be a molecule expressed on the surface of T cells or any other immune cells. In another embodiment of the combination of the first antigen and the second antigen, preferably, either the first antigen or the second antigen is a molecule specifically expressed on T cells, for example, and the other antigen is a molecule expressed on immune cells and different from the initially selected antigen.

[1018] Specific examples of molecules specifically expressed on T cells include CD3 and T cell receptors. In particular, CD3 is preferred. For example, in the case of human CD3, the site in CD3 to which the antigen-binding molecule of this disclosure binds can be any epitope present in the γ chain, δ chain, or ε chain sequence constituting human CD3. In particular, epitopes present in the extracellular region of the ε chain in the human CD3 complex are preferred. The polynucleotide sequences constituting the γ, δ, and ε chain structures of CD3 are NM_000073.2, NM_000732.4, and NM_000733.3, and their polypeptide sequences are NP_000064.1, NP_000723.1, and NP_000724.1 (RefSeq registry numbers). Examples of other antigens include Fc γ receptors, TLRs, lectins, IgA, immune checkpoint molecules, TNF superfamily molecules, TNFR superfamily molecules, and NK receptor molecules.

[1019] In one embodiment, the first antigen may be a molecule specifically expressed on T cells, preferably a T cell receptor complex molecule such as CD3, more preferably human CD3. In another embodiment, the second antigen may be a molecule expressed on T cells or any other immune cells, preferably a cell surface regulator on immune cells, more preferably a co-stimulatory molecule expressed on T cells, and even more preferably a protein of the "TNF superfamily" or "TNF receptor superfamily," including but not limited to human CD137.(4-1BB), CD137L, CD40, CD40L, OX40, OX40L, CD27, CD70, HVEM, LIGHT, RANK, RANKL, CD30, CD153, GITR, and GITRL. In a preferred embodiment, the first antigen may be CD3 and the second antigen may be CD137. In this document, the first antigen and the second antigen are defined interchangeably.

[1020] In some embodiments, the antigen-binding molecule of this disclosure specifically binds to all or part of a portion of a peptide of CD3. In particular embodiments, CD3 is human CD3 or cynomolgus monkey CD3, most particularly human CD3. In particular embodiments, the antigen-binding molecule is cross-reactive (i.e., specifically binds to) human and cynomolgus monkey CD3. In some embodiments, the antigen-binding molecule is capable of specifically binding to the ε subunit of CD3, particularly the human CD3 ε subunit of CD3 shown in SEQ ID NO: 13 (NP_000724.1) (RefSeq registration number shown in parentheses). In some embodiments, the antigen-binding molecule is capable of specifically binding to the CD3ε chain expressed on the surface of eukaryotic cells. In some embodiments, the antigen-binding molecule binds to the CD3ε chain expressed on the surface of T cells.

[1021] In some embodiments, the antigen-binding molecule of this disclosure specifically binds to all or part of a portion of a peptide of CD137. The term “CD137” as used herein, also known as 4-1BB, is a member of the tumor necrosis factor (TNF) receptor family. Examples of factors belonging to the TNF superfamily or TNF receptor superfamily include CD137, CD137L, CD40, CD40L, OX40, OX40L, CD27, CD70, HVEM, LIGHT, RANK, RANKL, CD30, CD153, GITR, and GITRL.

[1022] In some embodiments, the CD137 is human CD137. In some embodiments, advantageous examples of antigen-binding molecules in this disclosure include antigen-binding molecules that bind to the same epitope as the human CD137 epitope bound by an antibody selected from the group consisting of:

[1023] an antibody that recognizes a region in the human CD137 protein containing the sequence SPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTSNAEC DCTPGFHCLGAGCSMCEQDCKQGQELTKKGC (SEQ ID NO: 14),

[1024] an antibody that recognizes a region containingAntibodies that recognize the region containing the sequence DCTPGFHCLGAGCSMCEQDCKQGQELTKKGC (SEQ ID NO: 15),

[1025] antibodies that recognize the region containing the sequence LQDPCSNCPAGTFCDNNRNQICSPCPPNSFSSAGGQRTCDICRQCKGVFRTRKECSSTS NAEC (SEQ ID NO: 16), and

[1026] antibodies that recognize the region containing the sequence LQDPCSNCPAGTFCDNNRNQIC (SEQ ID NO: 17).

[1027] In embodiments of the above aspects, at least one of the first antigen-binding domain and the second antigen-binding domain comprises a non-antibody protein that binds to a specific antigen or fragment thereof. In some embodiments, the non-antibody protein is either a pair of ligands and receptors that bind specifically to each other. Such receptors include, for example, receptors belonging to the cytokine receptor superfamily, G protein-coupled receptors, ion channel receptors, tyrosine kinase receptors, immune checkpoint receptors, antigen receptors, CD antigens, co-stimulatory molecules, and cell adhesion molecules.

[1028] In one aspect, the antigen-binding molecule of this disclosure may further comprise a third antigen-binding domain. In one aspect, the third antigen-binding domain may be fused to either the first antigen-binding domain or the second antigen-binding domain.

[1029] In one aspect, the third antigen-binding domain may be Fab or scFv; in this case, the third antigen-binding domain may optionally be fused at its C-terminus to the N-terminus of the Fab heavy chain (VH region) of either the first antigen-binding domain or the second antigen-binding domain via a peptide linker.

[1030] In some embodiments, each of the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain of this disclosure may be a Fab molecule; in this case, the third antigen-binding domain may optionally be fused at its C-terminus to the N-terminus of the Fab heavy chain (VH region) of either the first antigen-binding domain or the second antigen-binding domain via a peptide linker.

[1031] In one aspect, examples of the peptide linker of this disclosure may be sequences selected from the group consisting of the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20, but are not limited thereto.

[1032] In one aspect, the third antigen-binding domain of this disclosure may be a cross-Fab molecule in which the variable regions of the Fab light chain and the Fab heavy chain are exchanged, and each of the first antigen-binding domain and the second antigen-binding domain may be a conventional Fab molecule.

[1033] In one aspect, the third antigen-binding domain of this disclosure can bind to a third antigen that is different from the first and second antigens described above. The third antigen-binding domain binding to the third antigen can be an antigen-binding domain that recognizes any antigen. The third antigen-binding domain binding to the third antigen in this disclosure can be an antigen-binding domain that recognizes a molecule specifically expressed in cancer cells or cancerous tissue.

[1034] In some embodiments, the third antigen is derived from a human, mouse, rat, monkey, rabbit, or dog. In some embodiments, the third antigen is a molecule specifically expressed on cells or organs derived from a human, mouse, rat, monkey, rabbit, or dog. The third antigen is preferably a molecule that is not systematically expressed on cells or organs. The third antigen is preferably, for example, a tumor cell-specific antigen, and also includes antigens expressed in association with malignant changes in cells, as well as abnormal glycan chains appearing on the cell surface or protein molecules during malignant transformation of cells. Specific examples include ALK receptor (pleiotropic receptor), pleiotropic factor, KS 1 / 4 pancreatic cancer antigen, ovarian cancer antigen (CA125), prostatic acidic phospholipid, prostate-specific antigen (PSA), melanoma-associated antigen p97, melanoma antigen gp75, high molecular weight melanoma antigen (HMW-MAA), prostate-specific membrane antigen, carcinoembryonic antigen (CEA), polymorphic epithelial mucin antigen, human milk fat globule antigen, colorectal tumor-associated antigens (e.g., CEA, TAG-72, CO17-1A, GICA 19-9, CTA-1, and LEA), Burkitt lymphoma antigen 38.13, CD19, human B lymphoma antigen CD20, CD33, melanoma-specific antigens (e.g., ganglioside GD2, ganglioside GD3, ganglioside GM2, and ganglioside GM3), tumor-specific transplantation antigen (TSTA), and T... Antigens, virus-induced tumor antigens (e.g., envelope antigens of DNA tumor viruses and RNA tumor viruses), colonic CEA, cancer-fetoprotein antigens (e.g., carcinoma-fetotrophoblast glycoprotein 5T4 and carcinoma-fetobladder tumor antigen), differentiation antigens (e.g., human lung cancer antigens L6 and L20), fibrosarcoma antigens, human T-cell leukemia-associated antigen Gp37, neogenic glycoproteins, sphingolipids, breast cancer antigens (e.g., EGFR (epithelial growth factor receptor)), NY-BR-16, NY-BR-16 and HER2 antigen (p185HER2), polymorphic epithelial mucin (PEM), malignant human lymphocyte antigen APO-1, differentiation antigens (such as I antigen found in fetal erythrocytes; primary endoderm I antigen found in adult erythrocytes; I antigen found in pre-implantation embryos or gastric cancer).(Ma); M18 found in breast epithelium; M39, SSEA-1 found in bone marrow cells; VEP8, VEP9, Myl, VIM-D5, D156-22 found in colorectal cancer; TRA-1-85 (blood type H), SCP-1 found in testicular and ovarian cancer; C14 found in colon cancer; F3 found in lung cancer; AH6 found in gastric cancer; Y hapten, Ley found in embryonic cancer cells; TL5 (blood type A), EGF receptor found in A431 cells; E1 series (blood type B) found in pancreatic cancer; FC10.2 found in embryonic cancer cells; gastric cancer antigen; CO-514 (blood type Lea) found in adenocarcinoma; NS-10 found in adenocarcinoma; CO- 43 (blood type Leb), G49; MH2 (blood type ALeb / Ley) found in colon cancer; 19.9 found in colon cancer; gastric cancer mucin; T5A7 found in bone marrow cells; R24 found in melanoma; 4.2, GD3, D1.1, OFA-1, GM2, OFA-2, GD2 and M1:22:25:8 found in embryonic cancer cells; SSEA-3 and SSEA-4 found in 4-cell to 8-cell embryos; cutaneous T-cell lymphoma-associated antigen, MART-1 antigen, sialylated Tn (STn) antigen, colon cancer antigen NY-CO-45, lung cancer antigen NY-LU-12 variant A, adenocarcinoma antigen ART1, paraneoplastic brain-testis-cancer antigens (tumor neuron antigen MA2 and paraneoplastic neuron antigen), ventral neuronal tumor antigen 2 (NOVA2). Hematologic cell carcinoma antigen gene 520, tumor-associated antigen CO-029, tumor-associated antigen MAGE-C1 (cancer / testis antigen CT7), MAGE-B1 (MAGE-XP antigen), MAGE-B2 (DAM6), MAGE-2, MAGE-4a, MAGE-4b, MAGE-X2, cancer-testis antigen (NY-EOS-1), YKL-40, and any fragments of these polypeptides and their modified structures (the modified phosphate groups, glycans, etc.), EpCAM, EREG, CA19-9, CA15-3, sialylated SSEA-1 (SLX), HER2, PSMA, CEA, and CLEC12A.

[1035] In a preferred embodiment, the third antigen is phosphatidylinositol proteoglycan-3 (GPC3). In another embodiment, the third antigen is DLL3 (δ-like 3). In some embodiments, the third antigen binding domain may be “DLL3” that binds to DLL3."Antigen-binding domain".

[1036] Unless otherwise specified, the term "DLL3" as used herein refers to any naturally occurring DLL3 (δ-like 3) from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed DLL3, as well as any form of DLL3 produced through cellular processing. The term also covers naturally occurring variants of DLL3, such as splice variants or allelic variants. The amino acid sequence of exemplary human D...

Claims

1. A method for measuring, determining, or quantifying the ratio (LINC ratio) of antigen-binding molecules (LINC forms) having at least one disulfide bond formed in a region outside the hinge region, said LINC ratio being the ratio of said LINC forms to the sum of said LINC forms and antigen-binding molecules (unLINC forms) not having a disulfide bond formed in a region outside the hinge region, said method comprising the steps of: (a) Adding the protease to composition (1) comprising the LINC form and the unLINC form to prepare composition (2); and (b) Perform electrophoresis or chromatography on composition (2).

2. The method of claim 1, wherein the protease is an enzyme that does not digest the LINC form but is capable of digesting the unLINC form.

3. The method according to claim 1 or 2, wherein the protease is a cysteine ​​protease capable of digesting human IgG1 antibodies.

4. The method according to any one of claims 1 to 3, wherein the protease is an enzyme capable of cleaving the hinge region of a human IgG1 antibody.

5. The method according to any one of claims 1 to 4, wherein the protease is an enzyme that digests human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP.

6. The method according to any one of claims 1 to 5, wherein the protease is IgdE.

7. The method of claim 6, wherein IgdE is derived from Streptococcus agalactiae.

8. The method according to claim 6 or 7, wherein IgdE is a protein selected from the group consisting of (a) to (d): (a) A protein comprising the amino acid sequence shown in SEQ ID NO: 61; (b) A protein encoded by the base sequence shown in SEQ ID NO: 62; (c) A protein comprising an amino acid sequence in which one or more amino acids are substituted, deleted, added, and / or inserted relative to the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP; and (d) A protein comprising an amino acid sequence having at least 80% or more, 85% or more, 90% or more, 95% or more, or 98% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 61, wherein the protein is capable of digesting human IgG1 antibody between T and H in the amino acid sequence KSCDKT / HTCPPCP.

9. The method according to any one of claims 1 to 8, wherein the protease is FabALACTICA (registered trademark).

10. The method according to any one of claims 1 to 9, Step (a) further includes obtaining a composition (3) containing the protease but not the LINC form or the unLINC form. In step (b), each of compositions (1) to (3) is subjected to non-reducing capillary SDS gel electrophoresis (CE-SDS) and electrophoretic images (1) to (3) of compositions (1) to (3) are obtained respectively. Electrophoresis image (1) includes: Peaks containing the LINC form and the unLINC form that has not been digested by the protease, as well as peaks that are neither derived from the unLINC form that has not been digested by the protease nor from the LINC form (peak Z). The electrophoresis diagram (2) includes: a peak originating from the LINC form (peak L), a peak originating from the unLINC form digested by the protease (peak unL), a peak originating from the protease (peak E), and a peak that is neither originating from the unLINC form digested by the protease, nor from the LINC form, nor from the protease (peak Z). The electrophoresis diagram (3) includes a peak (peak E) derived from the protease.

11. The method of claim 10, further comprising: (c) Calculate the ratio (%) using the following formula (I): in, A represents the area of ​​peak L in electrophoresis diagram (2). B represents the sum of the area values ​​of peaks unL, E, and Z in electrophoresis diagram (2). C is the area value of peak Z in electrophoresis diagram (1), and D is the area value of peak E in electrophoresis diagram (3).

12. The method according to any one of claims 1 to 9, wherein step (b) involves performing hydrophobic interaction chromatography (HIC) on the composition (2) and obtaining a chromatogram.

13. The method of claim 112, further comprising: (c) Calculate the ratio (%) using the following formula (II): in, A represents the area value of the peak originating from the LINC form in the chromatogram; and B is the sum of the area values ​​of all peaks in the chromatogram originating from the unLINC form digested by the protease.

14. The method according to any one of claims 1 to 13, wherein the antigen-binding molecule comprises a first antigen-binding domain and a second antigen-binding domain capable of being linked to each other via at least one disulfide bond.

15. The method of claim 14, wherein the at least one disulfide bond is formed between the first antigen-binding domain and the second antigen-binding domain.

16. The method according to claim 14 or 15, wherein the at least one disulfide bond is formed between the heavy chain of the first antigen-binding domain and the heavy chain of the second antigen-binding domain.

17. The method according to any one of claims 14 to 16, wherein the at least one disulfide bond is formed between the CH1 region of the first antigen-binding domain and the CH1 region of the second antigen-binding domain.

18. The method according to any one of claims 14 to 17, wherein the disulfide bond is formed between an amino acid residue at position 191 according to EU number in the heavy chain of the first antigen-binding domain and an amino acid residue at position 191 according to EU number in the heavy chain of the second antigen-binding domain, between an amino acid residue at position 195 according to EU number in the heavy chain of the first antigen-binding domain and an amino acid residue at position 195 according to EU number in the heavy chain of the second antigen-binding domain, or between an amino acid residue at position 197 according to EU number in the heavy chain of the first antigen-binding domain and an amino acid residue at position 197 according to EU number in the heavy chain of the second antigen-binding domain.

19. The method according to any one of claims 14 to 18, wherein the first antigen-binding domain and the second antigen-binding domain bind to a first antigen and a second antigen, respectively, the first antigen and the second antigen being proteins present on the surface of a cell, and wherein the antigen-binding molecule has activity that promotes interaction between cells expressing the first antigen and cells expressing the second antigen.

20. The method of claim 19, wherein the cell expressing the first antigen is a cell with cytotoxic activity, and the cell expressing the second antigen is a target cell of the cell with cytotoxic activity, and wherein the antigen-binding molecule promotes damage to the target cell by the cell with cytotoxic activity.

21. The method of claim 20, wherein the cell having cytotoxic activity is a T cell, NK cell, monocyte, or macrophage.

22. The method according to any one of claims 19 to 21, wherein the first antigen and the second antigen are independently selected from the group consisting of: receptors belonging to the cytokine receptor superfamily, G protein-coupled receptors, ion channel receptors, tyrosine kinase receptors, immune checkpoint receptors, antigen receptors, CD antigens, co-stimulatory molecules, and cell adhesion molecules.

23. The method according to any one of claims 14 to 22, wherein the first antigen-binding domain and the second antigen-binding domain are each capable of binding to CD3 and / or CD137.

24. The method according to any one of claims 1 to 23, wherein the antigen-binding molecule further comprises a third antigen-binding domain.

25. The method of claim 24, wherein the third antigen-binding domain is fused with either the first antigen-binding domain or the second antigen-binding domain.

26. The method according to claim 24 or 25, wherein the third antigen-binding domain is Fab or scFv.

27. The method according to any one of claims 24 to 26, wherein the third antigen-binding domain is fused at its C-terminus to the N-terminus of the Fab heavy chain (VH region) of either the first antigen-binding domain or the second antigen-binding domain, optionally via a peptide linker.

28. The method according to any one of claims 24 to 27, wherein the first antigen-binding domain, the second antigen-binding domain, and the third antigen-binding domain are each Fab molecules, wherein the third antigen-binding domain is fused at the C-terminus of its Fab heavy chain (CH1 region) to the N-terminus of the Fab heavy chain (VH region) of either the first antigen-binding domain or the second antigen-binding domain, optionally via a peptide linker.

29. The method according to claim 27 or 28, wherein the peptide linker comprises an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO:

20.

30. The method according to any one of claims 24 to 29, wherein the third antigen-binding domain is a cross-Fab molecule in which the variable regions of the Fab light chain and the Fab heavy chain are exchanged, and wherein the first antigen-binding domain and the second antigen-binding domain are conventional Fab molecules.

31. The method according to any one of claims 24 to 30, wherein the third antigen-binding domain is capable of binding to an antigen expressed on cancer cells or cancerous tissue.

32. The method according to any one of claims 24 to 31, wherein the third antigen-binding domain is capable of binding to DLL3, preferably human DLL3.

33. The method according to any one of claims 1 to 32, wherein the antigen-binding molecule further comprises an Fc region.

34. The method according to any one of claims 14 to 33, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region that may be the same as or different from each other, and each comprises an antibody variable region independently selected from the group consisting of (a1) to (a4): (a1) Contains the following antibody variable regions: Heavy chain variable region, which contains: Heavy chain complementarity-determining region (CDR) 1, which contains the amino acid sequence of SEQ ID NO: 27, Heavy chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 28, and Heavy chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 29; and The light chain variable region, which includes: Light chain CDR 1, which contains the amino acid sequence of SEQ ID NO: 30, The light chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 31, and Light chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 32; (a2) Contains the following antibody variable regions: Heavy chain variable region, which contains: Heavy chain complementarity-determining region (CDR) 1, which contains the amino acid sequence of SEQ ID NO: 33, Heavy chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 34, and Heavy chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 35; and The light chain variable region, which includes: Light chain CDR 1, which contains the amino acid sequence of SEQ ID NO: 30, The light chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 31, and Light chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 32; (a3) An antibody variable region that binds to the same epitope as the antibody variable region bound to (a1) or (a2); and (a4) is an antibody variable region that competes with (a1) or (a2) for binding to the antigen.

35. The method according to any one of claims 14 to 34, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region that may be the same as or different from each other, and each comprises an antibody variable region independently selected from the group consisting of (a1) to (a4): (a1) Contains the following antibody variable regions: The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 36, and The light chain variable region contains the amino acid sequence of SEQ ID NO: 37; (a2) Contains the following antibody variable regions: The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 38, and The light chain variable region contains the amino acid sequence of SEQ ID NO: 37; (a3) An antibody variable region that binds to the same epitope as the antibody variable region bound to (a1) or (a2); and (a4) is an antibody variable region that competes with (a1) or (a2) for binding to the antigen.

36. The method according to any one of claims 24 to 35, wherein the third antigen-binding domain comprises an antibody variable region independently selected from the group consisting of (a1) to (a4): (a1) Contains the following antibody variable regions: Heavy chain variable region, which contains: Heavy chain complementarity-determining region (CDR) 1, which contains the amino acid sequence of SEQ ID NO: 46, Heavy chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 47, and Heavy chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 48; and The light chain variable region, which includes: Light chain CDR 1, which contains the amino acid sequence of SEQ ID NO: 49, The light chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 50, and Light chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 51; (a2) Contains the following antibody variable regions: The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 52, and The light chain variable region contains the amino acid sequence of SEQ ID NO: 53; (a3) An antibody variable region that binds to the same epitope as the antibody variable region bound to (a1) or (a2); and (a4) is an antibody variable region that competes with (a1) or (a2) for binding to the antigen.

37. The method according to any one of claims 14 to 36, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising: Heavy chain variable region, which contains: Heavy chain complementarity-determining region (CDR) 1, which contains the amino acid sequence of SEQ ID NO: 27, Heavy chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 28, and Heavy chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 29; and The light chain variable region, which includes: Light chain CDR 1, which contains the amino acid sequence of SEQ ID NO: 30, The light chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 31, and The light chain CDR 3 contains the amino acid sequence of SEQ ID NO:

32.

38. The method according to any one of claims 14 to 37, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising: The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 36, and The light chain variable region contains the amino acid sequence of SEQ ID NO:

37.

39. The method according to any one of claims 24 to 38, wherein the third antigen-binding domain comprises an antibody variable region, the antibody variable region comprising: Heavy chain variable region, which contains: Heavy chain complementarity-determining region (CDR) 1, which contains the amino acid sequence of SEQ ID NO: 46, Heavy chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 47, and Heavy chain CDR 3, which contains the amino acid sequence of SEQ ID NO: 48; and The light chain variable region, which includes: Light chain CDR 1, which contains the amino acid sequence of SEQ ID NO: 49, The light chain CDR 2, which contains the amino acid sequence of SEQ ID NO: 50, and The light chain CDR 3 contains the amino acid sequence of SEQ ID NO:

51.

40. The method according to any one of claims 24 to 39, wherein the third antigen-binding domain comprises an antibody variable region, the antibody variable region comprising: The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 52, and The light chain variable region contains the amino acid sequence of SEQ ID NO:

53.

41. The method according to any one of claims 24 to 40, wherein the first antigen-binding domain and the second antigen-binding domain each comprise an antibody variable region, the antibody variable region comprising: The heavy chain variable region contains the amino acid sequence of SEQ ID NO: 36, and The light chain variable region contains the amino acid sequence of SEQ ID NO:

37. Furthermore, the third antigen-binding domain comprises an antibody variable region, which includes: The heavy chain variable region, which includes SEQ ID NO: 52, and The light chain variable region contains SEQ ID NO:

53.

42. The method according to any one of claims 14 to 41, wherein the first antigen-binding domain and the second antigen-binding domain are each Fab having a cysteine ​​residue at EU number positions 191, 195 or 197 in the heavy chain, and having a disulfide bond formed by two cysteine ​​residues.

43. The method according to any one of claims 1 to 42, wherein the antigen-binding molecule comprises five polypeptide chains selected from any combination of the group consisting of: (a1) A polypeptide chain (chain 1) containing the amino acid sequence of SEQ ID NO:

39. A polypeptide chain (chain 2) containing the amino acid sequence of SEQ ID NO:

40. A polypeptide chain (chain 3) containing the amino acid sequence of SEQ ID NO: 41, and Two polypeptide chains (chain 4 and chain 5) each containing the amino acid sequence of SEQ ID NO:

42. (a2) A polypeptide chain (chain 1) containing the amino acid sequence of SEQ ID NO:

43. A polypeptide chain (chain 2) containing the amino acid sequence of SEQ ID NO:

40. A polypeptide chain (chain 3) containing the amino acid sequence of SEQ ID NO: 44, and Two polypeptide chains (chain 4 and chain 5), each containing the amino acid sequence of SEQ ID NO: 42; and (a3) A polypeptide chain (chain 1) containing the amino acid sequence of SEQ ID NO:

45. A polypeptide chain (chain 2) containing the amino acid sequence of SEQ ID NO:

40. A polypeptide chain (chain 3) containing the amino acid sequence of SEQ ID NO: 44, and Two polypeptide chains (chain 4 and chain 5) each containing the amino acid sequence of SEQ ID NO:

42. in, Preferably, the five polypeptide chains (chains 1 to 5) are connected and / or associated with each other according to the orientation shown in Figure 3.